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Preface 
 
 
The present thesis is a presentation of the experimental work I have carried out during the last 3 
years in the Molecular Neuropharmacology Group at the Department of Neuroscience and 
Pharmacology, University of Copenhagen. 
 
All the experimental work presented in this thesis is related to aspects of cellular regulation of the 
dopamine transporter. 
 
The thesis consists of a general introduction to the dopamine system and the dopamine transporter, 
which serves as a background for the experimental data presented. This is followed by a short 
presentation and a general discussion of the results presented in the thesis. 
 
The full representation of the results is available in the following four papers (two published papers 
and two manuscripts) attached in the back of the thesis: 
 
Paper 1: Eriksen J, Rasmussen SGF, Rasmussen TN, Vægter CB, Cha JH, Zou MF, Newman AH, Gether U 
(2009) Visualization of Dopamine Transporter Trafficking in Live Neurons by Use of Fluorescent Cocaine 
Analogs. Journal of Neuroscience 29:6794-6808. 
 
Paper 2: Eriksen J, Yoshimoto WEB, Jørgensen TN, Gether U (2009) Constitutively Internalized Dopamine 
Transporter is Primarily Sorted to a Late Endosomal/Lysosomal Pathway in both Dopaminergic Neurons 
and Cell Lines. Manuscript, ready for submission. 
 
Paper 3: Madsen KL, Eriksen J, Milan-Lobo L, Han DS, Niv MY, Ammendrup-Johnsen I, Henriksen U, 
Bhatia VK, Stamou D, Sitte HH, McMahon HT, Weinstein H, Gether U (2008) Membrane localization is 
critical for activation of the PICK1 BAR domain. Traffic 9:1327-1343. 
 
Paper 4: Eriksen J, Klewe IV, Egebjerg J, Christensen KV, Gether U (2009) The dopamine transporter 
impairs dopamine D2 receptor surface expression/ signalling and reveals promiscuous monoamine 
transporter/receptor interaction. Manuscript. 
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Other related work carried out during my time as a PhD student is part of the following 
manuscripts, not included in the PhD thesis: 
 
Adkins EM, Samuvel DJ, Fog JU, Eriksen J, Jayanthi LD, Vaegter CB, Ramamoorthy S, Gether U (2007) 
Membrane Mobility and Microdomain Association of the Dopamine Transporter Studied with Fluorescence 
Correlation Spectroscopy and Fluorescence Recovery after Photobleaching. Biochemistry 46:10484-10497. 
 
Eriksen J, Jørgensen TN, Gether U (2009) Regulation of dopamine transporter function by protein-protein 
interactions: challenges and new discoveries. Review. Manuscript submitted to Journal of Neurochemistry. 
 
 
I would like to thank my supervisor Ulrik Gether for always showing great interest in my 
projects/ideas and also providing ideas and advise. 
Furthermore, I would like to thank all the people in the Molecular Neuropharmacology Group for 
their help and making it a pleasant environment. 
A special thanks to Donna Czerny, Nabeela Khadim and Anette Dencker Kristensen for the 
invaluable technical assistance, and Trine Nygaard Jørgensen, Kenneth Lindegaard Madsen and Ib 
Vestergaard Klewe for the frutiful discussions and cooperations. 
Finally, I would like to thank Anja for support and patience all the way, all the time. 
 
 
December 2009 
 
 
 
Jacob Eriksen 
 
 
 
Cover illustration: Cultured rat dopaminergic neurons labeled with the fluorescent cocaine analog JHC 1-64 (chemical structure 
overlaid), which specifically binds the dopamine transporter. 
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Summary 
 
The dopamine transporter (DAT) mediates reuptake of dopamine from the synaptic cleft and is a 
target for widely abused psychostimulants such as cocaine and amphetamine. Nonetheless, little is 
known about the cellular distribution and trafficking of natively expressed DAT. DAT and its 
trafficking was visualized in cultured live midbrain dopaminergic (DA) neurons using novel 
fluorescently tagged cocaine analogs. The ligands enabled specific labelling and visualization of 
DAT in live neurons. In the DA neurons, DAT was uniformly distributed in the plasma membrane 
of the soma, the neuronal extensions, and varicosities along these extensions. Moreover, DAT was 
constitutively internalized into vesicular structures and the internalization was blocked by lentiviral-
mediated expression of dominant-negative dynamin. DAT internalization and function was not 
affected by activation of protein kinase C (PKC) with phorbol-12-myristate-13-acetate (PMA) or by 
inhibition with staurosporine or GF109203X. These data are in contrast to findings for DAT in 
transfected heterologous cells and challenge the paradigm that trafficking and cellular distribution 
of endogenous DAT is subject to regulation by PKC. 
To further characterize the intracellular pool of constitutively endocytosed DAT several strategies 
were employed in both cell lines and cultured DA neurons. First, to investigate the constitutive 
trafficking of heterologously expressed DAT we fused the N-terminus of DAT to the intracellular 
tail of the single-membrane spanning protein Tac, thereby creating an extracellular antibody 
epitope. Upon expression in HEK293 cells this TacDAT fusion protein displayed functional 
properties similar to the wild type transporter. In an ELISA based internalization assay, TacDAT 
intracellular accumulation was increased by inhibitors of lysosomal degradation and moreover 
TacDAT colocalized with the late endosomal marker Rab7. In the DA cell line 1Rb3An27 TacDAT 
also co-localized with EGFP-Rab7 and not with the recycling endosomal marker EGFP-Rab11. To 
assess whether sorting to late endosomes/lysosomes was a property also inherent to natively 
expressed transporter, DAT was visualized directly in cultured DA neurons using the fluorescent 
cocaine analog JHC 1-64. These data showed pronounced colocalization upon constitutive 
internalization with Lysotracker, a late endosomal/lysosomal marker; however only little co-
lolization was observed with Alexa488-conjugated transferrin. Additionally, when expressing 
EGFP-Rab7 with lentivirus in cultured DA neurons a marked co-localization between JHC 1-64 and 
EGFP-Rab7 was observed. The data suggest that constitutively internalized DAT primarily is 
targeted to late endosomes and lysosomes both in heterologous cells and in cultured DA neurons. 
 
DAT has been shown to be regulated by the dopamine D2 receptor (D2R), the primary target for 
anti-psychotics, through a direct interaction. D2R is among other places expressed as an 
autoreceptor in DA neurons. Transient over-expression of DAT with D2R in HEK293 cells reduced 
surface expression of D2R while DAT surface levels remained unaffected. Furthermore ß-Arrestin2 
recruitment to D2R was compromised and D2R-mediated inhibition of cAMP accumulation was 
reduced as a consequence of the reduced surface level expression of D2R. The effects of DAT on 
D2R surface expression and signalling was not unique for DAT and D2R. Thus, transient co-
expression of ß2AR with DAT resulted in reduced surface levels of ß2AR. In addition, co-
expression of the serotonin transporter with D2R appeared to modulate the ß-Arrestin2 recruitment 
to D2R and the D2R-mediated inhibition of cAMP accumulation in a manner similar to co-
expression of DAT. The data suggest that DAT affect D2R function and expression with no 
apparent specificity. 
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Resumé (Danish) 
 
Dopamintransporteren er ansvarlig for genoptag af dopamin fra den synaptiske kløft og er det 
primære mål for virkningen af udbredte psykostimulantia så som kokain og amfetamin. Selvom 
DAT spiller en central rolle for virkningen af psykostimulantia, så er viden om fordeling og 
’trafficking’ af DAT i endogene systemer begrænset. I nærværende studie har vi brugt 
fluorescensmærkede kokainanaloger med høj affinitet for DAT. Disse kokainanaloger muliggør 
visualisering af DAT i levende primærkulturer af dopaminerge kulturer. 
I de dopaminerge nerveceller var DAT ensartet fordelt i plasma membranen både i soma og i 
nervecellens udløbere. FRAP (fluoresecens recovery after photobleaching) eksperimenter viste 
bidirektionel bevægelse af DAT, og desuden var der evidens for meget mobil DAT i både udløbere 
og varikositeter. 
DAT udviste konstitutiv endocytose og blev ophobet i vesikulære strukturer, der muligvis 
repræsenterer en intracellulær pulje af DAT. Den konstitutive endocytose kunne blokeres af 
lentiviral medieret ekspression af dominant negativ dynamin 1, og konstitutiv internaliseret DAT 
co-lokaliserede til dels med både EGFP-Rab5 og transferrin receptoren. Overraskende var DAT 
internalisering ikke påvirket af protein kinase C (PKC) aktivitet i vores primærkulturer af 
dopaminerge nerveceller. Hverken stimulering af PKC med PMA eller ved at hæmme PKC med 
GF109203X påvirkede internaliseringen eller dopaminoptag. Disse resultater er forskellige fra 
observationer i cellelinier, som exogent udtrykker DAT og sætter spørgsmålstegn ved paradigmet 
om PKC-medieret regulering af DAT i dopaminerge nerveceller. 
For yderligere at karakterisere den konstitutive internalisering, som vi observerede i de 
dopaminerge neuroner anvendte vi flere forskellige strategier til at detektere DAT i både cellelinier 
og dopaminerge nerveceller. For at undersøge internalisering af eksogent udtrykt DAT brugte vi et 
konstrukt med DAT N-terminalen fusioneret med den intracellulære del af enkelt transmembran 
domæne proteinet Tac for herved at skabe en ekstracellulær antistof-epitop. Når dette Tac-DAT 
fusionsprotein blev udtrykt i HEK293 celler udviste det funktionelle egenskaber svarende til 
vildtype transporteren og blev internaliseret i lighed med denne. I et ELISA eksperiment kunne vi 
kvantificere en konstitutiv tidsafhænigig DAT internaliserng i HEK293 og den medfølgende 
intracellulære akkumulering blev øget af leupeptin, en hæmmer af lysosomal degradering. Dette 
indikerer at Tac-DAT delvist blev sorteret til lysosomal degradering. For at videre undersøge denne 
hypotese udtrykte vi TacDAT i den dopaminerge cellelinie 1Rb3An27, og her undersøgte vi 
sorteringen af TacDAT v.h.a. co-udtryk af endosomale markører koblet til EGFP. Kvantificering 
viste at internaliseret TacDAT kolokaliserede med Rab7, som lokaliserer til sen endosomale 
vesikler, et forstadie til lysosomer. TacDAT kolokaliserede signifikant mere med Rab7 end Rab11, 
som lokaliserer til en anden type ’recycling’ endosomer. 
For at undersøge om dette også var gældende for konstitutivt internaliseret DAT enodgent, udtrykte 
vi EGFP-Rab markørerne v.h.a. lentivirus i primærkulturer med dopaminerge nerveceller. Ved 
hjælp af kokain-analogen, JHC 1-64 observerede vi at konstitutivt internaliseret DAT 
colokaliserede med Rab7 og ikke Rab11. Desuden var der en udpræget colokalisering mellem DAT 
og den lysosomale markør LysoTracker. Vi foreslår derfor at konstitutivt internaliseret DAT 
sorteres til degradering via rab7 positive vesikler til lysosomer både i cellelinier og primærkulturer 
med dopaminerge nerveceller, som udtrykker DAT endogent. 
Samlet giver resultaterne et billede af en dynamisk opretholdelse DAT homøostase i dopaminerge 
nerveceller. 
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Abbreviations 
 
 
 
a.a. amino acid 
ADHD Attention-deficit hyperactivity disorder 
BRET Bioluminescence resonance energy transfer 
CamKII Ca2+/calmodulin-dependent protein kinase II 
CFP Cyan fluorescent protein 
CNS Central nervous system 
D2R Dopamine D2 receptor 
DA Dopaminergic 
DAT Dopamine Transporter 
EGFP Enhanced green fluorescent protein 
ELISA Enzyme-linked immunosorbent assay 
ER Endoplasmatic reticulum 
ERK Extracellular signal-regulated kinase 
ESCRT Endosomal sorting complex required for transport 
FRAP Fluorescence recovery after photobleaching 
FRET Fluorescence resonance energy transfer 
GABA γ-aminobutyric acid 
GAT1 γ-aminobutyric acid transporter 1 
GPCR G protein-coupled receptor 
GluR2 Glutamate receptor subunit 2 
HEK Human embryonic kidney 
KO Knock out 
LeuT Leucine transporter 
MAPK Mitogen-activated protein kinase 
NET Norepinephrine transporter 
NSS Neurotransmitter:sodium symporter 
PAE Porcine aortic endothelial 
PC-12 Rat adrenal pheochromocytoma 
PET Positron emission tomography 
PI3K Phosphatidylinositol 3-kinase 
PICK1 Protein interacting with C-kinase 1 
PKC Protein kinase C 
PMA Phorbol 12-myristate 13-acetate 
SERT Serotonin transporter 
siRNA small interfering RNA 
SLC6 Solute Carrier 6 
SN Substantia nigra 
Tac T-cell activation 
TM Transmembrane domain 
VMAT2 Vesicular monoamine transporter 2 
VTA Ventral tegmental area 
YFP Yellow fluorescent protein 
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 INTRODUCTION 
 
 
It is now more than 50 years ago that Carlsson and coworkers, with the findings that the akinetic 
effects of reserpine in rabbits could be reversed by the dopamine precursor L-dopa, discovered the 
role of dopamine as a neurotransmitter (Carlsson et al., 1957; Montagu, 1957; Carlsson et al., 
1958), Since the seminal discoveries in 1957-58, a wealth of information has been obtained 
regarding the critical role of dopamine in regulating numerous different brain functions including 
control of locomotor activity, reward mechanisms, cognition and neuroendocrine systems. 
Moreover, it has been established how dysfunction of the dopamine system may be of central 
importance in a broad spectrum of neuropsychiatric disorders, such as Parkinson’s disease, 
schizophrenia, Tourette’s syndrome, attention-deficit hyperactivity disorder (ADHD) and drug 
addiction (Nestler, 2005; Albin and Mink, 2006; Iversen and Iversen, 2007). Consequently, major 
research resources have been dedicated to understanding the processes underlying these disorders 
together with the attempted development of drugs relieving patients from their devastating 
symptoms. 
 
Dopaminergic neurotransmission 
Dopamine is synthesized in dopaminergic (DA) neurons from the amino acid tyrosine. Via the 
vesicular monoamine transporter 2 (VMAT2) dopamine is filled into synaptic vesicles from where 
it is released both from dendritic and axonal release sites upon neuronal excitatory activity (figure 
1). DA neurons exhibit characteristic tonic and phasic firing patterns, where the tonic firing is 
dependent on an intrinsic pacemaker potential and the phasic firing is dependent on afferent input 
(Grace et al., 2007). Dopamine signals only through G-protein coupled receeptors (GPCRs), a 
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process often referred to as slow synaptic transmission (Greengard, 2001). Based on biochemical 
and pharmaceutical properties two main classes of dopamine receptors can be distinguished: D1-
like (D1, D5) and D2-like (D2, D3, and D4) dopamine receptors (figure 1). Dopamine receptors are 
expressed in a variety of target neurons and signal to a wide range of membrane bound and 
intracellular effectors such as ion channels, secondary messenger systems and enzymes (Werkman 
et al., 2006). 
The inactivation of neurotransmitters by reuptake into neurons was first discovered by Julius 
Axelrod and coworkers in the early 1960’s, as they demonstrated that radiolabelled norepinephrine 
was accumulated in sympathetic nerve endings (Hertting et al., 1961; Wolfe et al., 1962) and 
subsequently released upon stimulation (Hertting and Axelrod, 1961) with the molecular properties 
being virtually unknown. However, with the cloning of neurotransmitter transporter such as the 
dopamine transporter (DAT) from various species in the beginning of the nineties (Kilty et al., 
1991; Shimada et al., 1991; Usdin et al., 1991) the molecular identity of the proteins responsible for 
Figure 1: Schematic representation of a 
dopaminergic synapse. 
Cytosolic dopamine is filled into synaptic 
vesicles by the vesicular monoamine 
transporter 2 (VMAT). Dopamine is released 
into the synaptic cleft from presynaptic vesicles 
upon neuronal excitatory activity. Released 
dopamine reaches concentrations in the 
hundreds of micromolar range (Garris and 
Wightman, 1994) and binds pre- and 
postsynaptic dopamine receptors. The synaptic 
dopamine signal via D1-like and D2-like 
dopamine receptors result in a broad cascade 
of cellular responses mediated by second 
messengers. Termination of the signal is 
primarily accommodated by removal of the 
neurotransmitter by reuptake into the 
presynapse of the dopaminergic neuron 
facilitated by DAT. 
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the neurotransmitter reuptake was revealed. Later, the generation of the DAT knock out (KO) 
mouse showed that DAT was indeed essential for dopamine homeostasis and signalling in the brain 
(Giros et al., 1996). The disrupted clearance of released dopamine in the DAT KO mice resulted in 
about a 300-fold increase in the lifetime of dopamine in the extracellular space and a fivefold 
elevation in the basal extracellular dopamine levels (Gainetdinov et al., 1998; Jones et al., 1998). 
Even more strikingly, a profound depletion of intraneuronal dopamine stores (20-fold) and 
decreased amplitude of evoked dopamine release (4-fold) was found in DAT KO mice (Gainetdinov 
et al., 1998; Jones et al., 1998). These observations strongly suggest that in normal physiological 
situation, DAT is the principal inactivator of synaptic dopamine, and the major dopamine storage 
pools must be controlled by the DAT-mediated dopamine recycling (Jones et al., 1998; Gainetdinov 
and Caron, 2003). 
 
Dopaminergic projections 
Despite its critical physiological and pathophysiological role, dopamine is only synthesized and 
released from a relatively discrete number of neuronal groups adding up to 40-45,000 neurons in 
rats and 400,000 to 600,000 neurons in humans. These are primarily located in the ventral tegmental 
area (VTA) and the substantia nigra (SN; > 70% of the DA neurons) of the midbrain (Bjorklund and 
Dunnett 2007). Although few in number the midbrain DA neuron afferents exhibit a high degree of 
arborisation with up to 300,000 branch points per axon (figure 2A). Therefore each neuron covers a 
large area and can broadcast a dopamine signal and exert strong influence over a large number of 
neurons in their target regions; including the forebrain and basal ganglia (Bjorklund and Dunnett, 
2007; Matsuda et al., 2009).  
The DA projections from the midbrain are classically divided in nigrostriatal, mesolimbic and 
mesocortical systems (figure 2B) (Lindvall et al., 1983; Bjorklund and Dunnett, 2007). The 
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nigrostriatal system projects from the substantia nigra (SN) to the dorsal striatum, and is involved in 
cognitive integration, habituation, sensorimotor coordination and initiation of movement. The 
mesolimbic system projects from the ventral tegmental area (VTA) to limbic structures such as 
nucleus accumbens, hippocampus, and amygdala. The mesocortical system projects from the VTA 
to several cortical regions. The mesolimbic and mesocortical systems are involved in regulation of 
motivation, attention and reward (Iversen and Iversen, 2007). 
A fourth distinct dopamine pathway, the tuberoinfundibular system (figure 2B), is connected to the 
hormone secretory system of the pituitary gland. DA neurons project from the hypothalamus to the 
pituitary gland and regulate neuroendocrine function, particularly the release of prolactin (Leuner 
and Muller, 2006). 
Figure 2: Anatomy of a dopaminergic neuron and the major dopaminergic pathways in the human brain. 
A) 2D visualization of a dopaminergic neuron with its cell body and dendrites (black) in substantia nigra and its 
axonal afferents (grey) terminating in the striatum. Heavy axonal arborisation is evident in the striatum making 
one dopaminergic neurons capable of signalling to a large number of striatal neurons. Figure modified from 
(Matsuda et al., 2009). B) The major dopaminergic projections as described in the text. A9-A12 refers to the 
nomenclature introduced by Dahlström and Fuxe for the major dopaminergic cell groups characterized using 
catecholaminergic histofluorescence (Dahlstrom and Fuxe, 1964). Figure modified from (Leuner and Muller, 
2006). 
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The role of DAT as a terminator of dopamine signaling differs markedly between these systems. 
DAT is expressed at high levels in the striatum and accounts for around 95% of the dopamine 
uptake, conversely the prefrontal cortex shows very low levels of DAT expression (Sesack et al., 
1998) and the DAT accounts for only around 40% of dopamine uptake in the prefrontal cortex 
(Wayment et al., 2001). 
 
 
The dopamine transporter 
 
DAT structure 
DAT belongs to the family of neurotransmitter:sodium symporters (NSS) (also referred to as the 
SLC6 [solute carrier 6] gene family) that in addition to DAT includes transporters for the 
neurotransmitters norepinephrine, serotonin, glycine and γ-aminobutyric acid (GABA). This class 
of transporters is characterized by co-transport of Na+ and Cl-. At the structural level, the 
transporters share a predicted structure with 12 transmembrane domains (TM), an intracellular N- 
and C-termini and a large extracellular loop 2 between TM3 and TM4 harbouring glycosylation 
sites (3 glycosylation sites in DAT) (Beuming et al. 2006; Chen et al. 2004; Gether et al. 2006; 
Torres and Amara 2007). 
This predicted 12TM topology was supported by a high resolution crystal structure of a bacterial 
homologue, the Leucine transporter (LeuT) of the mammalian NSS family (Yamashita et al., 2005). 
LeuT shares an approximately 20% amino acid homology with the mammalian transporters with the 
highest homology in the TM regions and around the binding site (Beuming et al., 2006). The 
structure of the bacterial LeuT provided the first overview of the tertiary structure of SLC6 family 
members, and revealed an inverted repeat not elucidated in the primary structure, as TM 1-5 and 
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TM 6-10 are related by a twofold symmetry around an axis through the center of the membrane 
plane (figure 3). The partly unwound TM1 and TM6 together with TM3 and TM8 create the 
substrate binding site in the middle of the membrane plane (Yamashita et al., 2005). Interestingly 
the structural inverted symmetry is by no means unique to the SLC6 gene family. Recently several 
crystal stuctures from other bacterial transporter families have revealed a similar teritiary structure, 
suggesting a similar mechanism of transport for several transporters from various families and with 
different substrates (recently reviewed by (Abramson and Wright, 2009; Gouaux, 2009).  
 
Mechanism of transport 
The transport of dopamine across the plasma membrane against its concentration gradient is 
coupled to co-transport of Na+ and Cl-. The driving force for this energetically unfavourable 
transport is the sodium gradient across the plasma membrane generated by the Na+/K+-ATPase; 
also referred to as secondary active transport. DAT as other NSS family members is believed to 
Figure 3: Topology of the NSS family bacterial homolog LeuT. 
The bacterial SLC6 gene family bacterial homolog LeuT has an internal structural repeat of a 5TM helical bundle. 
TM1-5 is related to TM6-10 by a twofold symmetry around an axis through the center of the membrane plane. The 
binding pocket is formed by TM1 TM3, TM6 and TM8 in the middle of the membrane plane (Yamashita et al., 
2005). 
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function by alternately exposing the substrate binding site to the extracellular and intracellular 
environment through conformational changes in DAT (figure 4). This alternating access model 
depends on a gating mechanism that shield the binding site from the extracellular environment by 
an external gate and the intracellular environment by an internal gate. Orderly binding of ions and 
substrate is a prerequisite for the protein to undergo conformational changes that occlude the 
binding site from the extracellular space and expose it to the intracellular site (Rudnick, 2006). 
Following release of ions and substrate DAT returns to a conformation with the binding site 
exposed to the extracellular environment – ready to bind and transport a new dopamine molecule 
(figure 4). The turnover rate of DAT has been estimated to be around 0.5 dopamine molecule / 
sec*transporter (Sonders et al., 1997; Prasad and Amara, 2001) suggesting that it takes around two 
seconds for DAT to go through the whole transport cycle. 
Figure 4: DAT transport mechanism. 
Orderly binding of ions and substrate is a prerequisite for the protein to undergo conformational changes that 
occlude the binding site from the extracellular space and exposes it to the intracellular site. Following release of 
ions and substrate, DAT returns to a conformation with the binding site exposed to the extracellular environment – 
ready to bind and transport a new dopamine molecule. Modified from (Rudnick, 2006). 
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It is predicted for DAT that two Na+ and one Cl- are transported together with one positively 
charged dopamine molecule (Gu et al. 1994; Krueger 1990). Consequently, the transport process is 
electrogenic and can be analyzed by electrophysiology tools. However, electrophysiological 
experiments on Xenopus oocytes expressing DAT have revealed that the net movement of charges 
during substrate translocation is greater than the two positive charges expected for a transport cycle 
with a fixed stoichiometry (Meinild et al. 2004; Sonders et al. 1997). According to perforated-patch 
recordings in midbrain DA neurons (Ingram et al. 2002) these additional charges are likely due to 
an uncoupled Cl- flux that, together with the coupled current, is of a magnitude that can increase the 
firing rate of the DA neurons; hence, DAT mediated currents might play a role in modulating 
neuronal excitability (Ingram et al. 2002). 
 
DAT inhibitors and substrates 
DAT forms together with the highly homologous norepinephrine transporter (NET) and serotonin 
transporter (SERT) the NSS subfamily of monoamine transporters. The monoamine transporters 
have received substantial attention as important targets for CNS drugs. The norepinephrine 
transporter (NET) and serotonin transporter (SERT) are the prime targets for antidepressants, with 
the selective SERT and NET inhibitors being effective against both depression and anxiety 
disorders (Iversen, 2006). Several classes of compounds interact with DAT, including transported 
substrates and different groups of inhibitors (figure 5) that are used for diagnostic, research and 
therapeutic purposes as well as being substances of abuse and neurotoxins (Chen et al., 2004). 
The most well-known DAT interacting compounds are the psyhostimulants, cocaine and 
amphetamine. The term ‘psychostimulant’ generally refers to drugs that produce a variety of effects 
in humans including: increased energy, cardiovascular stimulation, elevated mood, and a decreased 
need for sleep. At higher doses, or after longer periods of use, psychostimulants can produce a 
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range of disordered thought processes, including severe psychotic episodes. In animals, 
psychostimulants increase locomotor activity and are readily self-administered due to their powerful 
reinforcing properties (Rothman and Baumann, 2003). 
Even though cocaine also inhibits the SERT and NET, DAT knock out (KO) mice show no 
stimulatory effects of cocaine suggesting that the psychostimulatory effects are mediated by DAT 
(Giros et al., 1996), and although DAT KO mice self-administers cocaine (Rocha et al., 1998), 
recent evidence from studies in a knock in mouse with a cocaine insensitive DAT suggest that both 
the main stimulatory and addictive effects of cocaine are mediated by DAT (Chen et al., 2006; 
Thomsen et al., 2009; Tilley et al., 2009). The same has been shown to be the case for the 
amphetamine effects (Giros et al., 1996; Fumagalli et al., 1998). 
Amphetamine and cocaine exert their psychostimulatory effects by increasing the extracellular 
levels of dopamine thereby increasing the dopamine signalling. However, their mechanism of 
actions differs because cocaine is a competitive inhibitor and amphetamine is a substrate. Cocaine 
binds DAT in the substrate-binding site (Beuming et al., 2008) without being transported, thereby 
inhibiting transport and reuptake of released dopamine. Amphetamine is a substrate that is actively 
Figure 5: Structure of selected DAT substrates and inhibitors 
Amphetamine and cocaine are psychostimulants and drugs of abuse. Methylphenidate (Ritalin) is used in the 
treatment of ADHD. ASP+ (4-(4-(dimethylamino)styrl)-N-methyl-pyridinium) is DAT substrate structurally 
similar to the neurotoxin MPP+ (Schwartz et al., 2003). JHC 1-64 is a DAT inhibitor. It is a cocaine-derivative 
conjugated with rhodamine (Cha et al., 2005). Both ASP+ and JHC 1-64 are tool compounds used for repeated 
monitoring of DAT activity and trafficking, respectively, in live cells. 
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transported by DAT (Wall et al., 1995; Sitte et al., 1998; Sulzer et al., 2005) and raise extracellular 
dopamine by several mechanism; hence, amphetamine does not only act as a competitive DAT 
substrate but also disrupts storage of vesicular dopamine and increases DAT mediated dopamine 
efflux (Sulzer et al., 2005). 
 
Amphetamine and DAT-mediated efflux 
There is increasing evidence that the amphetamine induced DAT-mediated efflux is not directly 
coupled to uptake (Pifl and Singer, 1999; Scholze et al., 2002b; Meinild et al., 2004) and might 
even involve a channel-like mode of DAT (Sitte et al., 1998; Kahlig et al., 2005).  
Several studies suggest that intracellular signalling via protein kinase C (PKC) is involved in 
amphetamine-mediated dopamine efflux (Browman et al., 1998; Kantor and Gnegy, 1998) and PKC 
activation alone might induce DAT-dependent dopamine efflux (Cowell et al., 2000). Gnegy and 
co-workers showed by use of specific PKC inhibitors that PKCß could be critical for amphetamine- 
and phorbol ester-induced dopamine efflux in rat striatal slices (Johnson et al., 2005b). 
Interestingly, it has been shown that phosphorylation of one or more serines in the distal DAT N-
terminus shifts the transporter from a ‘reluctant’ to a ‘willing’ efflux state without interfering with 
inward transport (Khoshbouei et al., 2004). This phosphorylation may involve PKC; however, 
another study suggested that binding of Ca2+/calmodulin-dependent protein kinase II (CaMKII) to 
the DAT C-terminus and CaMKIIα phosphorylation of the N-terminal serines stimulated 
amphetamine-mediated efflux (Fog et al., 2006). The effect was abolished in heterologous cells by 
mutation of five serines present in the distal DAT N-terminus. Similarly, chronoamperometry 
measurements in anesthetized mice exhibited reduced amphetamine-induced dopamine efflux in 
response to the CaMKII inhibitor KN93. 
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Amphetamine-induced dopamine efflux might also be regulated by syntaxin1A (Binda et al., 2008) 
previously shown to bind the DAT N-terminus (Lee et al., 2004). Perfusion of the patch pipette with 
the purified soluble cytosolic domain of syntaxin1A enabled amphetamine-induced dopamine efflux 
in a heterologous cell line as well as in midbrain DA neurons in culture at membrane potentials 
(resting neuronal membrane potential, -60 mV) normally not susceptible to amphetamine-induced 
dopamine efflux (Binda et al., 2008). Based on these findings, and the finding that amphetamine 
increased the interaction between DAT and syntaxin1A in a CaMKII-dependent manner, a 
mechanism is suggested in which amphetamine activation of CaMKII strengthens the 
DAT/syntaxin1A interaction, resulting in a mode of DAT in which efflux is possible (Binda et al., 
2008). 
 
Localization of DAT in the dopaminergic neurons 
Ultrastructural analyses of DAT localization in rat brain have been undertaken with 
immunoelectron microscopy. With gold-labelled antibodies against DAT, the transporter was 
shown to exclusively localize in neurons also expressing tyrosine hydroxylase, an enzyme 
necessary for dopamine synthesis (Nirenberg et al., 1996a; Hersch et al., 1997; Nirenberg et al., 
1997). The concentration of DAT was highest in striatal axon terminals and DAT was mainly 
localized to the plasma membrane along the axons, and a bit surprising DAT was found to be 
excluded from the active zone of striatal synapses (Nirenberg et al., 1996a; Hersch et al., 1997; 
Sesack et al., 1998). Thus, it is believed that DAT transports dopamine back into the neurons as it 
diffuses out of the synapse. 
DAT immunoreactivity was also observed in the nigral part of the nigrostriatal DA neurons. In the 
soma of the neuron DAT localized to the structures of the biosynthetic pathway, and DAT was also 
found in the distal parts of dendrites (Nirenberg et al., 1996a; Hersch et al., 1997). Some 
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localization within the endocytic pathway was also observed, as DAT was found in multivesicular 
bodies, which are precursors to lysosomes. No DAT immunoreactivity was observed within 
transport vesicles, but the explanation for this might be that the gold particles are larger than the 
transport vesicles and therefore mask them (Hersch et al., 1997). 
The same subcellular distribution with DAT in the plasma membrane along distal dendritic 
processes and no DAT in the plasma membrane of the soma was observed in DA neurons of the 
ventral tegmental area (Nirenberg et al., 1997b). However, when comparing the DAT expression 
levels with immunoelectron microscopy in two different areas of the nucleus accumbens a 
difference is observed (Nirenberg et al., 1997a) indicating that the expression of DAT is dependent 
on cell specific factors. 
 
 
Cellular regulation of dopamine transporter trafficking 
 
The mechanisms determining DAT distribution are largely unknown. Moreover, because of the 
sparse amount of DA neurons in the CNS and the general difficulties making biochemistry on 
neurons, most studies on DAT trafficking have been performed in heterologous expression systems. 
However, experiments in cell lines have identified both signalling pathways and protein interaction 
partners that regulate DAT function and availability. 
 
DAT in the biosynthetic pathway 
The biosynthetic pathway consists of the endoplasmic reticulum (ER) and the Golgi apparatus and 
comprises the machinery for membrane protein synthesis and processing (Ellgaard and Helenius, 
2003; Jackson, 2009). Several factors have been shown to influence the kinetics of passage through 
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the secretory pathway including folding and interactions with chaperones and coat complexes in the 
ER (Ellgaard and Helenius, 2003). ER export has been studied to varying degree in several 
members of the SLC6 family and especially two factors have been shown to influence the ER 
export in heterologous expression systems: 1) transporter oligomerization and 2) the cytoplasmic C-
terminus. 
Transporter oligomerization (reviewed in (Sitte et al., 2004)) has been reported for several of the 
members in the SLC6 gene family including DAT (Hastrup et al., 2001; Sorkina et al., 2003; Torres 
et al., 2003), SERT (Just et al., 2004), NET (Hahn et al., 2003), GABA transporter 1 (GAT1) 
(Scholze et al., 2002a) and recently Glycine transporter 1 and 2 (Bartholomaus et al., 2008), and 
several papers points towards oligomerization as a requirement for proper ER export. 
DAT oligomerize already at an early stage in the secretory pathway (Sorkina et al., 2003) and 
evidence from the homologous GAT1 suggests that oligomerization is necessary for proper ER 
export (Scholze et al., 2002a). However, oligomerization alone is not sufficient for proper ER 
export. Mutational analysis in DAT have shown that oligomerization capable mutants and thus 
presumably folded mutants can be retained in the ER (Sorkina et al., 2003; Torres et al., 2003; 
Miranda et al., 2004). As several subtle mutations in the intracellular C-terminus has been shown to 
confer ER retention in DAT (Sorkina et al., 2003; Bjerggaard et al., 2004; Miranda et al., 2004) this 
suggests a necessity for an intact C-terminus for proper transporter ER-export even though an intact 
C-terminus is not required for  oligomerization. 
Studies from GAT1 have shown that the C-terminus binds Sec24D (Farhan et al., 2004) a 
component of the COPII coat complex that facilitates transport from ER to Golgi, and it was 
suggested that oligomerization somehow stabilize the coat formation (Farhan et al., 2004) thus 
linking the requirement of oligomerization and an intact C-terminus. The Sec24D binding motif is 
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conserved in the whole SLC6 family and, accordingly, both SERT and DAT ER export was 
impaired when co-expressed with a dominant negative Sec24D (Farhan et al., 2007). 
 
DAT endocytic trafficking 
Several studies have investigated the dynamics of DAT residing in the plasma membrane, and 
results indicate that DAT internalizes both constitutively and in a regulated manner (Melikian, 
2004). The endocytosis of a membrane protein is a well-described way of regulating the function of 
the protein at the membrane. Agonist-dependent internalization is a general mechanism for down-
regulation of GPCRs and receptor tyrosine kinases at the plasma membrane (Kurten, 2003; Sorkin 
and von Zastrow, 2009). 
The route followed by a membrane protein in the endocytic pathway is not unidirectional as for 
membrane proteins in the biosynthetic pathway destined for the plasma membrane. Several 
pathways have been described, but in the end the fate of an internalized membrane protein is either 
lysosomal degradation or recycling to the plasma membrane. Vesicles with internalized protein 
initially fuse with a compartment known as the early endosome. The early endosome sorts 
membrane proteins either for recycling or to late endosomes. The recycling pathway can either be 
direct from the early endosome back to the plasma membrane (‘short loop recycling’) or through an 
endocytic recycling compartment (‘long loop recycling’). The early endosome matures into a late 
endosome and the pH drops through this maturation and in the late endosome yet another sorting 
event takes place. Some proteins are sorted into a trafficking pathway back to the trans Golgi 
network, and avoids degradation as the late endosome matures into a lysosome (Maxfield and 
McGraw, 2004). The endosomes are divided into subdomains that act as sorting regions for the 
incoming proteins, and Rab proteins, a group of small GTPases are important determinants of 
organelle subdomains in the endocytic pathway (Pfeffer and Aivazian, 2004; Stenmark, 2009). 
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The steady state DAT distribution in the enterochromaffin cell line, PC12, expressing the 
transporter has been shown to be 60% intracellularly and 40% on the cell surface in surface 
biotinylation experiments. Most of the intracellular DAT localized to a transferrin receptor positive 
compartment, likely to be the endocytic recycling compartment (Melikian and Buckley, 1999). 
Thus, constitutively internalized DAT was suggested to recycle through the endocytic recycling 
compartment as has been reported for the transferrin receptor. However the trafficking pathway 
observed was different from the route of the transferrin receptor (Loder and Melikian, 2003). 
Recent observations have supported constitutive recycling of DAT. Incubating porcine aortic 
endothelial (PAE) cells expressing yellow fluorescent protein (YFP) or cyan fluorescent protein 
(CFP) -tagged DAT with monensin to inhibit recycling, DAT surface expression decreased, when 
evaluated by both dopamine uptake and surface biotinylation (Sorkina et al., 2005). Knocking out 
either dynamin II or clathrin heavy chain with siRNAs, and thereby abolishing clathrin mediated 
internalization inhibited the effect of monensin. Thus, it was proposed that DAT is constitutively 
internalized in a clathrin-dependent manner and internalized DAT recycled back to the surface 
(Sorkina et al., 2005). A role for the intracellular DAT C-terminus in regulating DAT endocytosis 
has been suggested (Holton et al., 2005; Sorkina et al., 2005). The signal was defined in a 10 amino 
acid sequence (a.a. 587-597 in human DAT) and necessary for constitutive DAT internalization 
(Holton et al., 2005). Recently, an opposing signal was defined in the DAT N-terminus. It was 
shown that removal of the DAT N-terminus accelerated constitutive DAT internalization suggesting 
that the DAT N-terminus harbours an internalization braking mechanism (Sorkina et al., 2009). The 
relationship between these two signals remains to be elucidated. 
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Protein Kinase C and DAT trafficking 
Numerous studies have supported that DAT is subject to dynamic regulation in the plasma 
membrane thereby providing a mean of attenuating or increasing the strength of DA signalling. The 
most intensively studied mechanism is the regulatory effect of PKC activation. It has been 
demonstrated in several DAT transfected cell lines that activation of PKC by phorbol esters, such as 
phorbol 12-myristate 13-acetate (PMA), down-regulate dopamine transport (Zhu et al., 1997; 
Daniels and Amara, 1999; Melikian and Buckley, 1999; Chi and Reith, 2003; Sorkina et al., 2005; 
Eriksen et al., 2009). A similar down-regulation has also been reported using synaptosomal 
preparations (Copeland et al., 1996; Vaughan et al., 1997). The sustained DAT down-regulation in 
response to PKC activation results most likely from DAT endocytosis (Zhu et al., 1997; Daniels and 
Amara, 1999; Melikian and Buckley, 1999; Chi and Reith, 2003; Sorkina et al., 2005; Eriksen et al., 
2009) although an initial rapid trafficking-independent inactivation of the transporter might occur at 
the plasma membrane (Mazei-Robison and Blakely, 2005) as also reported for the SERT (Jayanthi 
et al., 2005). Remarkably, the functional effect of PKC activation on DAT is not directly coupled to 
DAT phosphorylation (Granas et al., 2003; Cervinski et al., 2005) even though PKC phosphorylated 
serines in the DAT N-teminus at several positions (Foster et al., 2002; Granas et al., 2003; Gorentla 
et al., 2009); hence, it was shown that truncation of the distal N-terminus containing these serines, 
or mutation of the serines to alanines, did not affect DAT down-regulation in response to PMA 
(Granas et al., 2003).   
It is, therefore, highly interesting that recent studies have suggested the involvement of another 
post-translational modification, ubiquitination, in PKC activated DAT down-regulation (Miranda et 
al., 2005; Sorkina et al., 2006; Miranda et al., 2007). Ubiquitination is a widespread post-
translational modification regulating protein homeostasis in several ways. Miranda et al. showed 
that DAT was constitutively ubiquitinated and that this was augmented upon PMA stimulation 
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(Miranda et al., 2005). The ubiquitination was dependent on the presence of three lysines in the 
intracellular DAT N-terminus (Lys19,  Lys27,  Lys35) and concomitant mutation of these to 
arginines essentially abolished both ubiquitination and phorbol ester stimulated DAT down 
regulation (Miranda et al., 2007).  Furthermore, fluorescence resonance energy transfer 
experiements (FRET) experiments with CFP-tagged DAT and YFP-tagged ubiquitin, demonstrated 
that ubiqutination was most prominent in endosomes supporting a role for ubiquitination as a signal 
for endocytosis (Miranda et al., 2005). In addition, an E3 ubiquitin ligase, NEDD4-2 was 
discovered in a small interfering RNA (siRNA) screen for proteins important for PKC-mediated 
DAT internalization in an endothelial cell line (Sorkina et al., 2006). Of note, knock-down of 
several other E3 ubiquitin ligases did not affect DAT endocytosis in the siRNA screen suggesting a 
specific requirement for NEDD4-2. In the siRNA screen, the ESCRT machinery-associated proteins 
epsin and Eps15/Eps15R were also identified as being important for PMA-mediated DAT 
endocytosis (Sorkina et al., 2006). Since DAT likewise colocalizes with overexpressed Hrs 
(Miranda et al., 2005), an endosomal sorting complex required for transport (ESCRT) 0 component, 
it is conceivable that ubiquitnated DAT is sorted by the ESCRT machinery. This is also in 
agreement with the fact that PKC-activation increased DAT degradation in HeLa and MDCK 
(Daniels and Amara, 1999; Miranda et al., 2005). It should be noted, however, that other studies 
have suggested that PMA-internalized DAT is recycled back to the plasma membrane (Melikian 
and Buckley, 1999; Sorkina et al., 2003; Sorkina et al., 2005). Of additional interest, Mortensen et 
al., identified a mitogen-activated protein kinase phosphatase, MKP3, as an inhibitor of PKC 
mediated DAT internalization acting downstream of the DAT ubiquitination (Mortensen et al., 
2008).  
Melikian and co-workers have recently reported that the intracellular DAT C-terminal motif that 
appeared necessary constitutive was also necessary for PKC-mediated DAT internalization (Holton 
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et al., 2005). The motif is relatively well conserved among NSS proteins and mutating the motif in 
NET also resulted in impaired transporter internalization (Holton et al., 2005). Further studies 
showed that alanine substitutions of only residues 587-590 appeared sufficient to abolish PKC-
mediated DAT down-regulation and accelerate constitutive DAT internalization (figure 6). Based 
on these results it was suggested that the four residue stretch is part of an endocytosis braking 
mechanism that is relieved upon PKC stimulation (Boudanova et al., 2008). It is noteworthy that the 
Figure 6: Ubiquitination and interaction with the endocytic machinery orchestrate PKC-mediated 
DAT internalization. 
According to (Sorkina et al. 2006), activation of PKC by phorbol esters (PMA) induces ubiquitination 
of the DAT N-terminus by the E3 ubiquitin ligase NEDD4-2. This results in endocytosis of DAT from 
the plasma membrane to endocytic compartments assisted by proteins in the endocytic machinery 
such as Eps15, Epsin and Hrs – possibly through interaction of these proteins with DAT. 
Additionally, activation of PKC has been hypothesized to mediate the release of an unknown protein 
factor (green with circle with ?) that interacts with a motif in the DAT C-terminus and in its bound 
state acts as an endocytic brake on the transporter (Boudanova et al. 2008). However, a possible 
relationship between the two mechanisms has not been elucidated. The phosphatise MKP3 is believed 
to antagonize PKC-mediated internalization by stabilizing DAT in the plasma membrane (Mortensen 
et al., 2008) 
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same residues have been suggested to bind the COPII coat component, Sec24D in several members 
of the NSS family, suggesting a role of this region also in transporter folding and ER export (Farhan 
et al., 2007). Nevertheless, the relationship between this C-terminal motif and ubiquitination of the 
N-terminus in PKC mediated DAT endocytosis has not been clarified and awaits further 
investigations.  
Additional kinase pathways have been shown to affect DAT surface expression. This includes 
downstream effectors of insulin signalling such as phosphatidylinositol 3-kinase (PI3K) and Akt. 
Inhibitors of both PI3K and Akt as well as overexpression of a dominant negative Akt mutant in 
heterologous cells decrease DAT surface levels (Carvelli et al., 2002; Garcia et al., 2005). An in 
vivo role of this pathway in regulating DAT levels was supported by studies of rats depleted of 
insulin by the diabetogenic agent streptozotocin. In these rats both Akt function and DAT surface 
expression was markedly reduced (Williams et al., 2007). There is also evidence that DAT is 
subject to regulation by mitogen-activated protein kinase (MAPK), i.e. MAPK inhibitors was 
shown to decrease dopamine uptake both in transfected HEK293 cells and in striatal synaptosomes. 
The effect may both involve alteration in DAT transport capacity and redistribution of DAT from 
the plasma membrane to the cytosol (Moron et al., 2003). DAT might moreover be subject to 
regulation by phosphatases, e.g. DAT has been proposed to exist in a complex with protein 
phosphatase 2A, similar to what have been suggested for SERT (Bauman et al., 2000). 
 
 
Regulation of DAT by substrates and inhibitors 
As previously described, amphetamine increases extracellular dopamine both by acting as a 
competitive substrate and mediating reversal of transport. Another mechanism by which 
amphetamine increases extracellular dopamine is by inducing a redistribution of DAT away from 
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the cell surface (Saunders et al., 2000; Chi and Reith, 2003; Sorkina et al., 2003; Kahlig et al., 
2006). The redistribution induced by amphetamine was blocked by cocaine (Saunders et al., 2000), 
however Kahlig et al. demonstrated that the presence of intracellular amphetamine, rather than the 
DAT transport cycle itself, was responsible for the effect (Kahlig et al., 2006). As it was observed 
for amphetamine-induced efflux, CaMKII activity was shown to be necessary for this 
amphetamine-induced redistribution (Wei et al., 2007). However, unlike amphetamine-induced 
efflux, the mechanism of amphetamine-induced redistribution does not involve N-terminal 
phosphorylation (Cervinski et al., 2005). 
Recently, a biphasic effect of amphetamine on DAT trafficking was observed by Gnegy and co-
workers (Johnson et al., 2005a; Chen et al., 2009; Furman et al., 2009b). Preceding the 
amphetamine-induced internalization of DAT just described, a rapid increase in surface expressed 
DAT was observed already after a 1 minute treatment of rat striatal synaptosomes with 
amphetamine (Johnson et al., 2005a). The increase in surface DAT was dependent on PKCβ 
activity (Furman et al., 2009b). Furthermore, disruption of the SNARE complex seems to abolish 
amphetamine-induced trafficking of DAT to the surface (Furman et al., 2009b). 
 
In addition to amphetamine, the endogenous substrate dopamine has likewise been shown to induce 
DAT internalization in both DAT-expressing HEK293 cells and striatal synaptosomes (Saunders et 
al., 2000; Chi and Reith, 2003). On the other hand, the DAT blockers cocaine and methylphenidate 
have been demonstrated to increase DAT surface expression in cell line experiments and 
synaptosomes (Daws et al., 2002; Little et al., 2002). The apparent conclusion from these 
experiments is that substrates induce internalization whereas blockers modestly increase surface 
expression of DAT. This conclusion is supported by in vivo observations showing that users of the 
amphetamine derivative, methamphetamine, have less DAT in the striatum and that cocaine users 
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have an increased level of DAT (Little et al., 1993). The molecular mechanisms underlying 
substrate and blocker induced DAT surface regulation is still enigmatic, however a recently it has 
been suggested that an inward-facing conformation of DAT is more prone to internalization than an 
outward-facing conformation of DAT (Sorkina et al., 2009), thus the effect of the substrate might be 
to increase the probability of DAT being in an inward-facing conformation, and this might be part 
of the explanation for the substrate and blocker effect on DAT endocytosis. 
 
G protein coupled receptors and DAT 
GPCRs constitute the largest family of membrane proteins in the human genome and are 
responsible for the majority of transmembrane signal transduction in response to hormones and 
neurotransmitters (Gether, 2000). As described above, several signalling pathways affect DAT 
function. Thus, it is not surprising that GPCRs and their downstream signalling cascades are 
involved in the regulation of DAT. Intriguingly; there is recent evidence suggesting also direct 
physical interaction between DAT and specific GPCRs. including the dopamine D2 receptor and 
possibly also the orphan receptor GPR37 (Marazziti et al., 2007).   
The dopamine D2 receptor short (D2R) is expressed as a presynaptic autoinhibitory receptor in DA 
neurons and two studies have provided evidence that this receptor is likely to regulate DAT 
function (Bolan et al., 2007; Lee et al., 2007). Liu and co-workers provided evidence that D2R 
directly interacts with DAT with the interaction site depending on residues 1-33 in the DAT N-
terminus and residues 311-344 in the D2Rs third intracellular loop (Lee et al., 2007). 
Overexpressing D2R in a cell line together with DAT increased dopamine uptake by 30-60% 
independently of the presence of D2R ligands and through an increased DAT surface expression. In 
vivo experiments with Tat-conjugated N-terminal DAT peptides decreased co-immunoprecipation 
of D2R with DAT as well as dopamine uptake in synaptosomes, and rats injected with the effector 
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peptides displayed increased locomotor activity (Lee et al., 2007). However, these peptides might 
interfere not only with D2R binding to the N-terminus but also with binding of other proteins such 
as syntaxin1A that was shown to bind to exactly the same region of DAT (Binda et al., 2008). It is 
nevertheless of interest that a correlation between schizophrenia and loss of DAT/D2R interaction 
recently has been reported. Co-immunoprecipitation of DAT with D2R was reduced to 60% in 
samples from the striatum of patients with schizophrenia compared to the control group, and in 
samples from patients with bipolar disease no difference was observed (Lee et al., 2009). 
In contrast to what Lee et al. reported, Bolan et al., observed in HEK293 cells co-expressing DAT 
and D2R that D2R activation increased dopamine uptake (up to 50%) via stimulation of a pertussis-
toxin sensitive extracellular signal-regulated kinase (ERK) 1- and 2-dependent pathway. The 
increase in uptake was according to biotinylation experiments the result of an increase in DAT 
surface expression (Bolan et al., 2007). In the same study, co-immunoprecipitation experiments and 
BRET (bioluminescence resonance energy transfer) analyses indicated close proximity of DAT and 
D2R but no experimental evidence for a direct interaction was provided. Notably, an N-terminally 
truncated DAT was also co-immunoprecipitated, thus questioning the necessity for the DAT N-
terminus in the interaction (Bolan et al., 2007). Taken together, there is strong evidence from two 
studies (Bolan et al., 2007; Lee et al., 2007) that D2R causes an increase in dopamine uptake 
through an increase in DAT surface expression. However, it seems unclear at this stage to what 
degree the effect is mediated directly via a physical interaction between the two proteins or via D2R 
activation of intracellular signalling cascades (figure 7). The sites in D2R and DAT that mediate the 
putative physical interaction are also not resolved. Of note, another D2-class receptor, the dopamine 
D3 receptor, was shown to up-regulate DAT surface expression in transfected HEK293 cells upon 
activation, however it was not investigated whether DAT and the D3 receptor interact (Zapata et al., 
2007). 
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Scaffolding of DAT 
Protein scaffolding serves to organize proteins into supermolecular complexes to bring different 
molecular components in close proximity allowing them to work in concert thereby ensuring spatial 
and temporal control of cellular processes. Scaffolding proteins are characterized by the presence of 
often multiple protein interaction domains serving as assembly modules gluing together the proper 
interaction partners; i.e. by connecting membrane proteins to their downstream signalling partners 
or anchoring them in the right cellular microdomains. Little is known about DAT scaffolding and 
microdomain localization. As mentioned previously, electron microscopy studies of rat striatum 
indicated that DAT is restricted from the active zone of the presynapse but otherwise widely 
expressed along the axons (Hersch et al., 1997). Moreover, DAT was found to partially localize to 
Figure 7: The dopamine D2 receptor (D2Rs) regulates DAT function possibly via a direct 
interaction. 
Results from recent studies suggest that the D2Rs increases DAT surface expression and thereby 
dopamine reuptake capacity either through a direct interaction with the transporter (Lee et al. 2007) 
or by receptor activation and subsequent stimulation of MAPK/ERK signalling pathway (Bolan et al. 
2007). Through coupling to Gi, D2Rs exerts an autoinhibitory action on vesicular dopamine release. 
These effects both support a decrease of dopamine in the synaptic cleft. 
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membrane rafts both in cell lines and synaptosomes (Foster et al., 2002; Adkins et al., 2007), and in 
cell lines DAT mobility appeared dependent on an intact actin cytoskeleton (Adkins et al., 2007).  
 A number of studies have investigated putative proteins and protein domains involved in DAT 
scaffolding. This includes PDZ domains that represent one of the most widespread protein 
recognition domains in cellular scaffolding processes, PDZ domains bind short linear consensus 
motifs mostly located at the C-terminus of their interaction partners and are often found in several 
copies in the same protein (Nourry et al., 2003; Kim and Sheng, 2004). DAT has a canonical PDZ-
binding sequence at its C-terminus and in a yeast two-hybrid screen the dimeric PDZ domain 
protein PICK1 (protein interacting with C-kinase 1) was identified as a DAT interaction partner. 
This interaction, which was validated by co-immunoprecipitation experiments from brain tissue, 
was suggested to promote DAT surface expression and induce a clustering phenotype in transfected 
cells (Torres et al., 2001). However, Bjerggaard et al. later challenged these findings by showing 
that although PICK1 binds the extreme DAT C-terminus the interaction does not play a role in ER 
export and surface targeting of the transporter. Indeed DAT C-terminal residues were important for 
proper membrane targeting of DAT, but mutations in DAT were identified that specifically 
disrupted PDZ domain interactions without affecting surface targeting and mutations were 
identified that disrupted surface targeting without affecting PICK1 binding (Bjerggaard et al., 
2004). Thus, the functional significance of the DAT PICK1 interaction remains to be settled. It is 
interesting to note that for other binding partners such as the glutamate receptor subunit 2 (GluR2) 
of the AMPA receptor and the acid sensing ion channel 2A it has been shown that PICK1 might 
affect endocytosis/recycling (Hanley and Henley, 2005; Lin and Huganir, 2007) or serve to recruit 
PKC to facilitate phosphorylation (Baron et al., 2002), respectively, but none of these effects have 
so far been shown for DAT. 
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An interaction between the C-terminus of DAT and the focal adhesion scaffolding protein Hic-5 
was identified in a yeast two hybrid screen (Carneiro et al., 2002).  Co-immunoprecipitation and 
GST pulldown studies demonstrated that the interaction was mediated by the membrane proximal 
part of the C-terminus of DAT and the multiple LIM domain-containing half of Hic-5. In HEK293 
cells co-expressing Hic-5 and DAT, a decrease in dopamine uptake by 30% was observed. The 
decrease in transporter activity was attributed to a decrease in cell-surface level of DAT as 
demonstrated by cell surface biotinylation experiments (Carneiro et al., 2002). For SERT, which 
also can bind Hic-5, the interaction was suggested to promote translocation from a membrane-
skeleton associated fraction to a cytoskeleton-associated fraction in platelets. This translocation was 
proposed to facilitate SERT internalization (Carneiro and Blakely, 2006). 
Recently the synaptic vesicle protein synaptogyrin-3 was identified as yet another putative 
scaffolding protein interacting with DAT (Egana et al., 2009). It was demonstrated that the N-
terminus of DAT also was capable of pulling down purified synaptic vesicles and in the 
catecholaminergic cell PC12 and MD9D cell lines, both containing VMAT-positive vesicles, 
overexpression of synaptogyrin-3 with DAT increased DAT uptake activity whereas synaptogyrin-3 
siRNA reduced DAT activity. Likewise, DAT activity was reduced by 40% in the presence of the 
VMAT2 inhibitor reserpine in PC12 cells but not in HEK293 cells. Based on these findings, the 
authors suggest the challenging hypothesis that the interaction between synaptogyrin-3 and DAT 
couples DAT to synaptic vesicles and that this coupling leads to an increase in DAT activity and 
presumably a more efficient filling of synaptic vesicles (Egana et al., 2009). In addition it was 
recently shown that not only DAT localize in a complex with the synaptic vesicles but also the 
enzymes catalyzing the synthesis of dopamine suggesting a complete dopamine synthesis and 
transport scaffold on the synaptic vesicles (Cartier et al., 2009). 
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Implications for a physiological role of dynamic DAT regulation 
The majority of the abovementioned studies have been carried out in ex vivo systems and there are 
no studies directly showing that dynamic DAT regulation in the plasma membrane affects the 
overall function of the DA system. As already discussed, data from genetic mouse models support 
an essential role for DAT in regulating DA signalling, however as a model for dynamic regulation 
of the DAT in the plasma membrane the genetic models have some shortcomings since chronic 
alterations in DAT levels inevitably will lead to adaptations in the DA signalling machinery (Jones 
et al., 1998). Therefore, pharmacological studies might to some extent more appropriately describe 
a potential effect of cellular regulation of DAT in the plasma membrane. Several studies have been 
carried with focus on the effect of DAT inhibitor occupancy and physiological parameters both in 
humans and mouse. These studies have primarily been undertaken to study the paradox that some 
high-affinity DAT blocker produce a locomotor effect/have addictive properties whereas others 
display no behavioural effects (Desai et al., 2005a; Desai et al., 2005b). A relationship between 
DAT occupancy measured using positron emission tomography (PET) and the subjective feeling of 
high has been studied in cocaine users. The result was that DAT occupancy of approximately 50% 
was required to produce a feeling of high (Volkow et al., 1997). Similar results have been obtained 
in animals where a high DAT occupancy was required to produce any behavioural effects (Desai et 
al., 2005a). However, the occupancy alone is not the only parameter of DAT blockers that 
determines the behavioural effect. It also seems that the rate of occupancy is highly important for 
producing behavioural effects upon DAT blocking. As cocaine produces greater locomotor reponse 
than does benztropines which have a slower rate of occupancy, but same efficacy (Desai et al., 
2005a). 
Overall pharmacological and behavioural data suggest that acute blockade of DAT at a high level of 
DAT occupancy together with a fast rate of occupancy induce detectable physiological effects in 
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both animals and humans. This might be translatable into potential effects of cellular DAT down-
regulation. Most effects changing DAT surface expression measured in cell systems are in the range 
of 10-50%. This would suggest that only maximal responses would generate measureable 
physiological responses according to the pharmacological data. However, as mentioned the rate of 
occupancy is also critical and, thus dynamic fast cellular down-regulation is likely to generate 
detectable effects on DA signalling that in turn might be detectable at the behavioural level. 
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SUMMARY OF RESULTS 
 
 
 
Study 1: Analyzing DAT trafficking in dopaminergic neurons 
Paper 1: Visualization of Dopamine Transporter Trafficking in Live Neurons by Use of 
Fluorescent Cocaine Analogs 
 
Motivation: With the development of the fluorescent cocaine analogs from Dr. Amy H. Newman’s 
laboratory at NIDA-IRS, National Institute of Health, it became a possibility to study dynamic 
trafficking aspects of DAT in a native system. Previously, the study of DAT dynamics in a native 
system has been hampered by the lack of tools to probe DAT, and accordingly most studies have 
been carried out in transfected cell lines that lack the complexity of DA neurons. By use of JHC 1-
64 in combination with the establishment of lentiviral transduction we therefore set out to 
investigate DAT trafficking properties in primary cultures of DA midbrain neurons.  
 
Summary: In HEK293 cells expressing DAT, the use of the cocaine analog, JHC 1-64, was 
verified as a tool for studying DAT trafficking. Several essential properties making JHC 1-64 a 
proper tool for studying DAT trafficking was observed: 1) JHC 1-64 binding is highly specific and 
binds DAT with a high affinity thereby providing a high signal-to-noise ratio; 2) JHC 1-64 does not 
permeate the plasma membrane, and therefore only labels surface DAT and 3) JHC 1-64 has an 
extremely slow off-rate, which is important for tracking DAT over en extended period of time.. 
In DA primary cultures JHC 1-64 specifically labelled neurons expressing obligate dopamine 
markers such as tyrosine hydroxylase, VMAT2, and DAT. The labelling was uniform in the DA 
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neurons and FRAP (fluorescence recovery after photobleaching) experiments showed a 
bidirectional movement of DAT in the neuronal extensions and a high DAT mobility. 
We were unable to detect any PKC regulation of DAT in the DA neurons when probing DAT 
internalization and dopamine uptake, although we did detect PKC activity in the DA neurons and 
observed PKC-mediated DAT internalization in HEK293 cells. However, a notable constitutive 
DAT internalization was evident. We further characterized the constitutive DAT internalization to 
be dynamin-dependent and displayed a partial colocalization with the early endosomal marker Rab5 
and the transferrin receptor. 
 
Study 2: Sorting of constitutively internalized DAT 
Paper 2: Constitutively Internalized Dopamine Transporter is Primarily Sorted to a Late 
Endosomal/Lysosomal Pathway in both Dopaminergic Neurons and Cell Lines 
 
Motivation: Based on the observations made in Paper 1 we wanted to further characterize the 
constitutive internalization of DAT in DA neurons. Previously, constitutive DAT internalization has 
been observed in cell lines, and it has been suggested that constitutively internalized DAT is sorted 
to recycling. We wanted to study the sorting fate of constitutively internalized DAT in the DA 
neurons together with a comparison of the DAT sorting pattern in cell lines. In this way we would 
be able to determine whether the constitutively internalized DAT is dependent on the cellular 
background as was the case for PKC-mediated internalization and whether constitutively 
internalized is sorted to degradation and/or recycling. 
 
Summary: To study the constitutive DAT internalization in the two cell lines HEK293 and 
1Rb3An27 we employed a new DAT construct, TacDAT. TacDAT is a fusion between the 1 TM 
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protein Tac and DAT, thus creating an extracellular N-terminal to which we added the high affinity 
FLAG antibody epitope. TacDAT displayed properties similar to wild-type DAT and enabled the 
quantification of transporter internalization in an ELISA assay and quantification of transporter 
sorting in a microscope-based assay. In HEK293 cells we show that both the inhibitor of lysomal 
proteases and the inhibitor of lysosomal degradation/recycling, monensin, increase the intracellular 
accumulation of DAT. Incubation of cells with monensin did not alter in the cell surface expression 
of DAT, and we conclude therefore that the monensin effect on intracellular TacDAT accumulation 
is not due to an inhibition of TacDAT recycling. Together with the observation that constitutively 
internalized TacDAT colocalized with the late endosomal marker EGFP-Rab7 we suggest that DAT 
is primarily sorted to a late endosomal/lysosomal pathway in HEK293. A similar pattern was 
observed in the DA cell line 1Rb27An3 where a quantification of colocalization between 
constitutively internalized TacDAT and the endosomal markers EGFP-Rab4, -Rab7, -Rab11, 
showed a significantly higher colocalization with Rab7 than with the recycling endosomal marker 
Rab11. This sorting pattern was distinct from the well described recycling protein, the ß2-adrenergic 
receptor, which displayed a significantly higher colocalization with Rab11. Probing DAT 
internalization with JHC 1-64 in 1Rb3An27 also exhibited the highest colocalization with EGFP-
Rab7. Finally, examining the sorting of constitutively internalized DAT in DA neurons using JHC 
1-64 in cultures transduced with the EGFP-tagged endosomal markers DAT, again, displayed the 
highest degree of colocalization with EFGP-Rab7. Additionally, constitutively internalized DAT 
also colocalized with the lysosomal marker, LysoTracker Green. We conclude that constitutively 
internalized DAT sorts to a late endosomal/lysosomal pathway in both cell lines and cultured DA 
neurons. 
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Study 3: The DAT C-terminus activates PICK1 
Paper 3: Membrane Localization is Critical for Activation of the PICK1 BAR domain 
 
Motivation: The DAT has previously been shown to bind the PDZ domain protein PICK1 in 
several systems (Torres et al., 2001; Bjerggaard et al., 2004; Madsen et al., 2005) via its extreme C-
terminus. However, the function of the interaction remains unclear. Previously, it has been shown 
that co-expression of PICK1 and the interaction partner glutamate receptor subunit 2 (GluR2) 
causes a co-clustering of both proteins (Perez et al., 2001).  
The aim of the present study was to understand the molecular determinants in PICK1 underlying 
this co-clustering phenotype. This was especially interesting in relation to the recently identified 
Bin/amphiphysin/Rvs (BAR) domain in the C-terminal half of PICK1. BAR domains are 
homodimeric modules that mediate curvature-dependent recognition and/or tubulation of lipid 
membranes (Peter et al., 2004; McMahon and Gallop, 2005). They are present in many proteins 
involved in cellular trafficking. The strongest evidence for a role of the BAR domain in PICK1 
function is the demonstration that transfection of wild-type (wt) PICK1 into cerebellar Purkinje 
cells derived from PICK1 knock-out mice can restore LTD, which was not observed for a PICK1 
mutant containing a mutant BAR domain deficient in lipid vesicle binding (Steinberg et al., 2006). 
Furthermore, understanding the molecular properties of the interaction between PICK1 and its 
binding partners might elucidate a role for the DAT/PICK1 interaction. 
 
Summary: In COS7 cells, co-expression of PICK1 together with membrane proteins containing a 
C-terminal PICK1 binding sequence (including the DAT C-terminus fused to Tac) results in a co-
clustering of both proteins that is not observed when each protein is expressed on its own. However, 
adding a PICK1 binding sequence to a cytosolic protein (eCFP) and coexpressing the protein with 
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PICK1 does not induce the clustering phenotype. This suggests that PICK1 needs to be recruited to 
the plasma membrane to induce the clustering phenotype which was supported by an experiment 
adding a myristoyl anchor to PICK1. This membrane localizing modification of PICK1 induced the 
clustering phenotype. Finally, it was shown that the co-clustering of PICK1 and the membrane 
protein ligand colocalized primarily with a Rab11 positive compartment. The data support 
altogether that in the absence of PDZ ligand, the PICK1 BAR domain is inhibited through a PDZ 
domain-dependent and linker-dependent mechanism. Moreover, they suggest that unmasking of the 
BAR domain’s membranebinding capacity is not a consequence of ligand binding to the PDZ 
domain per se but results from, and coincides with, recruitment of PICK1 to a membrane 
compartment. 
 
Study 4: Effects of DAT on D2R 
Paper 4: The dopamine transporter impairs dopamine D2 receptor surface expression/ 
signalling and reveals promiscuous monoamine transporter/receptor interaction 
 
 
Motivation: Recent papers have described a direct interaction between DAT and the D2R, an 
interaction that displays functional effects on DAT (Bolan et al., 2007; Lee et al., 2007). Given that 
other membrane protein interaction partners have been shown to affect D2R signalling (Rashid et 
al., 2007) we hypothesized that DAT might influence D2R function. 
 
Summary: Transient over-expressing DAT with D2R in HEK293 cells reduced surface expression 
of D2R while DAT surface levels remained unaffected. Furthermore ß-Arrestin2 recruitment to 
D2R was compromised and D2R-mediated inhibition of cAMP accumulation was reduced as a 
consequence of the reduced surface level expression of D2R. The effects of DAT on D2R surface 
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expression and signalling was not unique for DAT and D2R. Thus, transient co-expression of ß2AR 
with DAT resulted in reduced surface levels of ß2AR. In addition, co-expression of the SERT with 
D2R appeared to modulate the ß-Arrestin2 recruitment to D2R and the D2R-mediated inhibition of 
cAMP accumulation in a manner similar to co-expression of DAT. 
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DISCUSSION 
 
The cellular environment determines properties of DAT trafficking 
As already described in the introduction, the DA neuron is a highly complex cell type with a large 
axonal tree (figure 2). Therefore, it is important to take into account the native environment when 
studying the cellular regulation of proteins as different environment is likely to affect the properties 
of the behaviour of the protein. To the best of our knowledge, the use of the fluorescent cocaine 
analogues has for the first time allowed the direct visualization of DAT dynamics in a native 
environment. The distribution of DAT in the membrane when visualized with JHC 1-64 is uniform 
on the soma and along the neuronal extensions. This distribution is in agreement with studies of 
DAT in DA neurons in the brain. With immunoelectron microscopy DAT has been detected in the 
plasma membrane of DA neurons in both the midbrain and the target area (Nirenberg et al., 1996a; 
Hersch et al., 1997; Sesack et al., 1998). Using FRAP experiments we established that DAT 
exhibited bidirectional movement in the neuronal extensions; thus, we found no evidence of 
unidirectional targeting. Furthermore, the movement of DAT in the membrane was high with a 
diffusion constant of 0.5-1.1 10-9 cm2/sec and with a high mobile fraction (> 70%). This diffusion is 
consistent with a relatively freely diffusing membrane protein (Lippincott-Schwartz et al., 2001), 
although marginally faster than what has been observed for DAT in cell lines with a diffusion 
coefficiency around 0.3–0.4 × 10−9cm2/sec (Adkins et al., 2007; Sorkina et al., 2009). However, it 
should be noted that the previously published FRAP experiments were all conducted on DAT 
tagged N-terminally with a fluorescent protein, and it cannot be excluded that the addition of a 
bulky fluorophore to DAT could affect the DAT diffusion rate. It might also represent biological 
difference, since variations in DAT mobility between cell lines (Adkins et al., 2007) and between 
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subcellular regions (Sorkina et al., 2009) has 
been observed, suggesting that the transporter 
mobility is subject to cellular regulation 
possibly through protein protein interactions. 
The PKC regulated DAT endocytosis is the 
most well described DAT regulatory 
mechanism and therefore it was a surprise that 
we did not observe for the endogenous DAT in 
DA neurons. PKC activation was still 
detectable in the DA neurons as measured by 
the PKC activity FRET sensor CKAR. Thus, it 
is most likely not due to a decreased PKC 
activity in the neurons. To test whether the medium used for the neurons in some way could 
antagonize the effect of PKC activation, DAT-mediated dopamine uptake in our cultures were 
carried out after serum starvation and still we did not see any effect of PMA on uptake (figure 8). 
Previously PMA has been shown to decrease dopamine uptake (Vaughan et al., 1997; Chi and 
Reith, 2003) and decrease cell surface biotinylated DAT (Chi and Reith, 2003) in striatal 
synaptosomal preparations. However, the effects are observed at a concentration of 10 μM PMA. 
PMA is thought to activate PKC at a range from 1-100nM and structurally, phorbol esters resemble 
nonionic detergents, and to avoid nonspecific effects attributable to detergent properties, it is 
desirable to keep their concentrations low. PMA has nevertheless recently been reported to decrease 
the dopamine uptake by approximately 25% in another DA primary culture preparation. This was 
observed using a concentration of PMA as low as 100 nM (Hoover et al., 2007). The primary 
cultures used in this study were prepared from prenatal (E15) rats and cocultured with striatal 
Figure 8: Dopamine uptake in serum starved 
dopaminergic neurons. Dopamine uptake was carried out 
as in figure 9, Paper 1 (Eriksen et al., 2009) with the 
exception that the neurons were preincubated in uptake 
buffer for 2 hours before 30 minustes incubation with 
PMA (1 μM) or vehicle (0.1% DMSO). PMA treatment 
did not affect dopamine uptake (p= 0.41, n=3, one 
sample t-test) 
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neurons. It is interesting to speculate that co-culturing with striatal neurons might provide an 
environment that confers PKC sensitivity to the DAT in the DA neurons. Our experiment were 
carried out in cultures from P1-P3 rats, thus the maturity of the neurons might be another factor that 
determines PMA sensitivity of the DAT. Recently, Amara and co-workers described that the MAP 
kinase phosphatase, MKP3, antagonizes PKC-mediated DAT down regulation (Mortensen et al., 
2008). Interestingly MKP3 was differentially expressed in different cell lines, and it would highly 
interesting to see if knock-down of MKP3 would confer PKC sensitivity to the DA neurons. 
 
Sorting of DAT to a late endosomal/lysosomal pathway 
Constitutive DAT internalization has been described in several cell lines (Chi and Reith, 2003; 
Loder and Melikian, 2003; Sorkina et al., 2005). However, in this study the constitutive 
internalization has been described for the first time for endogenous DAT in DA neurons. The 
constitutive DAT internalization in DA neurons was not sensitive to PKC inhibition or activation 
showing that it was a PKC independent phenomenon, and as opposed to the PKC-mediated 
internalization it was observed in both DA primary cultures and cell lines. 
Curiously we were only able to observe internalization events in the soma and the proximal 
dendritic regions. When evaluating DAT in the distal extension, we did not observe any 
internalization events even though the neurite extensions represent the vast majority of DAT 
containing membrane in the preparations (figure 9). Thus, despite a profound DAT internalization 
in the soma, the amount internalized is small as compared to the extensive DAT/JHC 1-64 signal 
observed throughout the membrane of the DA neurons. The inability to detect DAT internalization 
in distal neuronal could be a matter of detection and resolution limitations in the confocal 
microscopy approach. Application of recently developed super-resolution microscopy techniques 
(Henriques and Mhlanga, 2009) could to help to resolve whether the lack of internalization in the 
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extensions represents a true biological phenomenon. Interestingly immunoelectron microscopy 
studies have also described that the majority of DAT located to intracellular membranes was 
observed in the midbrain and in the soma and proximal dendrites of the neurons (Nirenberg et al., 
1996b; Hersch et al., 1997; Nirenberg et al., 1997). Taken together, it is tempting to speculate that 
the soma of the DA neuron might represent an area primed for DAT internalization. This hypothesis 
is in agreement with an observation in cell lines, where a internalization-willing DAT mutant 
resided less in the cellular extrusions (Sorkina et al., 2009). 
 
The sorting pattern of constitutively internalized DAT observed in HEK293 cells, 1Rb3An27 cells 
and DA neurons suggest that the internalized DAT is sorted primarily to degradation. The sorting 
pattern was determined using several different approaches to minimize the chances that a distinct 
sorting pattern was observed due to assay artifacts. The first approach used in HEK293 was to 
perturb the sorting pathways in HEK293 cells chemically. The inhibitor of lysososmal proteases, 
leupeptin was used to perturb lysosomal function and the sodium ionophore monensin was used as a 
general perturbation of endosomal maturation. Monensin is believed to function by dissipating the 
proton gradient across membrane either by being a proton ionophore or by having an indirect effect 
on the Na+/H+ exchanger (Mollenhauer et al., 1990). As endosomal maturation is dependent on a 
Figure 9: JHC 1-64 labelling overlaps with the axonal marker Tau. 
Dopaminergic cultures (as described in Paper 1) were incubated with 10 nM JHC 1-64 for 20 minutes at RT before 
fixation. Then the specimens were blocked and permeabilized and incubated with either mouse anti-Tau1 (1:500) and 
secondary detection was done with Alexa Fluor 488 goat anti-mouse or Alexa Fluor 488 goat anti-rabbit, 
respectively. Most narrow neuronal extensions labeled with JHC 1-64 co-stained also for Tau-1. 
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sequential lowering of pH (figure 10), 
monensin will affect sorting both to 
recycling and to lysosomal 
degradation (Maxfield and McGraw, 
2004). Looking at the intracellular 
accumulation of TacDAT in HEK293 
cells, we saw an effect of both 
leupeptin and monensin. However, 
when testing the effect of monensin 
on DAT surface expression we did 
not see any effect. We conclude 
accordingly that both the effect of 
leupetin and of monensin on 
intracellular TacDAT are due to a blockade in the degradative pathway. This was further supported 
when determining the sorting pattern of TacDAT, using EGFP-tagged Rab proteins, which act as 
molecular switches in coordinating vesicular trafficking. Rab proteins can be used to identify 
intracellular compartments as different Rabs locate to specific endosomal compartments (Stenmark, 
2009). We used 4 different EGFP-tagged Rabs (figure 10): Rab4, a marker of early endosomes and 
involved in recycling from early endosomes (often referred to as ‘short loop recycling’), Rab5 also 
a marker of early endosomes and involved in endocytosis, Rab7, a marker of late endosomes, and 
finally Rab11 a marker of recycling endosomes and involved in ‘long loop recycling’. 
In all systems tested DAT colocalized primarily with Rab7 and to some degree the early endosomal 
markers Rab4 and Rab5. This localization was independent of the way we probed DAT 
Figure 10: The endocytic pathways. The figure shows the endocytic 
itineraries followed by various proteins. The sorting endosome is 
also known as the early endosome. The indicated t½ are 
approximate values and cell-type dependent. The Rab GTPases 
(Rab 4, Rab5, Rab7, and Rab11) are located to their site of action 
(the figure is modified from: (Maxfield and McGraw, 2004) 
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internalization, i.e. using antibodies or JHC 1-64. Additionally, we observed a profound 
colocalization of internalized DAT with the lysosomal marker Lysotracker. 
Altogether our data suggest that constitutively internalized DAT is sorted to degradation both in cell 
lines and in DA neurons. 
Previously, observations regarding sorting of constitutively internalized DAT all suggest that DAT 
is sorted to a recycling pathway (Loder and Melikian, 2003; Sorkina et al., 2005; Furman et al., 
2009a). In PC12 cells DAT has been suggested to have a fast constitutive recycling, however, when 
treating the cells with bafilomcyin, an inhibitor of vesicular proton pumps, no effect was seen on the 
surface expression of DAT, whereas a marked effect was seen on the well-known recycling 
membrane protein, the transferrin receptor. The conclusion that DAT recycled fast in PC12 cells 
was based on experiments at 18° C, which was supposed to inhibit exocytosis without interfering 
with endocytosis (Loder and Melikian, 2003), which is a simplification at best (Sorkin et al., 1991). 
A recent study has claimed that DAT recycles via a Rab11 dependent pathway as DAT plasma 
membrane DAT was increased upon co-expression of constitutively active Rab11, however, all 
experiments were steady state experiments and interestingly a dominant negative Rab11 did not 
exhibit any effect compared to a GFP control when quantifying DAT surface binding (Furman et 
al., 2009a). 
Taken together, the data supporting a recycling of constitutively internalized DAT are open for 
discussion, however, it can not be excluded that recycling plays a role in some systems. 
 
Studying DAT trafficking with the silent partner Tac 
In both paper 1 and 2, fusions between Tac and DAT are used to elucidate properties of DAT. Tac 
is a 1TM protein that has been used in several studies as a silent carrier used to determine 
trafficking signal in protein sequences studies (Mu et al., 2003; Lavezzari et al., 2004; Holton et al., 
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2005; Lavezzari and Roche, 2007). In paper 2 we use a head to tail fusion of the DAT N-terminus 
to the Tac C-terminus and show that this TacDAT displays properties similar to DAT with regard to 
transport and trafficking. For future purposes it is interesting to note that a fully functional head to 
tail fusion between SERT and Tac has been made (Jørgensen and Gether, unpublished 
observations). With a collection of Tac/transporter fusion proteins it will be possible to screen 
transporters for similarities and differences in trafficking patterns. 
Furthermore, as shown in paper 3, Tac can also be used to isolate DAT primary sequence signals. 
This is parallel to what been done before with DAT (Holton et al., 2005). By use of the TacDAT 
C24 (the distal 24 C-terminal amino acids in DAT fused to Tac) construct it was shown that this 
construct was able to cocluster PICK1 when the two proteins were expressed in COS7 cells. This 
phenotype is not observed for the full length DAT. When co-expressed with PICK1 DAT does not 
relocate to an intracellular compartment and cocluster with PICK1 (Bjerggaard et al., 2004). Based 
on these observations and the fact that PICK1 has been shown to exert trafficking effects on other 
interaction partners it is interesting to speculate that the DAT C-terminus by default is shielded in 
full length DAT and therefore is not influenced by co-expression of PICK1. Moreover, it is 
interesting to note that PICK1 in Paper 3 colocalizes primarily with Rab11 when co-expressed with 
its membrane protein ligands. This sorting pattern is different from what was observed and 
described for DAT in Paper 2. It is therefore also tempting to speculate that a regulatory mechanism 
could expose the DAT C-terminus and facilitate PICK1 binding and thereby divert DAT sorting to a 
Rab11 recycling pathway, sorting pattern is observed for the Tac constructs with a PICK1 binding 
sequence. Additionally the PICK1 binding has been shown to regulate the recycling of GluR2 
another PICK1 binding partner (Lin and Huganir, 2007).  
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Promiscous effects of DAT on D2R 
The DAT/D2R interaction has previously been show to increase DAT function (Bolan et al., 2007; 
Lee et al., 2007).  In the current study we show DAT also regulate D2R function. DAT exhibited a 
profound suppressive effect in HEK293 cells. An effect that was specific for DAT and D2R since 
DAT also suppressed the expression of the ß2-adrenergic receptor. DAT affected both the G-protein 
coupled and ß-arrestin2-dependent signalling of D2R. Whereas the effect of G-protein signalling 
could be explained by the suppressive effects on D2R expression whereas the effect on the ß-
Arrestin recruitment most likely was not an effect of the suppressed D2R expression. 
It was not determined whether the functional effects were a consequence of the interaction, and with 
the presumably not very well-defined interaction sites it is potentially a difficult task to establish a 
link between the functional effects of DAT on D2R and the interaction. However, the data suggests 
that DAT is capable of regulating function of GPCR. This concept is not new since other GPCRs 
have previously been shown to regulate the function of D2R. Expressing D2R with the dopamine 
D1 receptor that in itself couples to Gs proteins results in a receptor complex that show enlarged 
Gq/11 mediated increase in intracellular calcium upon dopamine activation (Rashid et al., 2007). 
D2R can also directly interact with the Adenosine A2 receptor (Canals et al., 2003) and A2 agonist 
treatment of striatal membranes decreased agonist affinity for striatal D2R (Ferre et al., 1991). It 
will be interesting to see if DAT regulates D2R in DA neurons – whether a knockdown of DAT 
would increase the expression of D2R and modify its signalling properties. A chronic knock down 
of DAT as in a DAT KO mouse would not be a suitable model since the increased extracellular 
dopamine in the DAT KO mice causes a desensitization-mediated down-regulation of D2R (Giros 
et al., 1996). 
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Figure 11: Generation of a functional pHluorin-DAT. A) Six different pHluorin-DAT constructs were generated with 
two different N-terminal linker and thre different C-terminal linkers around the inserted pHluorin. -, no linker +2 gly 
denotes a two glycine linker, long linker. The constructs were generated by engineering BsrGI into the region 
encoding the extracellular loop 2 at position 198 in DAT in the pCDNA3 synDAT construct using a standard 
QuickChange protocol. pHluorin was amplified from a pHluorin-ß2-adrenergic construct (Yudowski et al., 2009) 
with different primer sets. Two sense primers, both with a BsiWI site and the one with an additional 2 glycine linker. 
Three antisense primers, all with a BsiWI site, and one with an additional 2 glycine linker. Combining these primers 
six versions of pHluorin was generated digested with BsiWI and inserted into BsrGI digested pcDNA3 synDAT with a 
BsrGI site. The sequences of the constructs were verified by sequencing. B) Expression of the six pHluorin-DAT 
constructs in HEK293 cells. : HEK293 cells or CAD cells transfected with pCDNA3 pHluorin-DAT 1-6 were seeded 
in 8 well LabTek chambers coated with poly-ornithine. The cells were used for experiments two days after 
transfection. The cells were imaged in HEPES buffered saline (25 mM HEPES, pH 7.4, with 130 mM NaCl, 5.4 mM 
KCl, 1.2 mM CaCl2, 1.2 mM MgSO4, 5 mM D-glucose). Imaging was performed as described in Paper 1. 
 
Preliminary data and perspectives in the study of DAT trafficking 
 
pHluorin-DAT: a probe for DAT membrane insertion 
As our data per se does not exclude recycling and recycling might be a regulated feature in DAT, 
efforts were made to enable direct visualization of membrane insertion of DAT. For other 
membrane proteins, fusion with the fluorescent protein pHluorin has proven highly successful in 
detecting insertions in to the plasma membrane (Yudowski et al., 2006; Yudowski et al., 2007). 
pHluorin displays pH-sensitive fluorescence, i.e. when exposed to extracellular environment 
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(pH~7.4), it is highly fluorescent. On the other hand, when exposed to the acidic environment in the 
lumen of endosomal compartments (pH<6.0), the fluorescence is rapidly and reversible quenched. 
Accordingly, fusion of pHluorin to the extracellular part of DAT will enable discrimination between 
transporters localized at the cell surface and transporters localized in intracellular compartments. 
pHluorin-DAT constructs were made by inserting pHluorin into the second extracellular loop of 
hDAT. By combining 2 different C-terminal linkers and 3 different C-terminal linkers on pHluorin, 
six different constructs were made (figure 11A). When expressed in HEK293 cells, the 6 different 
pHluorin-DAT constructs had a maximum dopamine uptake that was 10% of wild type with none of 
the construct being significantly better than the other (data not shown), and when evaluating the 
expression by microscopy it was clear that a lot of cells displayed an intracellular accumulation of 
pHluorin-DAT (figure 11B). The intracellular accumulation likely represents ER retained pHluorin-
DAT as the pH in ER is 7.4 (Wu et al., 2001) and therefore pHluorin-DAT will be visible in this 
intracellular compartment as opposed to other intracellular compartments with lower pH (figure 
10). Although a lot of cells displayed ER retention, cells expressing low levels of pHluorin-DAT 
exhibited no intracellular fluorescence but only plasma membrane associated fluorescence. 
Therefore, it seems that high levels of pHluorin-DAT expression induce ER retention, most likely 
due to misfolding of the pHluorin-DAT construct. The misfolding phenotype was tried rescued by 
growing the cells at 30 °C with no effect (data not shown). However, since cells with low 
expression displayed a DAT distribution similar to wild type DAT and dopamine uptake was 
detectable, it was assumed that surface targeted DAT was functional. 
Next the pHluorin-DAT #3 construct was expressed in the DA cell line CAD (Qi et al., 1997) to test 
the properties in a DA cell line. As in HEK293 cells, both cells with a distinct surface expression 
and cells with ER retained DAT were observed (figure 12A). Incubating the cells with an acidic 
ringer buffer (pH 5.3) quenched the pHluorin-DAT signal (figure 12A), and the signal could be 
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rescued by adding a neutral ringer buffer (pH 7.4). Finally, adding ammonium chloride which 
neutralizes the pH in intracellular compartment made a distinct vesicular pHluorin-DAT signal 
Figure 12: Expression of a functional pHluorin-DAT in CAD cells. 
A) CAD cells transfected with pHluorin-DAT #3 were imaged as described in figure 11. The panel display the same 
cells first imaged in a neutral buffer, then in an acidic buffer that quenches the pHluorin signal. The signal is then 
rescued by applying a neutral buffer. Finally adding a buffer with ammonium chloride neutralizes the pH in the 
intracellular making pHluorin-DAT residing in vesicular compartments visible. Acidic solution (pH 5.3) was 
prepared by replacing HEPES in the imaging buffer with MES (pH 5.3), with all other components in the imaging 
buffer remaining unchanged. Ammonium chloride solution (pH 7.4) was prepared by substituting 50 mM NaCl in the 
imaging buffer with NH4Cl, with all other components remaining unchanged. B) For imaging with JHC 1-64 the 
cells were incubated with 5 nM JHC 1-64 for 20 minutes at room temperature and subsequently washed in buffer. 
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visible. This suggests that pHluorin-DAT has a cellular distribution like wild type DAT when 
expressed at low levels. We also tested binding of JHC 1-64 to pHluorin-DAT. JHC 1-64 
fluorescence colocalized with the pHluorin signal (figure 12B), and the pHluorin signal was specific 
as it was sensitive to low pH (figure 12B) This further supports that the transporter on the cell 
surface is functional. 
 
Even though pHluorin-DAT has a compromised expression it still seems functional and as it is 
possible to recognize and avoid cells with a compromised expression it seems feasible to undertake 
experiments with pHluorin-DAT. Using pHluorin-DAT, it might be possible to address 
fundamental questions regarding DAT insertion into the plasma membrane. E.g., what is the 
frequency and cellular location DAT membrane insertion and is this insertion of DAT regulated? 
 
Using the cocaine analogs as flow cytometry probes 
As already shown, the fluorescent cocaine analogs have provided a tool for studying DAT in new 
and interesting ways. In addition, experiments have shown that the Oregon Green cocain analog, 
MFZ 9-18 can be used in flow cytometry experiments to describe a population profile of PMA-
induced DAT down-regulation in HEK293 with average reduction of 31-35% of surface DAT 
(figure 13). The experiment is a proof of concept that the cocaine analogs can actually be used to 
probe changes in DAT surface expression using flow cytometry, and with this setup we intend to 
probe DAT surface expression in acute striatal synaptosomal preparations. Compared to uptake 
such an approach would not be sensitive to changes in membrane potential and thus more likely to 
represent a true quantitative readout of surface expression. The use of flow cytometry on striatal 
synaptosomes has been described previously (Wolf et al., 1991), and the with the setup it will be 
possible to detect changes in DAT surface expression upon acute in vivo or ex vivo stimulation with 
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e.g. insulin, which has previously 
been described to affect DAT 
surface expression in cell lines 
and in diabetogenized mice 
(Garcia et al., 2005; Williams et 
al., 2007). Furthermore, the setup 
would provide an elegant way of 
probing the PMA effect in striatal 
synaptosomes, providing 
information not available with 
either dopamine uptake or 
biotinylation experiments. 
Another experimental possibility 
with the flow cytometry setup 
would be to purify DA neurons 
from a dissociated midbrain 
preparation 
 
Figure 13: Flow cytometry was used to quantify DAT surface 
expression in HEK293 cells stably transfected with hDAT. The cells 
were seeded two days prior to experiments (3x106 in a 10 mm Petri 
dish). On the day of the experiment the cells were incubated in buffer 1 
(+/- 1μM PMA) for 30 min at 37°C. After incubation, the cells were 
detached from plates using PBS with 5 mM EDTA, and the cells were 
collected and sedimented at 300 x g for 5 min. The cells were 
incubated with 20 nM MFZ 9-18 (+1 mM dopamine in the control for 
unspecific binding) in PBS with 1% BSA for 10 min at 4°C. 
Subsequently, the cells were washed 3 times in PBS + 1% BSA. 
Fluorescence intensity profiles of cell populations (10,000μtimes in 
PBS with 1% BSA each followed by sedimentation at 300 x g for 5 
min, and the cells were then resuspended in 500  cells/sample) were 
measured using a FACS-Calibur instrument (BD Biosciences, 
Franklin Lakes, NJ). The reduction of DAT surface expression was 
between 31-35% in three independent experiments. The graph 
represents one of the experients. 
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Visualization of Dopamine Transporter Trafficking 
in Live Neurons by Use of Fluorescent Cocaine Analogs
Cellular/Molecular
Visualization of Dopamine Transporter Trafficking in Live
Neurons by Use of Fluorescent Cocaine Analogs
Jacob Eriksen,1* Søren G. F. Rasmussen,1* Trine Nygaard Rasmussen,1 Christian Bjerggaard Vaegter,1 Joo Hwan Cha,2
Mu-Fa Zou,2 Amy Hauck Newman,2 and Ulrik Gether1
1Molecular Neuropharmacology Group and Center for Pharmacogenomics, Department of Neuroscience and Pharmacology, The Panum Institute,
University of Copenhagen, DK-2200 Copenhagen N, Denmark, and 2Medicinal Chemistry Section, National Institute on Drug Abuse–Intramural Research
Program, National Institutes of Health, Baltimore, Maryland 21224
The dopamine transporter (DAT)mediates reuptake of dopamine from the synaptic cleft and is a target for widely abused psychostimu-
lants such as cocaine and amphetamine. Nonetheless, little is known about the cellular distribution and trafficking of natively expressed
DAT. Here we use novel fluorescently tagged cocaine analogs to visualize DAT andDAT trafficking in cultured livemidbrain dopaminer-
gic neurons. The fluorescent tags were extended from the tropane N-position of 2-carbomethoxy-3-(3,4-dichlorophenyl)tropane
using an ethylamino-linker. The rhodamine-, OR Green-, or Cy3-labeled ligands had high binding affinity for DAT and enabled specific
labeling of DAT in live neurons and visualization by confocal imaging. In the dopaminergic neurons, DAT was uniformly distributed in
the plasmamembrane of the soma, the neuronal extensions, and varicosities along these extensions. FRAP (fluorescence recovery after
photobleaching) experiments demonstrated bidirectional movement of DAT in the extensions and indicated that DAT is highly mobile
both in the extensions and in the varicosities (immobile fraction less than30%). DAT was constitutively internalized into vesicular
structures likely representing intracellular transporter pools. The internalization was blocked by lentiviral-mediated expression of
dominant-negative dynamin and internalized DAT displayed partial colocalization with the early endosomal marker EGFP-Rab5 and
with the transferrin receptor. DAT internalization and function was not affected by activation of protein kinase C (PKC) with phorbol-
12-myristate-13-acetate (PMA) or by inhibition with staurosporine or GF109203X. These data are in contrast to findings for DAT in
transfected heterologous cells and challenge the paradigm that trafficking and cellular distribution of endogenous DAT is subject to
regulation by PKC.
Introduction
The dopamine transporter (DAT) mediates reuptake of dopa-
mine from the synaptic cleft and in this way terminates dopami-
nergic signaling (Chen et al., 2004; Gether et al., 2006; Torres and
Amara, 2007). Alteration in dopamine signaling and DAT func-
tion is coupled to neurological and psychiatric diseases including
schizophrenia, bipolar disorder, ADHD (attention-deficit hyper-
activity disorder), Tourette’s syndrome, and Parkinson’s disease
(Gainetdinov and Caron, 2003; Torres et al., 2003; Gether et al.,
2006). DAT is also the principle target for widely abused psycho-
stimulants, such as cocaine and amphetamine (Chen et al., 2004;
Gether et al., 2006; Torres and Amara, 2007). The transporter
belongs to the family of neurotransmitter:sodium symporters
(NSS) [also called the SLC6 (solute carrier 6) family or Na/Cl
coupled transporters] that in addition includes the transporters
for norepinephrine, serotonin, glycine, and GABA. NSS proteins
use the transmembraneNa gradient as a driving force for trans-
port of substrate and are characterized by additional cotransport
of Cl (Chen et al., 2004; Gether et al., 2006; Torres and Amara,
2007; Zomot et al., 2007).
It is assumed that DAT is subject to specific cellular regulation
ensuring proper availability and activity of the transporter in the
neuron. The most widely described regulatory mechanism in-
volves redistribution of the transporter to an intracellular com-
partment in response to protein kinase C (PKC) activation
(Daniels and Amara, 1999; Melikian and Buckley, 1999; Blakely
and Bauman, 2000; Granas et al., 2003; Miranda et al., 2007).
DAT trafficking might also be regulated by other protein kinases
such as mitogen-activated protein kinase (MAPK) and Akt (Mo-
ro´n et al., 2003; Garcia et al., 2005) as well as being affected by
substrates and inhibitors. Both dopamine and amphetamine
have been shown to cause transporter internalization (Saunders
et al., 2000; Chi and Reith, 2003), whereas cocaine was shown to
acutely enhance DAT surface availability although the effect was
relatively modest (Daws et al., 2002). A constitutive internaliza-
tion signal in the DAT C terminus has recently been identified
(Holton et al., 2005; Sorkina et al., 2005); however, it is not
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known whether this signal operates in the natively expressed
transporter.
The vast majority of studies performed on DAT trafficking have
been performed in non-neuronal and transfected heterologous ex-
pression systems and not on endogenously expressed transporter.
One major problem is the relatively low number of dopaminergic
and thereby DAT expressing neurons in the brain. As a conse-
quence, it is generally difficult to obtain neuronal cultures contain-
ing a high fraction of dopaminergic neurons (di Porzio et al., 1987;
Silva et al., 1988; Rayport et al., 1992; Ingram et al., 2002) making
qualitative and quantitative studies of DAT regulation difficult. It
has also appeared notoriously difficult to develop an efficient anti-
body against an extracellular epitope of the DAT and, thus, labeling
of endogenousDAT in living cells has not been possible. To develop
tools that might permit visualization of DAT in living cells, we
recently synthesized a series of rhodamine-coupled fluorescent co-
caine analogs (Cha et al., 2005). Here we use one of these ligands
together with two new fluorescent cocaine analogs to visualize en-
dogenously expressedDATand its trafficking in primary cultures of
rat midbrain dopaminergic neurons.
Materials andMethods
Synthesis of fluorescent ligands. JHC 1–64 was synthesized as previously
described (Cha et al., 2005). MFZ 9–17 was synthesized by adding diiso-
propylethylamine (6.0 mg, 47.0 mol) to a solution of ()-N-(2-
aminoethyl)-2-carbomethoxy-3-(3.4-dichlorophenyl)-tropane (Cha et
al., 2005) (6mg, 16.85mol) andCy3N-hydroxysuccinimide ester (10mg,
13.05 mol) in DMF (2 ml) and the mixture was stirred overnight at 40–
45°C. The solvent was then removed under reduced pressure and the re-
sulting residue was purified directly by preparative thin-layer chromatog-
raphy, eluting with CHCl3-MeOH-28% NH4OH (70:30:1) to provide 13
mg (100%) of MFZ 9–17 as a red solid. MALDI-TOF MS calculated for
C48H59N4Cl2O9S2 ([MH]
) was as follows: 969.31; found: 969.30. MFZ
9–18 was prepared from ()-N-(2-aminoethyl)-2-carbomethoxy-3-
(3.4-dichlorophenyl)-tropane (Cha et al., 2005) (10.3 mg, 28.9 mol) and
Oregon Green 488-X, N-succinimidyl ester (15 mg, 24.09 mol) by the
same procedure as described for MFZ 9–17 in quantitative yield as an
orange solid. MALDI-TOF MS calculated for C44H41N3Cl2F2O9
([MH]) was as follows: 864.22; found: 864.23.
Molecular biology.A synthetic gene encoding the humanDAT (hDAT) in
the bicistronic vector pCIHygro and hDAT tagged at the N terminus with
enhanced green fluorescent protein (EGFP-hDAT) were kindly provided
by Dr. Jonathan A. Javitch, Columbia University (New York, NY) (Rees et
al., 1996; Saunders et al., 2000). The cDNAs encoding dynamin and the
dominant-negative dynamin mutant K44A in pFUGW-IRES-GFP were
kind gifts from Dr. Rosalind A. Segal (Harvard
Medical School, Boston, MA) (Zhou et al.,
2007). pHsSynXW EGFP-Rab5a was generated
by excising the cDNA encoding EGFP-Rab5A
from pEGFP Rab5A (a kind gift from Dr.
KatherineW. Roche, National Institute of Neu-
rological Disorders and Stroke, Bethesda, MD)
(Lavezzari et al., 2004) using Age1 and HpaI
restriction sites followed by insertion into the
lentiviral transfer vector pHsCXW(Leander Jo-
hansen et al., 2005). The CMV promoter was
replaced with the promoter of synapsin to en-
sure selective neuronal expression (Dittgen et
al., 2004).
Cell culture and transfection. Human embry-
onic kidney cells (HEK) 293 were grown in
DMEMwith GlutaMax (L-alanyl-L-glutamine),
10% fetal calf serum, and 0.01 mg/ml gentami-
cin (all reagents from Invitrogen) at 37°C in a
humidified 5% CO2 atmosphere. For stable ex-
pression of hDAT and EGFP-hDAT, HEK293
cells were seeded in 100 mm tissue culture
plates, grown to30% confluence, and subse-
quently transfected with 2 g of the pCIHygro constructs using Lipo-
fectamine according to the instructions from themanufacturer (Invitro-
gen). A stably transfected pool was selected with 200 g/ml hygromycin
(Invitrogen) starting 2 d after transfection and continuing until control
cells were dead, after which selection pressure were maintained with 100
g/ml hygromycin. For transient expression of hDAT, HEK293 cells
(3  106 cells) were seeded in 75 cm2 flasks. The cells were transfected
the day after seeding with 3 g of DNA and 9 l of Lipofectamine 2000
reagent according to the manufacturer’s instructions.
Preparation and culturing of neurons. Postnatally derived rat midbrain
dopaminergic neurons were isolated and grownmodified from (Rayport
et al., 1992). Briefly, the cultures were obtained from the ventral mid-
brain of 1- to 3-d-old pups. The dissected tissue sample was digested in a
papain solution for 30 min at 37°C while slowly superfused with a
mixture of 95% O2 and 5% CO2. The digested tissue was carefully tritu-
rated into single cells using increasingly smaller pipette tips. The cells
were centrifuged at 500  g for 5 min and resuspended in warm SF1C
consisting of 50% MEM (Modified Eagle’s Medium), 40% DMEM, and
10% F-12 Ham’s nutrient mixture (all from Invitrogen) supplemented
with bovine serum albumin (2.5 mg/ml), D-glucose (0.35%), glutamine
(0.5mM), 1%heat-inactivated calf serum (Invitrogen), kynurenic acid (5
mM), penicillin, streptomycin, liquid catalase (0.05%), and DiPorzio (di
Porzio et al., 1980) (containing insulin, transferrin, superoxide dis-
mutase, progesterone, cortisol, Na2SeO3, and T3). The neurons were
plated on a monolayer of glial cells grown on coverslips. The cells were
allowed to settle for2 h before addition of GDNF (Millipore Bioscience
Research Reagents) (10 ng/ml). The next day 5-fluorodeoxyuridine was
added to inhibit growth of glial cells. The cultures were used for experi-
ments after 4–16 d in vitro (DIV).
Lentivirus production and transduction. Lentiviral vectors were pro-
duced according to procedures modified from Naldini et al. (1996b).
HEK293T packaging cells (ATCC number CRL-11268) were plated on
poly-ornithine-coated 175 cm2 flasks and transiently triple transfected
with the following: (1) 18 g of a packaging plasmid encoding viral
structure proteins (pBR8.91) (Zufferey et al., 1997); (2) 12 g of an
envelope plasmid encoding the envelope protein VSV-G (pMD.G) (Nal-
dini et al., 1996a); and (3) 18 g of the transfer plasmid containing the
gene of interest (pFUGW-IRES-GFP Dynamin, pFUGW-IRES-GFP Dy-
namin K44A, pHsSynXW CKAR, or pHsSynXW EGFP-Rab5a). Trans-
fection was performed in DMEM (Invitrogen) supplemented with 10%
FBS (Invitrogen) using calcium phosphate precipitation. Medium was
replaced with fresh medium after 5 h. Approximately 48 and 72 h after
transfection, media containing lentivirus was collected, centrifuged at
900 g for 5 min to remove cellular debris, filtered through a 0.45 m
filter, and concentrated by ultracentrifugation at 50,000 g for 1.5 h at
4°C. The virus-containing pellet was resuspended in MEM (Sigma) at
Figure 1. Structure of fluorescently labeled cocaine analogs. Left, The rhodamine conjugate JHC 1–64. Right, The Oregon
Green conjugate MFZ 9–18. JHC 1–64 was synthesized as described previously (Cha et al., 2005). MFZ 9–18 was synthesized as
described in Materials and Methods. For both compounds, the fluorescent tag was extended from the N-position of 2-
carbomethoxy-3-(3,4-dichlorophenyl)tropane using an ethylamino-linker.
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1/280 of the original volume and stored in ali-
quots at80°C. The neuronal cultures were in-
cubated with concentrated lentivirus on days
2–3 in vitro and experiments were performed
6–8 d after infection.
Immunocytochemistry. Dopaminergic neu-
rons, grown on a monolayer of glial cells on
coverslips, were incubated with 10 nM JHC
1–64 in buffer 1 (25 mM HEPES, pH 7.4, with
130 mM NaCl, 5.4 mM KCl, 1.2 mM CaCl2, 1.2
mM MgSO4, 1 mM L-ascorbic acid, 5 mM
D-glucose) for 20 min at room temperature
(RT). Subsequently, the cells were washed and
fixed in 3.7% formaldehyde in PBS for 20 min
at 4°C before the specimen was permeabilized
and blocked in blocking/permeabilization
buffer (0.1% digitonin, 1% bovine serum albu-
min, and 5% goat serum in PBS). The neurons
were stained with either a rat anti-DAT anti-
body (1:1000; MAB369; Millipore Bioscience
Research Reagents), rabbit anti-VMAT2 (vesic-
ular monoamine transporter 2) antibody
(1:1000; Peel-Freez Biologicals), or a rabbit
anti-TH (tyrosine hydroxylase) antibody
(1:1000; Affinity Bioreagents) in blocking/per-
meabilization buffer for 1 h, washed 3 times in
PBS, and incubated for 30minwith either Alexa
Fluor 488 goat anti-rat or goat anti-rabbit anti-
body (1:500; Invitrogen). Finally, the speci-
mens were mounted on glass slides with Slow-
Fade Antifade (Invitrogen). The specimens
were imaged using a Zeiss LSM 510 confocal
laser-scanning station with an oil-immersion
63 1.4 NA objective (Zeiss). JHC 1–64 was
visualized using a 543 nmHeNe laser line and a
585 nm long-pass filter, whereas Alexa Fluor
488 was excited with the 488 nm laser line from
an argon–krypton laser and the emitted light
was detected using a 505–550 nm bandpass
filter.
Live cell imaging. HEK293 cells stably ex-
pressing either hDAT or EGFP-tagged hDAT
were grown in DMEM plus 10% FCS in poly-L-
ornithine-treated 8-well LabTek Chambers. On
the day of the experiment, the cells were incu-
batedwith the indicated fluorescent cocaine an-
alogs in PBS with 5 mM glucose for designated
time periods. After incubation, the living cells were imaged at RT using a
Zeiss LSM510with a 63NA1.4 objective (Zeiss). The compounds JHC
1–64 andMFZ 9–17 were visualized using a 543 nmHeNe laser line and
a 585 nm long-pass filter, whereas MFZ 9–18 and EGFP were detected
with a 488 nm argon–krypton laser line and a 505–530 nm bandpass
filter.
For imaging in dopaminergic neurons, ventral midbrain neurons
grown in 2-well LabTek chambers on a glial monolayer for 4–16 DIV
were used for all live neuron imaging studies. The neurons were incu-
bated with 5 nM JHC 1–64 or 10 nM MFZ 9–18 in buffer 1 (25 mM
HEPES, pH 7.4, with 130 mM NaCl, 5.4 mM KCl, 1.2 mM CaCl2, 1.2 mM
MgSO4, 1 mM L-ascorbic acid, 5 mM D-glucose) for 20 min at room
temperature. As controls for JHC 1–64’s DAT specificity in neurons, the
cultures were either preincubated with 1 mM dopamine, 1 Mmazindol,
10M desmethylimipramine, or 1M citalopram in uptake buffer for 15
min, before addition of 5 nM JHC 1–64 to the buffer and incubation for
20min at RT. The cells were imaged as described for theHEK293 live cell
experiments.
To detect internalization in midbrain dopaminergic neurons, the cul-
tures were incubated with 5 nM JHC 1–64 for 30 min at 4°C, before the
buffer was removed and replaced with 37°C warm uptake buffer (con-
taining vehicle, 450 mM sucrose, or 1 M PMA) and incubated for 30 or
60 min at 37°C (or 4°C for a temperature control). For the transferrin
cointernalization experiments we used Alexa Fluor 488-conjugated
transferrin (1:100; Invitrogen). After incubation the neurons were im-
aged at room temperature with same settings as described for the
HEK293 cells and the distribution of JHC 1–64 on the neurons were
analyzed with a Z-scan.
Time lapses were performed on midbrain dopaminergic neurons
grown in LabTek chambers and incubated with 5 nM JHC 1–64 in buffer
1 for up to 1 h at 37°C to allow labeling of the DAT and subsequent
constitutive internalization of the JHC 1–64/DAT complex. Next, the
cells were washed once with buffer 1 and analyzed on the Zeiss LSM510
station with a heated stage kept at 37°C. The JHC 1–64/DAT complex
was visualized by excitation with a 543 nm HeNe laser line. Pictures are
an average of 2 line scans. Time series were obtained with 300 pictures in
20 min.
Fluorescence recovery after photobleaching. Cultures of midbrain dopa-
minergic neurons were labeled with 5 nM JHC 1–64 for 20 min followed
by washing the cells in buffer 1. The neurons were subsequently kept in
bufferwith 10MRTI55 during the experiment to avoid any rebinding of
JHC 1–64 to DAT. The fluorescence recovery after photobleaching
(FRAP) measurements and calculations were performed essentially as
described (Adkins et al., 2007). Spot photobleaching using circular re-
gions of interest (ROIs) of 1–3 m in diameter were placed on the neu-
Figure2. Specific labelingof EGFP-DATwith the fluorescent cocaine analog JHC1–64. Top, LiveHEK293 cells stably expressing
EGFP-DAT without JHC 1–64 preincubation. Middle, Live HEK293 cells stably expressing EGFP-DAT preincubated with 5 nM JHC
1–64 for 20 min at RT. Bottom, Live HEK293 cells stably expressing EGFP-DAT preincubated with 1 mM dopamine for 15 min
followed by 5 nM JHC 1–64 for 20min at RT. EGFP fluorescence (left) was visualized using a 488 nm argon laser for excitation and
a 505–530 nm bandpass filter for recording of fluorescence. For visualization of JHC 1–64 we used a 543 nm HeNe laser for
excitation and a585 nm long-pass filter for recording of fluorescence. The shown images are representative of at least five
similar experiments with the same result.
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ronal extensions or boutons of the selected neurons, followed by bleach-
ing of the region with the 488 nm laser line at 100% output for700 ms
to obtain 30–70% bleaching compared with prebleach image. The pin-
hole was kept fully open to ensure complete bleaching through the cell.
The transmission intensity was no higher than 1%, and the bleaching of
the sample due to imaging was negligible according to experiments on
fixed cells (data not shown). Images were obtained every 500 ms for an
average of 1min using the 543 nm laser line and a 585 nm long-pass filter.
Measurements up to 5 min were also performed, with no change in
diffusion time or mobile fraction observable after the first minute. Im-
ages were processed with Photoshop 6.0 (Adobe), and recovery curves
were calculated using nonlinear least-squares fits in ORIGIN 5.0 (Orig-
inLab) set to the general equation for FRAP as by (Yguerabide et al.,
1982). The diffusion coefficient was determined using the following
equation:
D  1
2/4D, (1)
where  is radius of the ROI set in the Zeiss program, and the D is
determined from the fit of the recovery curve. Because the thickness of
the cell was less than the bleached volume in the z direction, Equation 1
was used to determine diffusion coefficients. All measurements were
performed at 22°C.
Dopamine uptake in neurons. The media was
removed from midbrain neurons grown on a
glial monolayer in 24-well plates (13–15 DIV)
and buffer 1, containing 1 M PMA, 1 M stau-
rosporine, 1 M GF109203X, or vehicle was
added before incubation for 30 min at 37°C.
The incubation was terminated by aspirating
the buffer followed by addition of 400 l of
buffer 1 containing 1 M the catechol-O-
methyltransferase inhibitor Ro 41–0960
(Sigma) and 100 M pargyline (Sigma). Subse-
quently, 50l of vehicle or 10M cocaine (final
concentration) for determination of nonspe-
cific binding was added before addition of ei-
ther 100 nM [3H]dopamine [2,5,6-( 3H)-
dopamine (7–21 Ci/mmol) (GE Healthcare)]
or 100 nM [3H]dopamine plus 1 M unla-
beled in 50 l of buffer 1. After 3 min of incu-
bation at RT, the cells were washed twice with
500l of ice-cold buffer 1, lysed in 250l of 1%
SDS, and left for 1 h at 37°C. Nonspecific bind-
ing was determined in the presence of 100 M
cocaine. All samples were subsequently trans-
ferred to 24-well counting plates (PerkinElmer
Life Sciences) followed by addition of 500 l of
Opti-phase HiSafe 3 scintillation fluid
(PerkinElmer Life Sciences). The samples were
counted in a Wallac Tri-Lux  scintillation
counter (PerkinElmer Life Sciences). All deter-
minations were performed in triplicate.
[ 3H]dopamine uptake experiments in HEK293
cells transiently expressing the hDAT to deter-
mine inhibition constants for the fluorescent
ligands were done as recently described (Cha et
al., 2005).
Results
Synthesis of fluorescent cocaine ligands
Wehave recently synthesized fluorescent co-
caine analogs containing rhodamine as the
fluorescent moiety (Cha et al., 2005). Of
these, JHC 1–64 showed the highest affinity
for the human DAT (hDAT) (Cha et al.,
2005). The fluorescent tag was extended
from the N-position of 2-carbomethoxy-
3-(3,4-dichlorophenyl)tropane using an
ethylamino-linker (Fig. 1). To generate a ligand with a different flu-
orescent spectrum we coupled an Oregon Green moiety to the tro-
pane nitrogen of the parent compound 2-carbomethoxy-3-(3,4-
dichlorophenyl)tropane, using the ethylamino linker to give MFZ
9–18 (Fig. 1). Likewise, to generate a more photostable ligand than
JHC 1–64, we coupled a Cy3 moiety to the ethylamino-linked tro-
pane nitrogen of the parent compound to give MFZ 9–17 (supple-
mental Fig. S1, available at www.jneurosci.org as supplemental ma-
terial). In this way, all three ligands possessed the identical
pharmacophore and only differed in the fluorescent moiety ex-
tended from the tropane nitrogen (Fig. 1; supplemental Fig. S1,
available at www.jneurosci.org as supplemental material).
To estimate the affinity of the two new ligands for the hDAT
we determined the potency by which they inhibited [3H]dopam-
ine uptake into COS-7 cells transiently expressing the hDAT. The
calculated KI values were 104 nM [SE interval (69.2;156 nM), n
3] for MFZ 9–17 and 142 nM [SE interval (57.5;353 nM), n 3]
for MFZ 9–18. For JHC 1–64, we previously reported a KI value
of 62 nM based on [3H]dopamine uptake inhibition experiments
and a value of 18 nM based on [3H]CFT competition binding
Figure 3. Specific labeling of DAT with the fluorescent cocaine analog MFZ 9–18. A, Live HEK293 cells stably expressing DAT
preincubated with 10 nMMFZ 9–18 for 20min at RT (top) or with 1mM dopamine for 15min followed by 10 nMMFZ 9–18 for 20
min at RT (bottom). MFZ 9–18 was visualized using a 488 nm argon laser for excitation and a 505–530 nm bandpass filter for
recording of fluorescence. B, Live HEK293 cells stably expressing DAT preincubated with 10 nMMFZ 9–18 and 5 nM JHC 1–64 for
20minatRT. The left panel shows fluorescence in the585nmchannel, themiddlepanel shows fluorescence in the505–530nm
channel, and the right panel showsoverlay of the twochannels. The shown images are representativeof three similar experiments
with the same result.
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experiments (Cha et al., 2005). Thus,
coupling of either Oregon Green or
Cy3 instead of rhodamine to the parent
compound 2-carbomethoxy-3-(3,4-
dichlorophenyl)tropane was also well tol-
erated by the transporter resulting in two
additional high affinity fluorescently
tagged DAT ligands.
Visualization of DAT in living HEK293
cells by the fluorescent cocaine analogs
To demonstrate DAT labeling by JHC
1–64, we used HEK293 cells stably ex-
pressing hDAT with EGFP fused to the N
terminus. The EGFP-hDAT cells were in-
cubated for 20 min with vehicle, 5 nM JHC
1–64, or 5 nM JHC 1–64 plus 1 mM dopa-
mine at RT. The cells were subsequently
analyzed by confocal imaging. Recording
from the EGFP channel (505–530 nm)
showed that EGFP-hDAT was uniformly
expressed in the plasma membrane (Fig.
2). An essentially identical pattern was ob-
served in the JHC 1–64 channel (585
nm) upon labeling with JHC 1–64 but no
fluorescence was observed in the absence
of JHC 1–64 and no fluorescence was ob-
served when EGFP-hDAT was blocked
with dopamine (Fig. 2). Specific labeling of
DAT by JHC 1–64 is further supported by
our previous observation that JHC 1–64
only labeledDAT transfected andnot non-
transfected HEK293 cells (Cha et al.,
2005). Together, our data strongly suggest
that JHC 1–64 labels DAT with high spec-
ificity and signal-to-noise ratio.
DAT could also be specifically labeled
with MFZ 9–17 (supplemental Fig. S1,
Figure 4. Visualization of DAT internalization in HEK293 cells expressing EGFP-DAT using the fluorescent cocaine analog JHC
1–64.A, PMApromotes internalization of the EGFP-DAT/JHC 1–64 complex in live HEK293 cells stably expressing EGFP-DAT. The
cells were incubated in the presence of 5 nM JHC 1–64 in PBS plus 5mM glucose at RT for 20min before incubation in the absence
4
(top) or presence of 1M PMA (bottom) for 30min at 37°C.B,
JHC 1–64 only labels EGFP-DAT in the plasmamembrane and
not internalized EGFP-DAT. HEK293 cells stably expressing
EGFP-DATwas incubated for 30min at 37°C in the presence of
1MPMAtoobtaina fractionof internalizedEGFP-DATbefore
labeling for 20min in theabsence (top) or presenceof 5nM JHC
1–64 at RT. C, JHC 1–64 has a slow off-rate from EGFP-DAT
and JHC 1–64 colocalizes with internalized DAT even after 90
min of incubation. HEK293 cells stably expressing EGFP-DAT
was incubated with 5 nM JHC 1–64 for 20 min at RT before
incubation for 30 min at 37°C. As in A, this resulted in robust
internalization of the DAT/JHC 1–64 complex (top). Subse-
quently, an excess of the high-affinity cocaine analog RTI-55
was added (10M) before incubation for up to 90min at 37°C.
JHC 1–64only slowly dissociated from the cell surface and the
dissociation was only visible after 90min (bottom). However,
even after 90 min of incubation, JHC 1–64 remained colocal-
izedwith EGFP-DAT, suggesting JHC1–64as a reliablemarker
for endocytosed DAT. Left panels show fluorescence in the
505–530 nm channel (EGFP), middle panels show fluores-
cence in the585 nm channel (JHC 1–64), and right panels
show overlay of the two channels. The shown images are rep-
resentative of at least three similar experiments with the
same results.
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available at www.jneurosci.org as supplemental material) and
MFZ 9–18 (Fig. 3). The Oregon Green label in MFZ 9–18 was
visualized with the same settings of the microscope as for EGFP
(Fig. 3A), whereas the Cy3 label inMFZ 9–17 was visualized with
the same settings as those used for JHC 1–64 (supplemental Fig.
S1, available at www.jneurosci.org as supplemental material). For
both ligands, we obtained a uniform labeling of the plasma mem-
brane that was completely blocked by an excess of dopamine con-
sistent with specific labeling of DAT. Additionally, simulta-
neous labeling with the spectrally distinct compounds JHC
1–64 and MFZ 9–18 revealed overlapping pattern as also
would be expected if both ligands specifically bound the hDAT
(Fig. 3B).
Visualization of DAT internalization
Activation of PKC by phorbol esters, such as PMA, is known to
cause acute internalization of the DAT in heterologous cell sys-
tems (Daniels and Amara, 1999; Melikian and Buckley, 1999;
Blakely and Bauman, 2000; Granas et al., 2003; Miranda et al.,
2007). To investigate whether we could use the fluorescent co-
caine analogs to visualize this internalization, we incubated
HEK293 cells stably expressing the EGFP-hDAT with 5 nM JHC
1–64 for 20 min at RT followed by incubation for 30 min at 37°C
in the presence or absence of 1 M PMA. While no apparent
change in distributionwas observedwith vehicle, PMA treatment
led to the appearance of intracellular fluorescence in vesicular
structures both in the EGFP and in the JHC 1–64 channel con-
sistent with internalization of the transporter (Fig. 4A). In an-
other experiment, we treated the cells with PMA before labeling
with JHC 1–64. In the EGFP channel we observed, as expected,
clear signs of internalizationwith significant intracellular fluores-
cence in vesicular structures; however, we did not observe any
intracellular fluorescence from JHC1–64 (Fig. 4B). This suggests
that JHC 1–64 labels DAT at the surface and that in the time
frame of the experiment, the compound does not pass the plasma
membrane and label intracellularly localized DAT, to any mea-
surable extent.
We also tested whether JHC 1–64 itself would influence DAT
trafficking by use of HEK293 cells transfected with a modified
hDAT containing an extracellular HA-tag in the second extracel-
lular loop (HA-DAT) (Sorkina et al., 2006). Insertion of this
extracellular tag permitted application of an ELISA-based assay
to quantify surface expression as well as it permitted application
of antibody feeding experiments to assess internalization. Ac-
cording to the ELISA assay, JHC 1–64 did not alter surface ex-
pression of HA-DAT (supplemental Fig. S2A, available at www.
jneurosci.org as supplemental material). In the antibody feeding
experiment,we performed confocal imaging after labelingwith JHC
1–64 (supplemental Fig. S2B, available atwww.jneurosci.org as sup-
plementalmaterial), anti-HA antibody (Alexa Fluor 488 conjugated
HA.11) (supplemental Fig. S2C, available at www.jneurosci.org as
supplementalmaterial), or both JHC 1–64 and conjugated anti-HA
antibody (supplemental Fig. S2D, available at www.jneurosci.org as
supplementalmaterial). After 60min, we observed for all three con-
ditions weak intracellular accumulation of JHC 1–64- and HA.11-
positive vesicles (supplemental Fig. S2B–D, available at www.
jneurosci.org as supplemental material). This represents most likely
modest constitutive internalizationofHA-DATthat is unaffectedby
JHC 1–64. Note that Chi and Reith (2003) also have reported con-
stitutive internalization of DAT in HEK293 cells; however, they ob-
served that close to 20% of surface expressed transporter was inter-
nalized over an hour, which appears much higher than indicated
from our imaging experiments. Most likely, this apparent discrep-
ancy results from the use of different methods and/or different ex-
pression levels.
Labeling of DAT with JHC 1–64 is reversible but the off-rate
is slow
We also wanted to evaluate the reversibility of the DAT labeling.
This was done first by using HEK293 EGFP-hDAT cells that were
labeled with JHC 1–64 followed by treatment for 30 min at 37°C
with 1 M PMA. The cells were subsequently washed and incu-
bated at 37°C in buffer containing 10 M of the nonfluorescent
cocaine analog RTI-55. The degree of JHC 1–64 labeling was
followed over time and after 90min of incubation the fluorescent
labeling of the plasma membrane was reduced, consistent with
dissociation of JHC1–64 from theDATbinding pocket (Fig. 4C);
however, the dissociation was slow, i.e., the dissociation was
barely apparent after 45 min of incubation (data not shown).
Importantly, labeling of internalized transporter was only slightly
reduced as reflected by clear colocalization of EGFP and JHC 1–64
fluorescence even after 90 min of incubation, indicating that JHC
1–64 is a reliable reporter of endocytosed DAT (Fig. 4C).
To further verify that the slow loss of fluorescence was indeed
a product of a slow off-rate for JHC 1–64 from DAT and not a
nonspecific membrane partitioning, we measured the ability of
JHC 1–64 to inhibit [3H]dopamine uptake in DAT expressing
HEK293 cells after washout at various time points to allow disso-
ciation andprevent rebinding of JHC1–64. The cells were labeled
with 100 nM JHC 1–64, 500 nM JHC 1–64, or vehicle for 30 min
before washing and incubation for 0, 20, 40, or 60 min at 37°C.
[3H]dopamine uptake was then assayed after two additional
washes. After 60 min washout of either 100 or 500 nM JHC 1–64,
[3H]dopamine uptake was still markedly blocked and almost un-
changed compared with 0 min washout (i.e., 10% of vehicle
treated for 100 nM JHC 1–64 and5% of vehicle treated for 500
nM JHC 1–64) with only a tendency toward loss of inhibition was
seen (supplemental Fig. S3, available at www.jneurosci.org as
supplemental material). These data strongly suggest very slow
dissociation of JHC 1–64 from DAT and further support that
JHC 1–64 can be used as a tool to track DAT molecules in live
cells over even an extended period of time.
Visualization of endogenous DAT in live neurons
We wanted next to see whether we could use the ligands to visu-
alize DAT endogenously expressed in neurons. We prepared
postnatal cultures of rat midbrain neurons and assessed DAT
expression by labeling with JHC 1–64. Incubation of the cultures
with 5 nM JHC 1–64 for 15 min resulted in labeling of a fraction
(20%) but not all neurons in the culture (data not shown). No
significant labeling was observed of the glial cell layer on which
the postnatal neurons were grown (Fig. 5A–C). The labeling of
the individual neurons indicated a widespread and generally uni-
form distribution of the DAT in the neurons with plasma mem-
brane staining not only in the neuronal extensions and varicosi-
ties but also of the somas (Fig. 5A–C). Coincubation with either
an excess of cocaine (10 M) (data not shown), dopamine (1
mM), or the inhibitormazindol (1M) blocked all staining except
labeling of some irregular rounded structures that likely repre-
sented dead or dying cells (Fig. 5A,B). To validate that we indeed
were visualizing endogenously expressed DAT and not SERT or
NET, we coincubated with an excess of either the specific SERT
inhibitor citalopram or the specific NET inhibitor desmethylimi-
pramine of which neither affected JHC 1–64 staining (Fig. 5B).
We also performed stainings with MFZ 9–18 (Fig. 5D), which
revealed a labeling pattern very similar to that observed for JHC
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1–64 and like the JHC 1–64, labeling was blocked completely by
preincubation with an excess of dopamine (data not shown).
Note that when interpreting surface staining of somas and neu-
ronal extensions it is important to be aware of fibers engaging
other neurons. This cannot be excluded in, e.g., Figure 5D,
whereas, e.g., the overlay of transmission and fluorescence in
Figure 5A strongly suggests uniform labeling of the soma and
proximal extensions. To address this question further and to
enable correlation between labeling and neuronal morphol-
ogy, the surface distribution of DAT was further studied by
performing Z-scans through dopaminergic neurons labeled
with JHC 1–64. The scans unraveled clear labeling of the soma
and a large and uniformly labeled neurite tree (Fig. 6; supple-
mental Movie 1, available at www.jneurosci.org as supplemen-
tal material).
To investigate whether the neurons stained by our fluorescent
cocaine analogs possessed the expected features of dopaminergic
neurons, we performed a series of immunostainings with anti-
bodies against DAT itself, tyrosine hydroxylase (TH), and the
vesicularmonoamine transporter-2 (VMAT2), all obligatemark-
ers of dopaminergic neurons (Rayport et al., 1992; Nirenberg et
al., 1996). The immunostainings were performed subsequent to
labeling of the cells with JHC 1–64 (10 nM) for 20 min. In the
fixed and permeabilized cells JHC 1–64 staining of the neurons
was markedly weaker than that seen in live cells; however, we still
saw a similar labeling pattern with labeling of the plasma mem-
brane of the soma, the neuronal extensions and varicosities along
these extensions (Fig. 7). Importantly, the labelingwas also under
these conditions blocked by cocaine and dopamine (data not
shown). As compared with live cells, the specific labeling ap-
peared somewhat more punctuate/clustered, which is likely to
represent an artifact of the fixation and permeabilization proce-
dure (Fig. 7). Nonetheless, costaining with JHC 1–64 and DAT
antibody (MAB369, directed against the intracellular
N-terminal) showed almost perfect overlap in the neurons fur-
ther supporting the specificity of JHC 1–64 labeling (Fig. 7A).
Most neurons labeled by JHC 1–64 were also labeled with the
antibodies against TH and VMAT2. The TH immunoreactivity
was found in the cytoplasmof the soma aswell as in the cytoplasm
of discrete varicosities and along the neuronal extensions (Fig.
7B). As a result, the TH staining did not overlap directly with the
plasma membrane staining observed for JHC 1–64 (Fig. 7B).
Figure 5. Visualization of endogenously expressed DAT in cultured postnatal midbrain neurons using fluorescent cocaine analogs. A, Labeling with JHC 1–64 is blocked by dopamine. The
neuronal cultureswere incubatedwith 5 nM JHC 1–64 for 20min (top) or preincubatedwith 1mMdopamine for 15min before incubation for 20minwith 5 nM JHC 1–64 (bottom). JHC 1–64 labeled
20% of the neurons in the culture. Left panels show transmitted light, middle panels show JHC 1–64 fluorescence, and right panels show overlay. B, JHC 1–64 labeling is blocked by the
high-affinity DAT inhibitormazindol but not by the selective SERT inhibitor citalopramor the selective NET inhibitor desmethylimipramine. The neuronal cultureswere preincubated for 15minwith
either 1Mmazindol (left), 10Mdesmethylimipramine (middle), or 1M citalopram (right) before incubationwith 5 nM JHC 1–64 for 20min. C, Enlarged picture of the JHC 1–64-labeled neuron
shown inA. Thepicture showsawide anduniformdistributionof JHC1–64 labeling in theplasmamembraneof both the somaand theneuronal extensions.D, Visualizationof endogenousDATwith
MFZ 9–18. The neuronal cultures were incubated with 10 nM MFZ 9–18 for 20 min. Preincubation with dopamine abolished this labeling (data not shown). The labeling pattern for MFZ 9–18
strongly resembled that seen for JHC 1–64. JHC 1–64was visualized by using a 543 nmHeNe laser for excitation and a585 nm long-pass filter for recording of fluorescence, whereas MFZ 9–18
was visualized using a 488 nm argon laser for excitation and a 505–530 nm bandpass filter for recording of fluorescence. The experiments shown are representative of at least three similar
experiments with the same results.
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While JHC 1–64 staining, and thus DAT, was present not only in
the varicosities but also along the neurites as well as in the plasma
membrane of the soma, the VMAT2 staining was localized solely
to the varicosities (Fig. 7C).
Membrane mobility of the DAT assessed by FRAP
To assess lateral mobility of the DAT in the plasmamembrane of
live neurons we performed FRAP (fluorescence recovery after
photobleaching) measurements after labeling for 20 min with 5
nM JHC 1–64. For the bleaching we used the 488 nm argon laser,
a relatively short bleach period (700 ms), and a circular bleach
spotwith an average diameter of 1m.The pinholewas kept fully
open to ensure complete bleaching through the cell and the
bleaching was performed either at the edge of the varicosities or
along the neuronal extensions (Fig. 8A). The resulting curves
revealed fast recoveries and mobile frac-
tions of larger than70% both in the var-
icosities and along the neuronal extensions
(Fig. 8A) (mobile fraction, varicosities 
72.0  10.2%; mobile fraction, exten-
sions  75.3  7.3%, n  20–22). The
calculated diffusion coefficients were
0.65  0.06  109 cm2/s in the exten-
sions and 1.14 0.11 109 cm2/s, n
30–34). These values indicate that the JHC
1–64-occupied transporter is relatively
freely moving in the membrane and that
the lateral mobility might be even higher
in the varicosities than in the extensions.
Themobility of DATwas further inves-
tigated by assessing whether DAT prefer-
entiallymoved unidirectionally or bidirec-
tionally in the neuronal extensions. The
neurons were incubated for 20 min with 5
nM JHC 1–64, after which an extended
piece of a neuronal extension (Fig. 8B,
white box) was bleached with the 488 nm
argon laser for several seconds followed by
acquisition of images at appropriate time
intervals. As shown in Figure 8B, we ob-
served recovery of fluorescence from both
sides reaching one another after 40 s.
The recovery appeared to occur with the
same rate from either side. This is consis-
tent with no directional movements of
surface expressed DAT in the neuronal ex-
tensions of cultured dopaminergic
neurons.
Assessment of DAT internalization in
dopaminergic neurons
Our data from the transfected HEK293
cells showed that we could assess internal-
ization of the JHC 1–64-labeled trans-
porter by live confocal imaging. To per-
form similar experiments in the
dopaminergic neurons, we first preincu-
bated the neurons with 5 nM JHC 1–64 at
4°C followed by incubation for up to 1 h at
37°C in the absence of any stimuli. During
this period we observed a marked sponta-
neous redistribution of the JHC 1–64-
labeled DAT, as indicated by the appear-
ance of an increasing number of distinct JHC 1–64-positive
intracellular vesicles in both the proximal neuronal extensions
and in the soma (examples of vesicles indicated by arrows in Fig.
9A). Under control conditions at 4°C over the same time period
we did not see any signs of redistribution but only staining of the
plasma membrane (Fig. 9A). The redistribution of JHC 1–64-
labeled DAT was also completely blocked by incubation with
hypertonic sucrose, a crude and nonspecific inhibitor of clathrin-
mediated endocytosis (Heuser and Anderson, 1989; Hansen et
al., 1993) (Fig. 9A). Altogether, the data suggest that DAT under-
goes marked constitutive internalization in dopaminergic neu-
rons. Interestingly, in DAT expressing HEK293 cells we observed
only modest constitutive redistribution upon incubation of the
cells at 37°C up to 1 h (supplemental Fig. S4A, available at
www.jneurosci.org as supplementalmaterial), indicating a clear dif-
Figure 6. Z-scan of JHC 1–64-labeled dopaminergic neuron. The scan unravels labeling of the soma and a large and generally
uniformly labeled neurite tree. The series of pictures shown represent as indicated 1m sections starting from the surface and
ending 11m above the surface. The neuronal cultures were incubated with 5 nM JHC 1–64 for 20 min before the analysis was
performed. JHC 1–64 was visualized using a 543 nm HeNe laser for excitation and a585 nm long-pass filter for recording of
fluorescence (see also supplemental Movie 1, available at www.jneurosci.org as supplemental material).
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ference between natively expressed and heterologously expressed
DAT.
We tested next whether PMA affected DAT internalization in
the neurons; however, in contrast to our findings inHEK293 cells
(supplemental Fig. S4, available at www.jneurosci.org as supple-
mental material), PMA had no observable effect on internaliza-
tion of JHC 1–64-labeled DAT in the neurons, hence, JHC 1–64-
positive intracellular vesicles appeared with a similar rate and to
the same degree in the presence of PMA as in the absence of PMA
(Fig. 9A). Careful examination of neuronal extensions and vari-
cosities also did not reveal any signs of DAT redistribution in
response to PMA. To assess whether the enhanced constitutive
internalization seen in the neurons compared with HEK293 cells
was the result of generally increased PKC activity, we incubated
the cells with the PKC inhibitor staurosporine; however, also this
treatment did not alter the observed constitutive DAT internaliza-
tion (Fig. 9A) even though the same concentration of staurosporine
was capable of blocking PMA-induced internalization in HEK293
cells (supplemental Fig. S4B, available at www.jneurosci.org as sup-
plemental material). We tried in addition the more selective PKC
inhibitor GF109203X but due to autofluorescence from this com-
pound we were not able to obtain reliable imaging results (data not
shown).
Together, the data suggest that endogenously expressed DAT
is not subject to regulation by PKC in cultured dopaminergic
neurons. This is not due to lack of PKC expression since staining
with antibody directed against PKC suggested strong expression
of the kinase in the DAT-positive neurons (supplemental Fig.
S5A, available at www.jneurosci.org as supplemental material).
To demonstrate that PKC is not only expressed in the DAT-
positive neurons but also activated under the same experimental
conditions used above, we took advantage of a genetically en-
coded fluorescence resonance energy transfer (FRET)-based re-
porter for PKC activity, C kinase activity reporter (CKAR) (Vio-
lin et al., 2003; Gallegos et al., 2006). CKAR consists of cyan
fluorescent protein (CFP) and yellow fluorescent protein (YFP)
tethered together by a substrate peptide specific for PKC and an
FHA2phosphopeptide-bindingmodule. PhosphorylationofCKAR
by PKC results in a decrease in the FRET signal between CFP and
YFP, which can be measured as an increase in CFP/YFP emission
ratio (Violin et al., 2003; Gallegos et al., 2006). First, we transiently
expressedCKAR inHEK293 cells andmeasured theCFP/YFP emis-
sion ratio over time. PMA (1 M) caused a rise in the CFP/YFP
emission ratio, corresponding to a decrease in the FRET signal and
consistent with PMA-mediated activation of PKC (supplemental
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Figure 7. JHC 1–64 labels dopamine transporter (DAT)-positive, tyrosine hydroxylase (TH)-
positive, and VMAT2-positive neurons. Cultured postnatalmidbrain neuronswere labeledwith
10 nM JHC 1–64 for 20 min before they were fixed and stained for either DAT (A), TH (B), or
VMAT2 (C). A, Costaining of dopaminergic neuron with JHC 1–64 and rat anti-DAT antibody
(MAB369) shown in two different magnifications. DAT immunoreactivity overlaps extensively
in the extensions and in the plasma membrane of the soma. B, Costaining of dopaminergic
4
neuronwith JHC1–64andanti-THantibody. Top row, Threedifferent overlays of JHC1–64and
TH staining. Although present in the same neuron, the staining did not overlap, i.e., JHC 1–64
primarily stained the plasma membrane, whereas the TH staining appeared intracellular. The
rounded strongly stained structure in the left picture is likely to represent a dead or dying cell
and, thus, does not represent specific DAT staining by JHC 1–64. Similar rounded structures can
also be seenwhen stainingwith JHC 1–64 in the presence of an excess of dopamine or inhibitor
(Fig. 5B). Bottom row, JHC 1–64 labeling alone (left), TH staining alone (middle), and overlay
(right) corresponding to a neuronal extension with characteristic varicosities. C, Costaining of
dopaminergic neuronwith JHC1–64andanti-VMAT2antibody. JHC1–64 labeling alone (left),
VMAT2 staining alone (middle), and overlay (right) corresponding to several neuronal exten-
sions. Bottom, Overlay of JHC 1–64 and VMAT2 labeling of an entire dopaminergic neuron. The
image illustrates thewidespread presence of DAT and its colocalizationwith VMAT2. JHC 1–64
was visualized by using a 543 nm HeNe laser for excitation and a585 nm long-pass filter for
recording of fluorescence. DAT antibody, TH antibody, and VMAT2 antibody were visualized
either using Alexa Fluor 488 goat anti-rat or anti-rabbit antibody. The experiments shown are
representative of at least three similar experiments with the same results.
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Fig. S5B,C, available at www.jneurosci.org as supplemental mate-
rial). Next, we expressed CKAR in our midbrain neuronal cultures
using lentiviral transduction. The dopaminergic neurons expressing
CKAR were identified with JHC 1–64. As shown in supplemental
Figure S5C (available at www.jneurosci.org as supplemental mate-
rial), stimulation with PMA resulted in a significant increase in the
CFP/YFP emission ratio, demonstrating PMA-mediated activation
of PKC in dopaminergic neurons similar to what was observed in
HEK293 cells.
To obtain further support for the ab-
sence of PKC regulation in cultured DAT-
positive neurons, aswell as to obtain a quan-
titative measure, we analyzed the effect of
PKC activation and inhibition on [3H]do-
pamine uptake.Uptakewasmeasured by in-
cubating neurons in culture with 100 nM
[3H]dopamine for 3min, resulting in a spe-
cific uptake of 403  58 pmol/min/well
(mean SE, n 4, nonspecific uptake de-
termined in the presence of 10M cocaine).
As shown in Figure 9B, neither PKC activa-
tion with PMA nor PKC inhibition with
staurosporine or GF109203 had any de-
tectable effect on the measured uptake.
Using a 10 times higher concentration of
[3H]dopamine did also not reveal any ef-
fect of PMA on uptake in the dopaminer-
gic neurons (uptake in response to 1 M
PMA was 98.9  3.9% of control uptake;
mean SE, n 3).
To investigate further the constitutive
internalization of JHC 1–64-labeled DAT,
we used recombinant lentiviral vectors to
mediate expression of the dominant-
negative dynamin mutation K44A (van
der Bliek et al., 1993; Robinson, 1994). To
identify transduced cells the vector also
encoded GFP separated from dynamin by
an internal ribosome entry site (dynamin
K44A IRES-GFP). Accordingly, GFP-
positive cells indicated efficient lentiviral
transduction. First, we performed experi-
ments in DAT expressing HEK293 cells
(supplemental Fig. S6, available at www.
jneurosci.org as supplemental material).
In these cells, transduction with lentivirus
encoding dynamin K44A, but not wild-
type dynamin, strongly inhibited PMA-
induced internalization, in agreement
with previous observations for heterolo-
gously expressed DAT in MDCK cells
(Daniels and Amara, 1999) (supplemental
Fig. S6, available at www.jneurosci.org as
supplemental material). Next, we trans-
duced our dopaminergic neurons and
constitutive internalization of JHC 1–64-
labeled DAT was assessed as described in
Figure 9A. A substantial reduction in the
amount of constitutively internalized JHC
1–64-labeled DAT was observed in the
neurons expressing dynamin K44A,
whereas this was not the case in neurons
expressing dynamin wild type (Fig. 10A).
This suggests that endogenously expressed DAT undergoes con-
stitutive endocytosis via a dynamin-dependent pathway. Note
that although the general transduction efficiency of neurons in
the culture was high, only a relatively small fraction of the DAT-
positive neurons was transduced and expressed the dynamin
constructs, which underlines the general difficulty in achieving
heterologous expression in this type of neurons.
To assess whether JHC 1–64-labeled DAT indeed was consti-
tutively internalized to an endosomal compartment we trans-
Figure 8. DAT is highly mobile in the plasma membrane of dopaminergic neurons. A, FRAP measurements on JHC 1–64-
labeled DAT in dopaminergic neurons in culture. The neurons were incubated with 5 nM JHC 1–64 for 20 min at RT, washed in
buffer, and kept in bufferwith 10MRTI55during the experiment to avoid anypotential rebindingof JHC1–64 toDAT. Left, FRAP
wasmeasured at two anatomically distinct locations in the neurons: corresponding to the neuronal extensions and corresponding
to the varicosities. Right, Representative FRAP measurements corresponding to an extension and a varicosity. The calculated
average diffusion coefficients (D) are indicated. The mobile fractions constituted in the boutons 72.0  10.2% and in the
extensions 75.3 7.3% (n 20–22) of the labeled transporters. B, Illustration of bidirectional lateral movements of DAT
along the neuronal extensions. The neurons were labeled as described above with JHC 1–64 before bleaching the area indicated
by thewhite box using the 488nm laser line at 100%output for700ms to obtain 30–70%bleaching comparedwith prebleach
image. Subsequently, thebleachedareawasmonitoredand images takenwith appropriate time intervals. The experiment shown
is representative of at least three similar experiments.
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duced the neuronal culture with lentivirus
encoding the early endosomal marker
Rab5A tagged with EGFP (EGFP-Rab5A)
(Zerial and McBride, 2001; Deneka et al.,
2003; Lavezzari et al., 2004). As for the dy-
namin constructs, we observed generally a
high transduction efficiency in the culture
with rather low transduction efficiency in
the dopaminergic neurons.However, in all
experiments we were able to identify a
number of healthy DAT-positive neurons
expressing EGFP-Rab5A. EGFP-Rab5A
localized, as would be expected, to vesicu-
lar structures in the neurons as well as
some nonvesicular cytosolic expression
was apparent (Fig. 10B). In constitutive
internalization experiments, performed as
described in Figure 9A, we observed in the
dopaminergic neurons after 60 min of in-
cubation at 37°C several vesicles positive
for both JHC 1–64/DAT and EGFP-
Rab5A, supporting constitutive internal-
ization into early endosomes (Fig. 10B). In
some cases, we observed vesicles close to
the plasma membrane likely reflecting re-
cent endocytic events (Fig. 10B, right
arrow).
We also performed constitutive inter-
nalization experiments upon labeling
DAT with JHC 1–64 and the transferrin
receptor with Alexa Fluor 488-conjugated
transferrin. The transferrin receptor is in-
ternalized into early endosomes followed
by sorting to recycling endosome (Blan-
pied et al., 2002). After 30 min, we ob-
served modest JHC 1–64/DAT internal-
ization and marked overlap with
transferrin receptor-positive vesicles,
again consistent with constitutive inter-
nalization of DAT into early endosomes.
After 60 min, both JHC 1–64/DAT and
transferrin receptor internalization were
more pronounced; however, there was a
tendency toward less colocalization of JHC
1–64 with transferrin-positive vesicles,
which may be indicative of differential
sorting of DAT and transferrin receptor
(Fig. 10C).
We further explored the constitutively
endocytosed JHC 1–64/DAT complex by
confocal live imaging. We allowed consti-
tutive internalization to occur by incubat-
ing JHC 1–64-labeled dopaminergic neu-
rons for 1 h of incubation at 37°C and
subsequently performed time laps with
300 pictures in 20min at 37°C. A represen-
tative example of a movie resulting from
this protocol is provided in the supple-
mental material (supplemental Movie 2,
available at www.jneurosci.org). The acquired movies revealed
multiple JHC 1–64/DAT-positive vesicles undergoing frequent
“stepwise” movements. A careful analysis suggested that the ves-
icles could be divided into at least two major types depending on
their mobility pattern. One type of vesicle was essentially immo-
bilized during the observation period of 10 min (vesicles indi-
cated by red arrows in Fig. 11). In contrast, other vesicles under-
went often rapid movements over rather long distances during
Figure 9. Visualization of constitutive DAT internalization in cultured midbrain dopaminergic neurons (7–10 DIV) using JHC
1–64. A, Images of representative neurons incubated under indicated conditions. JHC 1–64 was visualized by using a 543 nm
HeNe laser for excitation and a585 nm long-pass filter for recording of fluorescence. The images show the fluorescence on a
gray scale with darkest pixels representing the largest fluorescence. The neurons were first incubated with 5 nM JHC 1–64 for 30
min at 4°C to label surface DAT. Subsequently, the neuronswere further incubated at 37°C for 30min (top left), at 37°C for 60min
(top right), at 4°C for 60min (middle left), at 37°C for 60min in the presence of 450mM sucrose (middle right), at 37°C for 60min
in the presence of 1M PMA (bottom left), and at 37°C for 60 min in the presence of 1M staurosporine (bottom right). The
images suggest that the JHC 1–64/DAT complex undergoes temperature-dependent constitutive internalization that is blocked
by sucrose. Moreover, and in contrast to what was observed in HEK293 cells, there is no effect on internalization in response to 1
M PMA. Note that the sucrose treatment slightly alters the appearance of the neuron and makes the membrane looks thicker
than in neurons thatwere not treatedwith sucrose. Scale bar, 20m. The experiments shown are representative of at least three
similar experiments.B, [ 3H]dopamine uptake in culturedmidbrain neuronswas unaffected by PKC activationwith 1MPMAand
by PKC inhibition with staurosporine and GF109203X. [ 3H]dopamine uptake under control conditions was 403 58 pmol/min/
well. Data are means SE, n 4, p 0.68, one-sample t test.
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the observation period. The movements of
these vesicles appeared to occur both toward
and away from the soma (see supplemental
Movie 2, available at www.jneurosci.org as
supplemental material). In conclusion, the
data support the existence of an intracellular
transporter pool contained in vesicles with
distinctmobilitypatterns,whichcanbevisu-
alized using fluorescently labeled cocaine
ligands.
Discussion
Despite the physiological importance of
DAT and its role as drug target, little is
known about trafficking of DAT in its na-
tive environment and how these processes
are regulated. Due to the lack of appropri-
ate tools, the majority of studies has been
performed with epitope-tagged trans-
porter in transfected, heterologous cells
and, hence, the significance of many ob-
servations has not been evaluated in dopa-
minergic neurons where DAT is endog-
enously expressed. Here we have
addressed this problem by using fluores-
cently tagged, high-affinity cocaine ana-
logs that permitted direct visualization of
endogenously expressedDAT in live dopa-
minergic neurons.
Previously, we demonstrated synthesis
of rhodamine-coupled cocaine analogs
with preserved high affinity for the DAT
(Cha et al., 2005). Here we introduce two
additional high-affinity analogs coupled to
two different fluorescent labels, OR Green
and Cy3, each with distinct spectral prop-
erties. To validate the usefulness of these
analogs, we performed a series experi-
ments in transfectedHEK293 cells and, to-
gether, the data strongly support that the
fluorescently tagged compounds label
DAT with high specificity and can be used
to track DAT in live cells. For JHC 1–64,
we provide evidence for a very slow
Figure 10. DAT internalizes in dopaminergic neurons into early endosomes in a dynamin-dependent manner. A, Constitutive
internalization is inhibited by overexpression of the dominant-negative dynamin mutation K44A. The neurons were transduced
after 2–3 DIVwith lentivirus encoding dominant-negative dynamin K44A orwild-type dynamin, both coupled to GFP expression.
The analysiswasperformedafter 8–10DIV. Theneuronswere first incubatedwith 5nM JHC1–64 for 30minat 4°C to label surface
DAT. Subsequently, the neurons were further incubated for 60 min at 37°C to allow DAT internalization. In neurons expressing
dynamin K44A, a substantial reduction in the amount of constitutively internalized DATwas observed,whereas overexpression of
wild-type dynamin did not block internalization. In neurons overexpressingwild-type dynamin, selected internalized JHC 1–64-
positive vesicles are indicated by arrows. B, DAT internalizes into early endosomes. The neurons were transduced after 2–3 DIV
with lentivirus encoding the early endosomalmarker EGFP-Rab5A and analyzed after 8–10 DIV. Constitutive internalization was
allowed as described above. In neurons expressing EGFP-tagged Rab5A, partial overlap between JHC 1–64- and EGFP-Rab5A-
positive vesicleswas seen. Selected costained vesicles are indicated by arrows. Some costained vesicleswere localized close to the
plasmamembrane, probably indicating recent endocytic events.However, JHC1–64-positive vesicles thatwerenot EGFP-Rab5A-
4
positive were also observed. Left panels show fluorescence in
the 585 nm channel (JHC 1–64), middle panels fluores-
cence in the 505–530 nm channel (GFP or EGFP), and right
panels show overlay of the two channels. The experiments
shownare representativeof 3–5 independent experiments.C,
Internalized DAT partially colocalizes with the transferrin re-
ceptor. Dopaminergic neurons at 8–10 DIV were incubated
for 30min at 4°Cwith 5 nM JHC 1–64 to label surface DAT and
with AlexaFluor 488-conjugated transferrin to label the trans-
ferrin receptor. Subsequently, the neurons were further incu-
bated for 30 (30	) and 60 (60	) min at 37°C to allow internal-
ization. At 30min, JHC 1–64/DAT internalizationwasmodest
butwithmarkedoverlapwith transferrin-positive vesicles. Af-
ter 60min, amore pronounced JHC 1–64/DAT internalization
was observed with partial colocalization with transferrin-
positive vesicles. Selected costained vesicles are indicated by
arrows. The experiment shown is representative of three in-
dependent experiments.
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dissociation-rate permitting tracking of DAT molecules in live
cells over even an extended period of time.
It is a potential concern that by using the fluorescently tagged
cocaine analogs we study an inhibitor-occupied transporter. Pre-
viously, it has been suggested that cocaine causes acute upregu-
lation of DAT surface expression in transfected HEK293 cells
(Daws et al., 2002). Thus, inhibitor binding might affect DAT
trafficking; however, although the effect of cocaine on DAT traf-
ficking was significant, the magnitude of the response was rela-
tively modest (Daws et al., 2002). In addition, cocaine was found
not to affect PMA-induced DAT internalization in GFP-
expressingMDCK cells (Daniels and Amara, 1999).Wewere also
unable to see any effect of JHC 1–64 on surface expression and
constitutive trafficking of HA-tagged DAT in HEK293 cells;
hence the effect of JHC 1–64 on endogenous DAT trafficking is
likely to be absent or very minor.
Labeling of midbrain dopaminergic neurons with either JHC
1–64 or MFZ 9–18 revealed a uniform distribution of the DAT
with labeling of somas, extensions, and varicosities. Z-stacking
analysis allowed us to correlate staining with neuronal morphol-
ogy and validate the widespread labeling ofDAT in the individual
neurons (Fig. 6). As expected, neurons that were stained with
JHC 1–64 also displayed staining for VMAT2; however, whereas
the VMAT2 staining localizes solely to varicosities along the ex-
tensions, JHC 1–64 staining, and thus DAT, was present not only
in the varicosities but also along the extensions as well as in the
plasma membrane of the soma. Of interest, the network of neu-
ronal extensions in the DAT-positive neurons is likely to be
mostly axonal as supported by costainings of our culture forDAT
and for the dendritic marker MAP2 (supplemental Fig. S7, avail-
able at www.jneurosci.org as supplemental material).
Although the expression pattern in cultured neurons might
not be identical to that found in situ, it is interesting to consider
our observations in context of earlier EM studies in rat brain
(Nirenberg et al., 1996, 1997; Hersch et al., 1997). These studies
also provided evidence for widespread expression of DAT in ax-
ons as well as in dendrites. Moreover, they suggested perisynap-
tic/extrasynaptic localization of DAT challenging the classical
paradigm of preferential presynaptic localization of DAT (Niren-
berg et al., 1996, 1997; Hersch et al., 1997). Altogether, the
present data add further support to the notion that DAT is not
fulfilling its indispensable role in maintaining low extracellular
levels of dopamine by being discretely expressed close to the do-
pamine release sites but rather by being present throughout the
plasma membrane in the dopaminergic neurons.
This view is further supported by our FRAP measurements
providing evidence that the JHC 1–64-labeled DAT in cultured
dopaminergic neurons is highly mobile with mobile fractions
constituting 70% of the JHC 1–64-labeled transporter mole-
cules both in varicosities and in the neuronal extensions. The
calculated diffusion coefficients (0.5–1.1  109 cm2/s) were
consistent with a relatively freely diffusing protein in the mem-
brane (Lippincott-Schwartz et al., 2001). Of note, these values
resembledmore the values thatwe obtained previously for EGFP-
tagged DAT in HEK293 cells (0.4  109 cm2/s) than for
EGFP-tagged DAT expressed in neuronally derived N2a cellsFigure 11. Tracking of internalized JHC 1–64/DAT-positive vesicles in culturedmidbrain dopa-
minergic neurons. The neurons (6 DIV) were labeled with 5 nM JHC 1–64 at 37°C for 1 h to allow
labelingand internalizationof theDAT/JHC1–64 complex. Subsequently, time lapswereperformed
with 300 pictures in 20 min using a heated stage (37°C) on the LSM510 confocal microscope. JHC
1–64was visualizedbyusing a543nmHeNe laser for excitation anda585nm long-pass filter for
recording of fluorescence. The images show the fluorescence on a gray scalewith darkest pixels rep-
resenting the largest fluorescence.A representativeexampleofamovie resulting fromthisprotocol is
provided in the supplementalmaterial (supplementalMovie 2, available atwww.jneurosci.org). Se-
4
lected images from this movie at indicated time points are shown. The larger fraction of the
vesicles seemed to be stationary (exemplified by the 2 vesicles indicated by the red arrows),
whereas a smaller fractionunderwent often rapidmovements over rather longdistances during
the observation period (vesicles indicated with green arrows). Scale bar, 20m.
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(0.1  109 cm2/s) (Adkins et al., 2007). Thus, DAT appar-
ently displays less restricted diffusion in dopaminergic neurons
and thereby in a native environment comparedwith a transfected
neuronal cell line.
In heterologous cell lines, it is well established that activation
of PKC by PMA leads to DAT internalization. The effect is not
caused by direct phosphorylation of DAT (Granas et al., 2003)
but more likely the result of ubiquitination of a cluster of lysines
in the N terminus (Miranda et al., 2007). Although well estab-
lished in heterologous cells, the effect on internalization has not
yet been assessed for endogenously expressed DAT in cultured
neurons. Interestingly, the current data strongly support that
DAT is not subject to regulation by PKC in neurons as we were
unable to see any difference compared with control after PMA
stimulation or inhibition of PKC with staurosporine. Moreover,
the lack of an effect in response tomodulation of PKCactivitywas
supported by dopamine uptake experiments showing no change
in response to PMA and two different PKC inhibitors. The lack of
an effect was also unlikely caused by enhanced tyrosine kinase
activity, which was suggested to inhibit PMA-mediated redistri-
bution of the GABA transporter-1 (Quick et al., 2004); hence,
pretreatment with the tyrosine kinase inhibitor genistein did not
uncover an effect of PMA on DAT in the neurons (data not
shown). Of note, our findings agree with recent observations in
cultured prenatal midbrain neurons that were transfected with
epitope-tagged DAT and in which no visible effect of PMA was
seen (Sorkina et al., 2006). However, PMA treatment of cocul-
tures of midbrain and striatal neurons, as well as PMA treatment
of striatal, synaptosomal preparations, was previously found to
reduce DAT uptake activity (Vaughan et al., 1997; Chi and Reith,
2003; Hoover et al., 2007). Thus, although we were unable to see
PKC-mediated regulation in cultured midbrain neurons we can-
not exclude that under certain conditions endogenous DAT
might be subject to regulation by this kinase.
While unable to observe an effect of PKC modulation, we
observed constitutive, temperature-dependent intracellular ac-
cumulation of JHC 1–64-labeled transporter over time.We were
only able to visualize the constitutive internalization in the soma
and proximal neuronal extensions. This might suggest that the
internalization only occurs here; however, we cannot exclude
that we do not have sufficient resolution to see endocytosis in the
thin neurites. Constitutive DAT internalization has been shown
before in transfected heterologous cells (Holton et al., 2005;
Sorkina et al., 2005) and aC-terminalmotif has been suggested to
mediate this constitutive internalization (Holton et al., 2005). In
this study, we demonstrate that constitutive trafficking is indeed
not restricted to heterologously expressed transporter but also is
seen for DAT expressed in its native environment and that this
internalization likely is mediated via a dynamin-dependent path-
way. Dynamins have been identified as a key component and
marker of clathrin-mediated endocytosis (van der Bliek et al.,
1993; Robinson, 1994); hence, it is likely that constitutive endo-
cytosis of endogenous DAT follows the same pathway as that
suggested previously for heterologously expressed DAT (Sorkina
et al., 2005; Rappoport, 2008). However, it is important to note
that nonclathrin but dynamin-dependent pathways such as raft-
mediated endocytosis also have been identified and may be re-
sponsible for or contribute to constitutive DAT endocytosis (La-
joie and Nabi, 2007). Of further interest, we obtained data
suggesting that internalized JHC 1–64-labeled DAT colocalized
in part with EGFP-Rab5A, a small GTPase localized to the early
endocytic pathway (Zerial and McBride, 2001; Deneka et al.,
2003; Lavezzari et al., 2004) and with the transferrin receptor,
another marker of the early endocytic pathway (Blanpied et al.,
2002). The colocalizationwas only partial, which is not surprising
given that constitutive endocytosis is not a synchronized event
elicited by a specific stimuli; hence, it would be expected that we
after the incubation period also will see JHC 1–64-labeled DAT
in other endosomal compartments along the endocytic pathway.
For transferrin, the colocalization seemed to diminish over time
possibly reflecting differential postendocytic sorting of DAT and
the transferrin receptor.
The visualization of endocytosed JHC 1–64-labeled trans-
porter suggests furthermore that cultured dopaminergic neurons
contain a pool of intracellular transporter. Live imaging of the
internalized transporter allowed us to follow movements of the
intracellular vesicles. In this way, we identified JHC 1–64-
positive vesicles that either were essentially immobilized or un-
dergoing rapid movements during the observation period. Fu-
ture studies are required to characterize the functional
implications of these observations; however, it is tempting to
speculate that the endocytosed JHC 1–64-labeled DAT unravel a
recruitable pool of transporters that might permit rapid adapta-
tion of the neuron to immediate changes in the need for neuro-
transmitter reuptake. Interestingly, a pool of intracellular trans-
porters has before been suggested to exist for DAT (Buckley et al.,
2000; Johnson et al., 2005) as well as for the homologous GABA
transporter-1 (Wang and Quick, 2005).
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Supplementary Figure 1 
 
 
 
 
 
 
Fig. S1. Specific labeling of DAT with the fluorescent cocaine analogue MFZ 9-17. A, 
Structure of the Cy3 conjugate MFZ 9-17. The compound was synthesized as described in 
Experimental Procedures by extending the fluorescent tag from the N- position of 2β-
carbomethoxy-3β-(3,4-dichlorophenyl)tropane using an ethylamino-linker. B, Live HEK293 cells 
stably expressing DAT preincubated with 10 nM MFZ 9-17 for 20 min at RT (upper panels) or 
with 1 mM dopamine for 15 min followed by 10 nM MFZ 9-17 for 20 min at RT (lower panels).  
MFZ 9-17 was visualized using a 543 nm HeNe laser for excitation and a >585 nm long pass 
filter for recording of fluorescence. Left panels show fluorescence in the >585 nm channel, 
middle panels transmitted light and right panels overlay of the two channels. 
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Fig. S2. JHC 1-64 does not influence DAT surface expression or constitutive 
internalization in HEK293 cells. A, HEK293 cells transiently expressing DAT containing an HA 
tag in the second extracellular loop (HA-hDAT) (Sorkina et al., 2006) were incubated with PMA 
or indicated conentrations of JHC 1-64 for 1 hour before quantification of surface DAT by ELISA 
as described in Supplementary Material and Methods. None of the tested JHC 1-64 
concentrations differed significantly from vehicle whereas PMA significantly downregulated HA-
DAT surface expression (P<0.05, n=3, one sample t-test). Data are means ± SE. B, C, HEK293 
cells expressing HA-hDAT were incubated with 5 nM JHC 1-64 (B) or 1 μg/ml Alexa Fluor 488-
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conjugated HA.11 antibody (C) in buffer 1 for 20 minutes at RT to label HA-hDAT. 
Subsequently, the cells were either washed in buffer 1 and imaged (0’) or incubated for 60 
minutes at 37°C and then washed and imaged (60’). At time 0’ no intracellular accumulation of 
either JHC 1-64 or HA.11 was visible. However, after 60 minutes of incubation at 37°C a weak 
intracellular accumulation of JHC 1-64 (B) and HA.11 (C) was observed (60’). This most likely 
represents modest constitutive internalization of HA-hDAT. (D) HEK293 cells expressing HA-
hDAT were incubated with both 5 nM JHC 1-64 and 1 μg/ml Alexa Fluor 488-conjugated HA.11 
antibody for 20 min at RT before the cells were either washed and imaged (0’) or incubated for 
60 minutes at 37°C and then washed and imaged (60’). In this experiment a similar pattern was 
observed indicating that constitutive DAT internalization does not seem to be affected by JHC 1-
64. The overlays with transmission pictures confirm the specificity of JHC 1-64 as only cells 
labelled with HA.11 is labelled also with JHC 1-64 (D) showing that DAT is necessary for JHC 1-
64 binding. Images are representative of three independent experiments. 
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Supplementary Figure 3 
 
 
 
 
 
 
 
Fig. S3. JHC 1-64 has a slow off-rate from DAT and inhibits DA uptake after prolonged 
wash-out. HEK293 cells transiently transfected with DAT were incubated with either 100 nM 
JHC 1-64, 500 nM JHC 1-64 or vehicle (0.01% DMSO or 0.05% DMSO) for 30 minutes at RT. 
The cells were subsequently washed and incubated for 0, 20, 40, or 60 minutes at 37ºC. 
Following two additional washes [3H]dopamine uptake was assayed. At all time points and at 
both concentrations, JHC 1-64 inhibited [3H]dopamine uptake significantly. A tendency towards 
an increased uptake over time is seen. Data are means ± SE, n=3. 
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Fig. S4. PMA-induced internalization of JHC 1-64 labeled DAT in HEK293 cells is blocked 
by sucrose and staurosporine.  A, HEK293 cells stably expressing wild type DAT were 
labeled with 5 nM JHC 1-64 at RT for 20 min before incubation for 30 min (upper panels) and 60 
min (lower panels) at 37°C in the absence or presence of 1μM PMA with and without addition of 
450 mM sucrose as indicated, or B, pre-incubated with 1 μM staurosporine as indicated. JHC 1-
64 was visualized using a 543 nm HeNe laser for excitation and a >585 nm long pass filter for 
recording of fluorescence. The images show the fluorescence on a gray scale with darkest 
pixels representing the largest fluorescence. In the absence of PMA, there is hardly any 
redistribution of JHC 1-64 labeled DAT even after one hour of incubation. In the presence of 
PMA, intracellular fluorescence appeared in vesicular structures during the incubation period 
consistent with internalization of the transporter. This redistribution was completely blocked by 
sucrose in agreement with internalization through a clathrin-dependent pathway. Furthermore 
the PMA-induced internalization was blocked by the non-specific PKC inhibitor staurosporine. 
Scale bar 20 μm. 
Eriksen et al.    7 
Supplementary Figure 5 
 
 
 
 
 
Fig. S5. Protein kinase C is expressed and activated upon PMA stimulation in 
dopaminergic neurons.  A, Midbrain neurons in primary culture were fixed, permeabilized and 
stained with a rat anti-DAT antibody (MAB369, 1:1000) and a rabbit PKC antibody (1:1000. 
Ac543-550, Calbiochem) recognizing a PKC consensus sequence. Secondary detection was 
obtained with Alexa Fluor 488 goat anti-rat and Alexa Fluor 568 goat anti-rabbit. DAT positive 
neurons also displayed substantial staining for PKC. As expected PKC staining was also seen 
in other neurons in the culture and in the glial cells. B, The CKAR PKC FRET sensor was 
transiently expressed in HEK293 cells and a CFP (C) and FRET (Y) picture was acquired every 
minute for 20 minutes. After 10 minutes, 1 μM PMA or 0.1% DMSO was added to the cells 
(indicated by arrow), and a decrease in the FRET signal was observed (as indicated by the rise 
in the C/Y ratio). C, CKAR was expressed in midbrain neuronal cultures by lentiviral 
Eriksen et al.    8 
transduction and the dopaminergic neurons were identified by labelling with JHC 1-64 (see inset 
picture). The dopaminergic neurons were imaged and stimulated with PMA as described for 
HEK293 cells with the exception that images were only acquired every second minute to reduce 
bleaching. The effect of PMA was quantified as the difference between the slope after 
PMA/vehicle and the slope before PMA/vehicle. There was a significant difference between 
vehicle and PMA-treated cells in both HEK293 cells (P<0.001, n=22 cells per condition) and DA 
neurons (P<0.5, n=7 neurons for vehicle and n=8 neurons for PMA), indicating that PMA 
activates PKC in both HEK293 cells and DA neurons. 
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Supplementary Figure 6 
 
 
 
 
 
 
 
 
 
Fig. S6. Dominant negative dynamin K44A blocks PMA-mediated JHC 1-64/DAT 
internalization in HEK293 cells. HEK293 cells stably expressing hDAT were transduced with 
lentivirus encoding either dynamin K44A or dynamin wild type. To identify transduced cells the 
vector also encoded GFP separated from dynamin by an internal ribosome entry site (dynamin 
K44A IRES-GFP). Accordingly, GFP positive cells indicated efficient lentiviral transduction. Five 
days after transduction, the cells were labeled with 5 nM JHC 1-64 at RT for 20 min before 
incubation for 30 min at 37°C in the presence of 1μM PMA. Cells expressing dynamin K44A 
showed almost no PMA-induced internalization, whereas cells overexpressing dynamin wild 
type retained the PMA-induced DAT internalization. 
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Supplementary Figure 7 
 
 
 
 
 
 
 
 
 
 
Fig. S7. Little co-localization between DAT and the dendritic marker MAP2. Midbrain 
neurons in culture were fixed, permeabilized and stained with rat anti-DAT antibody (MAB369, 
1:1000) and rabbit anti-MAP2 (1:1000) antibody. Secondary detection was obtained with Alexa 
Fluor 488 goat anti-mouse or Alexa Fluor 488 goat anti-rabbit, respectively. Extensive networks 
of DAT positive fibers were observed in the culture; however, only little overlap was seen with 
MAP2. In the representative picture, a network of DAT positive fibers surrounds the MAP2 
positive dendritic tree of another non-dopaminergic neuron.    
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Supplementary Materials and Methods 
 
Molecular Biology 
pCDNA3.1 CKAR was a generous gift from Dr. Alexandra Newton, San Diego, CA. To clone 
CKAR into the lentiviral vector pHSynXW, CKAR was PCR amplified from the pCDNA3.1 vector 
with a 5’ primer introducing a BsiWI site and a 3’ primer recognizing a sequence 3’ to the 
multiple cloning site in pCDNA3.1. The PCR fragment was digested with BsiWI and XbaI and 
ligated into pHSynXW digested with BsiWI and SpeI creating pHSynXW CKAR. 
 
HA-hDAT surface ELISA 
HEK293 cells transfected with hDAT with an extracellular HA epitope (HA-hDAT, as described 
in Sorkina et al. 2006) were seeded in 96 well plates (35,000 cells/well) the day before 
experiment. On the day of the experiment the cells were incubated with JHC 1-64 (500 nM, 100 
nM and 5 nM), PMA (1µM) or DMSO (0.1%) for 1 hour at 37ºC. After incubation, the cells were 
fixed in 4% PFA in PBS for 20 minutes on ice, washed twice in PBS, blocked in PBS + 5% goat 
serum for 30 minutes and incubated with HA.11 antibody (1:1000; Covance, Princeton, NJ) in 
PBS + 5% goat serum for 60 minutes. Following 4 washes in PBS, the cells were then 
incubated with HRP-conjugated goat anti-mouse antibody (1:1000; Pierce) for 30 minutes and 
subsequently washed 4 additional times in PBS. The HRP activity was detected and quantified 
instantaneously by chemiluminescence using Supersignal ELISA femto maximum sensitivity 
substrate (Pierce) and a Wallac Victor2 luminescence counter (PerkinElmer Life Science). 
 
JHC 1-64/HA.11 feeding experiment 
HEK293 cells, transiently transfected with HA-hDAT were grown in DMEM + 10% FCS and 
seeded in poly-L-ornithine treated 8-well LabTek Chambers (60,000 cells/well) the day before 
the experiment. On the day of the experiment, the cells were washed once in buffer 1, and then 
incubated with 5 nM JHC 1-64, 1μg/ml Alexa Fluor 488 conjugated HA.11 (Covance), or both for 
20 minutes to allow labeling of the transporters with a minimum of trafficking occurring. Then the 
cells were either washed (0 minutes constitutive internalization) or incubated for 60 minutes at 
37ºC (60 minutes constitutive internalization). Imaging was performed as described for EGFP-
tagged DAT and JHC 1-64. 
 
JHC 1-64 off-rate experiment 
HEK293 cells transfected with pCDNA3 hDAT were seeded in 24 well plates (100,000 cells per 
well) the day before the experiment. On the day of the experiment, the cells were washed once 
in buffer 1, and then incubated with either 500 nM, 100 nM JHC 1-64 or vehicle (0.05% or 
0.01% DMSO) for 30 minutes at RT. The solution was then aspirated and the cells washed once 
before incubation in buffer 1 for 0, 20, 40 or 60 minutes at 37°C. Subsequently the cells were 
washed twice and [3H]dopamine uptake was assayed as described in Experimental Procedures. 
 
CKAR imaging 
HEK293 cells were transfected with pCDNA3.1 CKAR (encoding a fluorescence resonance 
energy transfer-based reporter for PKCactivity, C kinase activity reporter) and seeded in LabTek 
chambers as described above. On the day of the experiment the cells were washed once in 
buffer 1 and incubated for at least 20 minutes at RT before microscopy. The cells were imaged 
at RT on a Zeiss Axiovert 200 with a 63x NA1.4 oil objective, and a cooled charge-coupled 
device camera (Coolsnap, Photometrics) controlled by MetaMorph software (Meta Imaging, 
Universal Imaging Corporation, V. 4.6). CFP and FRET images were obtained with 436 nm 
excitation from a TILL xenon lamp light source through a CFP/YFP beam splitter (JP4PC, 
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Chroma) and two separate emission filters (a 480/40 nm filter for CFP and a 535/40 nm filter for 
FRET, both filters from Chroma Technologies) on a LUDL filter wheel allowing a rapid change of 
filters. A CFP and corresponding FRET image was acquired every 1 minute (40 ms 
exposure/image). After 10 minutes 1 μM PMA or 0.1% DMSO was added and pictures were 
collected for another 10 minutes. 
 Midbrain dopaminergic neurons were transduced with CKAR virus on day 2 in vitro and 
experiments were done after 7-9 DIV. The cells were washed once in buffer 1 and then 
incubated with 20 nM JHC 1-64 to help identify doapminergic neurons and left at RT for at least 
20 minutes. The neurons were washed once in buffer 1 before imaging. CFP and FRET images 
were obtained every 2 minutes (80 ms exposure/image) and after 10 minutes 1 μM PMA or 
0.1% DMSO was added and pictures were collected for another 10 minutes. 
 The data were analyzed using ImageJ (Rasband, W.S., ImageJ, U. S. National Institutes 
of Health, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-2008). The somas of the 
cells were outlined, the mean pixel intensity for each cell soma was obtained and the average 
image background pixel intensity was subtracted from each cell. The ratio between CFP and 
YFP for each cell at each time point was calculated as a measure for FRET as previously 
described (Violin et al., 2003). As a measure of the change in FRET after addition of either 
vehicle or PMA, the slope ΔC/Y(t) of the curve representing the 6 minutes before stimulus was 
calculated and subtracted from the slope ΔC/Y(t) 0-6 minutes after stimulus. 
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Abstract 
The dopamine transporter (DAT) mediates reuptake of dopamine from the synaptic cleft and is 
target for widely abused psychostimulants such as cocaine and amphetamine. DAT is known to 
undergo marked constitutive endocytosis but little is known about the fate and sorting of the 
endocytosed transporter. Here we show that DAT upon constitutive endocytosis is sorted primarily 
to late endosomes and lysosomes rather than into a recycling pathway. To study sorting in 
heterologous cells lines we fused the one-transmembrane segment protein Tac to DAT, thereby 
generating a transporter (TacDAT) with an extracellular N-terminal antibody epitope suited for 
trafficking studies. TacDAT was fully functional and endocytosed constitutively in HEK293 cells. 
The intracellular accumulation was increased by the lysosomal protease inhibitor leupeptin and by 
monensin, an inhibitor of lysosomal degradation and recycling. However, monensin did not affect 
TacDAT surface expression, and constitutively internalized TacDAT primarily colocalized with the 
late endosomal marker Rab7. In the dopaminergic cell line 1Rb3An27, TacDAT, also constitutively 
internalized, and co-localized primarily with Rab7 as compared to the marker of recycling 
endosomes, Rab11. This pattern was distinct from a bona fide recycling membrane protein, the ß2-
adrenergic receptor, which colocalized primarily with Rab11. Constitutively internalized wild type 
DAT probed with the fluorescently tagged cocaine analogue, JHC 1-64, also exhibited Rab7 
colocalization in 1Rb3An27 cells. Finally, constitutively internalized DAT visualized with JHC 1-
64 in cultured dopaminergic neurons colocalized both with Rab7 and the lysosomal marker, 
LysoTracker Green. We conclude that independent of cell type DAT is constitutively internalized 
and primarily sorted to a late endosomal/lysosomal pathway. 
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Introduction 
The dopamine transporter (DAT) mediates reuptake of dopamine from the synaptic cleft and 
terminates in this way dopaminergic signalling and mediates recycling of released dopamine (Chen 
et al., 2004, Gether et al., 2006, Torres and Amara, 2007). Alteration in dopamine signalling and 
DAT function is coupled to neurological and psychiatric diseases including schizophrenia, bipolar 
disorder, ADHD (Attention Deficit Hyperactivity Disorder), Tourette’s syndrome and Parkinson’s 
disease (Gainetdinov and Caron, 2003, Torres et al., 2003, Gether et al., 2006). DAT is also the 
principle target for widely abused psychostimulants, such as cocaine and amphetamine (Chen et al., 
2004; Gether et al., 2006; Torres and Amara, 2007). The transporter belongs to the family of 
neurotransmitter:sodium symporters (NSS) (also called the SLC6 [solute carrier 6] family or 
Na+/Cl- coupled transporters) that also includes the transporters for other neurotransmitters such as 
the norepinephrine, serotonin, glycine and GABA. NSS proteins utilize the transmembrane Na+ 
gradient as a driving force for transport of substrate and are further characterized by additional co-
transport of Cl- (Chi and Reith, 2003, Gether et al., 2006, Torres and Amara, 2007).  
Numerous studies have supported that DAT is subject to dynamic regulation in the plasma 
membrane thereby providing a mean of attenuating or increasing the strength of dopaminergic 
signalling. The most intensively studied mechanism is the regulatory effect of protein kinase C 
(PKC) activation. It has been demonstrated in several DAT transfected heterologous cell lines as 
well as in synaptosomes that activation of PKC by phorbol esters, such as phorbol 12-myristate 13-
acetate (PMA), down-regulates dopamine transport (Copeland et al., 1996, Vaughan et al., 1997, 
Zhu et al., 1997, Daniels and Amara, 1999, Melikian and Buckley, 1999, Chi and Reith, 2003, 
Sorkina et al., 2005, Eriksen et al., 2009). The sustained DAT down-regulation in response to PKC 
activation is believed mainly to be a result of DAT endocytosis through a clathrin-dependent 
mechanism (Daniels and Amara, 1999, Melikian and Buckley, 1999, Chi and Reith, 2003, Sorkina 
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et al., 2005). DAT trafficking is also regulated by other protein kinases such as mitogen-activated 
protein kinase (MAPK) and Akt (Moron et al., 2003, Garcia et al., 2005) as well as by substrates 
and inhibitors (Zahniser and Sorkin, 2009).  
In addition, DAT undergoes a marked constitutive endocytosis, a property that first was 
described in heterologous cell lines (Chi and Reith, 2003, Loder and Melikian, 2003, Sorkina et al., 
2005). Subsequent mutational analyses suggested that this constitutive internalization is promoted 
by a non-conventional trafficking motif in the DAT C-terminus (Holton et al., 2005, Sorkina et al., 
2005) and possible negatively regulated by residues residing in the membrane proximal DAT N-
terminus (Sorkina et al., 2009). Recently, we demonstrated by use of the fluorescent cocaine 
analogue JHC 1-64 as label that DAT endogenously expressed in cultured midbrain dopaminergic 
neurons also undergoes constitutive internalization that, however, was neither sensitive to activation 
or inhibition of PKC (Eriksen et al., 2009). The constitutive DAT internalization was dynamin-
dependent and internalized transporter partially colocalized with the early endosomal markers Rab5 
and partially with endocytosed transferrin (Eriksen et al., 2009).  
A major question is the fate of the constitutively internalized transport protein. Previous 
studies in heterologous have indicated that DAT might be sorted to a recycling pathway (Loder and 
Melikian, 2003, Sorkina et al., 2005); however, postendocytic sorting of constitutively internalized 
DAT has not yet been analyzed in dopaminergic neurons as well as postendocytic sorting of 
constitutively internalized DAT in heterologous cells has not been analyzed in dynamic imaging 
experiments using co-expressed markers of distinct endocytic compartments. Here we investigate 
the postendocytic sorting of constitutively internalized DAT in both heterologous cells and cultured 
dopaminergic neurons. We take advantage of a fusion protein between the one-transmembrane 
segment protein Tac and DAT, which provides a transporter (TacDAT) with an extracellular N-
terminal antibody epitope. In the absence of a DAT antibody directed towards an endogenous 
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extracellular epitope, TacDAT enables the application of antibody feeding experiments and 
implementation of ELISA-based trafficking assays. Moreover, by use of the fluorescent cocaine 
analogue JHC 1-64 we are able to analyze postendocytic sorting of DAT in cultured dopaminergic 
neurons. Taken together, our data suggest that constitutively internalized DAT is sorted to a late 
endosomal/lysosomal degradative pathway in both neurons and cell lines. 
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Materials and Methods 
Molecular biology. TacDAT was generated by a two step PCR. First amplifying A) FLAG-Tac 
from pCDNA3 FLAG-Tac (Madsen et al., 2008) with primers generating an overhang identical to 
the N-terminal part of synDAT and B) amplifying part of synDAT from pCDNA3 synDAT with a 
5’ overhang identical to the C-terminal part of FLAG-Tac. Second, the products from the first round 
of PCR was used as template for generating a TacDAT fragment that was subsequently cloned into 
the pCDNA3 synDAT vector using KpnI and BamHI. pCDNA3.1 FLAG-ß2-adrenergic receptor 
was a kind gift from Dr. Mark von Zastrow . pEGFP-Rab4 was a kind gift from Dr. Jose A. 
Esteban. pEGFP-Rab7 and pEGFP-Rab11 were kind gifts from Dr. Katherine W. Roche. 
pHsSynXW EGFP-Rab7 and -Rab11 was generated by PCR amplifying the cDNA encoding region  
EGFP-Rab7 and 11 from pEGFP-Rab4 and pEGFP-Rab11, respectively. After digestion with 
BsiWI + MluI fragments were ligated into the lentiviral transfer vector pHSynCXW (Eriksen et al., 
2009). EGFP-Rab4 was cloned into pHsSynXW by excising EGFP-Rab4 from pEGFP-Rab4 with 
NheI and SalI and ligated into pHsSynXW digested with SpeI and SalI. The sequences of the 
cDNAs were verified by sequencing. 
 
Cell cultures and lentivirus production. HEK293 cells and 1Rb3An27 cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal calf serum, and transfected using 
standard Lipo2000 protocols two days prior to the experiment. Dopaminergic neurons and lentivirus 
were prepared as previously described (Eriksen et al., 2009). Briefly, Postnatally derived rat 
midbrain dopaminergic neurons prepared using a protocol modified from (Rayport et al., 1992). 
Briefly, the cultures were obtained from the ventral midbrain of 1- to 3-d-old pups. The dissected 
tissue sample was digested in a papain solution for 30 min at 37°C while slowly superfused with a 
mixture of 95% O2 and 5% CO2. The digested tissue was carefully triturated into single cells using 
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increasingly smaller pipette tips. The cells were centrifuged at 500 x g for 5 min and resuspended in 
warm SF1C consisting of 50% MEM (Modified Eagle’s Medium), 40% DMEM, and 10% F-12 
Ham’s nutrient mixture (all from Invitrogen) supplemented with bovine serum albumin (2.5 
mg/ml), D-glucose (0.35%), glutamine (0.5mM), 1% heat-inactivated calf serum (Invitrogen), 
kynurenic acid (5 mM), penicillin, streptomycin, liquid catalase (0.05%), and diPorzio (di Porzio et 
al., 1980). The neurons were plated on a monolayer of glial cells grown in LabTek wells. The cells 
were allowed to settle for 2 h before addition of GDNF (Millipore Bioscience Research Reagents) 
(10 ng/ml). The next day 5-fluorodeoxyuridine was added to inhibit growth of glial cells. 
Lentiviral vectors were produced according to procedures modified from Naldini et al (Naldini et 
al., 1996). HEK293T packaging cells were transiently triple transfected with the following: (1) 
packaging plasmid encoding viral structure proteins (p BR 8.91); (2) envelope plasmid encoding 
the envelope protein VSV-G (pMD.G); and (3) transfer plasmid containing the gene of interest 
(pHsSynXW EGFP-Rab4, -Rab7, -Rab11). Transfection was performed in DMEM (Invitrogen) 
supplemented with 10% FBS (Invitrogen) using calcium phosphate precipitation. Medium was 
replaced with fresh medium after 5 h. Approximately 48 and 72 h after transfection, media 
containing lentivirus was collected, centrifuged, filtered, and concentrated by ultracentrifugation at 
50,000 x g for 1.5 h at 4°C. The virus-containing pellet was resuspended in MEM (Sigma) at 1/280 
of the original volume and stored in aliquots at -80°C. The neuronal cultures were incubated with 
concentrated lentivirus on days 2–3 in vitro and experiments were performed 8–12 d after infection. 
 
[3H]Dopamine uptake experiments. Uptake assays were carried out as described previously (Loland 
et al., 2004) using 2,5,6-[3H]dopamine (9–13 Ci/mmol, Amersham Pharmacia Biotech), and 
HEK293 cells transfected with equal amounts of pCDNA3 synDAT or 1μg pCDNA3 were plated in 
either 24-well (105 cells per well). The uptake assays were carried out 2 d after transfection for 3 
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min at room temperature (20–22 °C) in uptake buffer (25 mM HEPES, 130 mM NaCl, 5.4 mM 
KCl, 1.2 mM CaCl2, 1.2 mM MgSO4, 1 mM L-ascorbic acid, 5 mM D-glucose and 1 M of the 
catechol-O-methyltransferase inhibitor Ro 41-0960 (Sigma), pH 7.4). 
 
ELISA internalization assay. HEK293 cells were transfected with Tac or TacDAT using 
Lipofectamine2000 at a 1:3 ratio to obtain similar surface expression and seeded in 96 well plates 
(35,000 cells/well) the next day. The experiment was performed 2 days after transfection. First, the 
cells were incubated with M1 (1μg/mL) in DMEM, 30 minutes at 4 °C, then media was replaced 
with 37 °C DMEM and placed at 37 °C (or 4 °C for surface quantification) for various periods with 
different compounds to drive internalization. To strip off surface M1, the cells were incubated with 
an acid strip buffer (0.5 M NaCl and 0.2 M acetic acid) for 5 minutes on ice, then washed twice 
with PBS and fixed in 4% paraformaldehyde in PBS and again washed twice in PBS. The cells 
were then blocked and permeabilized in PBS with 5% goat serum and 0.05% Triton X-100 for 30 
minutes (background subtraction was done with cells that were not permeabilized). Then the cells 
were incubated with horseradish peroxidase-conjugated goat antimouse antibody (1:1000; Pierce) in 
PBS + 5% goat serum for 30 minutes, and washed two times in blocking buffer + two times in PBS. 
SuperSignal ELISA Femto Maximum Sensitivity Substrate (Pierce) was added to the wells and the 
luminescence was detected in a Wallac Victor2 after 2 minutes. 
 
 
Surface ELISA. HEK293 cells transfected with HA-hDAT or TacDAT were seeded in 96 well 
plates (35,000 cells/well) the day before experiment. On the day of the experiment the cells were 
incubated with monensin (25 μM) or bafilomycin A (1 μM) for 1 hour at 37ºC. After incubation, the 
cells were fixed in 4% PFA in PBS for 20 minutes on ice, washed twice in PBS, blocked in PBS + 
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5% goat serum for 30 minutes and incubated with M1 (1:5000) or HA.11 antibody (1:1000; 
Covance, Princeton, NJ) in PBS + 5% goat serum for 60 minutes. Following 4 washes in PBS, the 
cells were then incubated with HRP-conjugated goat anti-mouse antibody for 30 minutes and 
subsequently washed 4 additional times in PBS. The HRP activity was described above. 
 
Immunofluorescence antibody internalization assays. HEK293 cells or 1Rb27An3 cells were 
transfected with Lipofectamine2000 two days prior to experiment and seeded on coverslips treated 
with poly-ornithine the next day. The cells were incubated with M1 antibody (1μg/mL) in DMEM 
for 30 minutes at 4° C. The media was then replaced with 37° C DMEM and placed at 37° C for 
various periods to drive internalization. The internalization was stopped by washing with cold PBS 
followed by fixation in 4% paraformaldehyde in PBS, washed 3 times in PBS and permeabilized in 
PBS with 5% goat serum and 0.2% saponin. Alexa568 anti-mouse (1:500, Molecular Probes) 
against M1 in PBS + 5% goat serum was added for 30 minutes and then the specimens were washed 
3 times in PBS prior to mounting. 
For the colocalization experiments the cells were transfected with equal amounts of TacDAT 
or FLAG-tagged ß2-adrenergic receptor and EGFP-Rab4, -Rab7 or -Rab11 and seeded on coverslips 
treated with poly-ornithine. On the day of the experiement the cells were incubated with Alexa568-
conjugated M1 antibody for 30 minutes at 4° C, the media was then replaced with 37° C DMEM (+ 
10 μM isoproterenol for experiments with the ß2-adrenergic receptor) and placed at 37° C for 1hour 
to allow internalization. The cells were subsequently fixed in 4% PFA in PBS and mounted. The 
stained cells were visualized using a Zeiss LSM 510 confocal laser-scanning microscope using an 
oil immersion NA1.4 63x objective. EGFP was excited with the 488 nm laser line from an argon–
krypton laser, and the emitted light was detected using a 505–550 nm bandpass filter, whereas the 
Alexa Fluor 568 dye was excited at 543 nm with a helium–neon laser, and the emitted light was 
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detected using a 585 nm long-pass filter. The resulting images were combined using IMAGEJ 
software. 
 
Colocalization quantification. Quantification of colocalization with EGFP-tagged Rab4, Rab7 and 
Rab11 was done using the RG2B colocalization plug-in to IMAGEJ (RasbandW. S., ImageJ, U. S. 
National Institutes of Health, Bethesda, MD, USA, http://rsb.info.nih.gov/ij/, 1997–2006) as 
described (Chmelar and Nathanson, 2006, Madsen et al., 2008). Single cells were defined as regions 
of interest to avoid noise from untransfected cells and non-specific staining. A minimum threshold 
pixel intensity of 120 was set for each channel and the minimum ratio for pixel intensity between 
the two channels was set to 0.5. Results are displayed as percent colocalization as determined by 
dividing the area of colocalization pixels by the total area over the threshold of the M1 signal. 30-35 
cells were used for quantification under each condition. Statistical significance was determined 
using a one way ANOVA with a Bonferroni multiple comparison test. Differences were considered 
significant when p < 0.05. 
 
DAT internalization with JHC 1-64.  1Rb3An27 cells or dopaminergic neurons were grown in poly-
L-ornithine treated LabTek Chambers. On the day of the experiment the cells were incubated with 
the indicated fluorescent cocaine analogues in uptake buffer with for designated time periods. 
To detect internalization in midbrain dopaminergic neurons and 1Rn27An3 cells, the cultures were 
incubated with 5 nM JHC 1-64 in uptake buffer for 30 minutes at 4°C, before the buffer was 
removed and replaced with 37°C warm uptake buffer and incubated for 60 minutes at 37°C. For the 
Lysotracker co-localization experiment we used Lysotracker Green (100nM; Molecular Probes) in 
the last 10 minutes of incubation, and subsequently the cells were washed in uptake buffer. After 
incubation, the living cells were imaged at RT using a Zeiss LSM 510 with a 63x NA1.4 objective 
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(Zeiss, Jena, Germany). JHC 1-64 was visualized using a 543 nm HeNe laser line and a 585 nm 
long pass filter, EGFP were detected with a 488 nm argon-krypton laser line and a 505-550 nm band 
pass filter and the distribution of JHC 1-64 on the neurons were analyzed with a Z-scan. 
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Results 
To enable the study of DAT trafficking with high specificity and to detect even small amounts of 
DAT endocytosis we generated a DAT construct with a high-affinity extracellular antibody epitope. 
To avoid disruption of the extracellular loops in the DAT, we decided to add an extra 
transmembrane segment to the N-terminus. This was done by making a head-to-tail fusion of the 
DAT and the single transmembrane segment protein Tac resulting in the fusion protein, TacDAT 
(Fig 1A). By fusing protein segments to the C-terminus of Tac, Tac fusion proteins has previously 
been used as a ‘silent reporter’ in several trafficking studies (Mu et al., 2003, Lavezzari et al., 2004, 
Holton et al., 2005, Lavezzari and Roche, 2007). At the Tac N-terminus, a FLAG epitope was 
introduced after the cleaved signal sequence (Madsen et al., 2008), which permitted the use of the 
mouse monoclonal M1 anti-FLAG antibody. Staining with M1 antibody of HEK293 cells 
expressing TacDAT demonstrated in the absence of permeabilization a clear surface staining, which 
confirmed that the N-terminal antibody epitope is exposed on the extracellular side of the plasma 
membrane and that the protein is expressed at the cell surface (Fig 1B). TacDAT was functionally 
analyzed in [3H]dopamine uptake experiments in transiently transfected HEK293 cells (Fig. 1C). 
TacDAT mediated efficient uptake (Vmax = 511 ± 104 fmol/min/105, means ± SE, n=3) although the 
uptake was reduced as compared to DAT (Vmax = 2486 ± 236 fmol/min/105, means ± SE, n=3, p = 
0.011, paired t-test). The Km value for TacDAT was not significantly different from DAT (p > 
0.05), i.e. Km for TacDAT was 0.40 μM [0.36; 0.47 μM] (mean [SE interval] n=3) and 0.92 μM [SE 
interval (0.62 - 1.4 μM), n=3] for DAT. As our experiment would involve TacDAT with the M1 
antibody bound, we made sure that M1 binding to TacDAT did not impair transporter function as 
determined by measuring [3H]dopamine uptake in the presence of bound M1 antibody (Fig. 1D).  
 
 12
Previously, an HA-tag was successfully introduced into the second extracellular loop of DAT 
(Sorkina et al., 2006). We decided to compare this tag directly with the FLAG tag in Tac-DAT in a 
cell-surface ELISA assay by generating a TacDAT construct also harbouring the HA-tag. 
Interestingly, the signal from the FLAG epitope was almost 10-fold higher than the equimolar 
signal from the HA epitope (Fig. 1E), making TacDAT preferred for studying low abundant DAT 
trafficking events. 
Next we wanted to test whether it was possible to detect previously proposed DAT trafficking 
properties using TacDAT in antibody based internalization assays. HEK293 cells transfected with 
TacDAT, or with Tac as a negative control, were incubated with M1 antibody at 4°C to label 
surface Tac or TacDAT. Subsequently, the cells were incubated at 37 °C to allow internalization for 
30 minutes (Fig. 2A). After 30 minutes of internalization, a visible intracellular accumulation of 
TacDAT was seen, consistent with constitutive endocytosis as previously described for DAT (Loder 
and Melikian, 2003, Sorkina et al., 2005). No visible intracellular accumulation of Tac was 
observed (Fig 2B and C). To further investigate the trafficking properties of TacDAT, we 
stimulated TacDAT expressing HEK293 cells with phorbol-12-myristate-13-acetate (PMA). 
Addition of PMA (1 μM) during the 30 min internalization period increased substantially the 
amount of intracellular localized TacDAT (Fig. 2C), showing that TacDAT is internalized in 
response to PMA as is the case for DAT. Tac alone did not respond to PMA (data not shown).  
Our data suggest that TacDAT not only is functional but also has retained the well-described 
trafficking properties of DAT in HEK293 cells. We decided, therefore, to use TacDAT in our 
further investigations. The presence of the efficient extracellular FLAG epitope allowed the use of a 
quantitative ELISA-based internalization assay. To perform the assay, TacDAT or Tac expressing 
cells were labelled with M1 antibody at 4 °C before internalization was allowed for 5-60 min with 
or without addition of PMA or the substrate amphetamine. Surface antibody was removed by acid 
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strip and intracellular transporter was measured by ELISA upon permeabilization of cells (Fig. 2D). 
Internalization was calculated as the amount of intracellularly accumulated TacDAT relative to 
initial TacDAT surface expression. In HEK293 cells transiently expressing TacDAT, a time-
dependent and saturating internalization was observed (Fig. 2E). Incubation with either 
amphetamine (10 μM) or PMA (1 μM), increased TacDAT internalization over time (Fig. 2E), 
whereas in cells transfected with Tac no increase the internalization of Tac at any time point was 
observed for PMA or amphetamine as compared to untreated Tac (Fig. 2E). The largest effects of 
the treatments were seen after 60 minutes of incubation (Fig. 2F) with a tendency towards saturation 
for all conditions (Fig. 2E).  
Next, we explored whether we could use the quantitative ELISA assay to investigate the fate 
of the constitutively internalized transporter (Fig. 2C and E). Specifically, we attempted to assess  
whether the internalized TacDAT was sorted to either lysosomal degradation or recycling by using  
compounds blocking either lysosomal degradation (the protease inhibitor leupeptin) or both 
recycling and lysosomal degradation (the proton ionophore, monensin). Leupeptin (100µg/ml, 1 
hour) increased significantly the accumulated M1 antibody signal in HEK293 cells transiently 
expressing TacDAT whereas no significant effect was seen in cells transiently expressing Tac (Fig. 
3A). An even more pronounced effect was observed for monensin on the intracellular accumulation 
of TacDAT (Fig. 3A). This effect could be the result of either inhbited lysosomal degradation or 
inhibited recycling. If it was the result of blocking recycling, a concomitant decrease in surface 
expression would be expected during the same period. We tested this using the surface ELISA 
assay; however, we observed no decrease in surface expression by incubating cells transiently 
expressing TacDAT for 60 min with monensin (Fig. 3B). We also tested the effect of bafilomycin 
A1, an H+-ATPase inhibitor, which is known to blocks recycling of the transferrin receptor and 
thereby reduce transferrin receptor surface expression (Presley et al., 1997). However, similar to 
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what we observed for monensin, bafilomycin A1 did not affect TacDAT surface expression (Fig. 
3B). We also tested the effect of bafilomycin A1 and monensin on HA-DAT in HEK293 cells and 
did not observe any effect the compounds on HA-DAT surface expression (Fig. S1) 
Rab proteins are small GTPases that organize membrane protein trafficking (Stenmark, 2009) 
and it has been demonstrated that Rab4 and Rab11 are critical for recycling of membrane proteins 
from early endosomes (‘short loop recycling’) and recycling endosomes (‘long loop recycling’), 
respectively (Jones et al., 2006). To assess whether constitutively endocytosed DAT recycled 
through any of these two pathways we co-expressed HA-DAT with dominant negative mutants 
(D.N.) of Rab4 (Rab4 D.N.) or Rab11 (Rab11 D.N.) (Yudowski et al., 2009); however, neither 
coexpression with Rab4 D.N. nor with Rab11 D.N. affected DAT steady state surface expression as 
compared to co-expression of Rab4 WT or Rab11 WT arguing further against a noteworthy 
continuous recycling of the transport protein in HEK293 cells (Fig. S2). 
Rab proteins also represent widely used markers of distinct endosomal compartments. We 
therefore employed confocal imaging together with co-expression of TacDAT and Rab proteins 
tagged with enhanced green fluorescent protein (EGFP) in HEK293 cells. This included EGFP-
Rab4 to visualize early endosomes and possibly the ’short loop recycling’ pathway, EGFP-Rab7 to 
visualize late endosomes, or EGFP-Rab11 to visualize recycling endosomes and the ‘long loop’ 
recycling pathway (Jones et al., 2006, Stenmark, 2009). The internalization assay was carried out 
with 1 hour of internalization as described in Fig. 2A, except that we used a primary fluorophore-
conjugated M1 antibody. This allowed us to visualize internalization without permeabilizing the 
cells, thereby keeping the cells intact and not disrupting any membranes or endosomal 
compartments. According to the resulting confocal images, TacDAT co-localized only to a limited 
degree with EGFP-Rab4 (Fig. 3C). Similarly, the co-localization of EGFP-Rab11 was limited with 
clearly distinct localization patterns for the M1 signal and the EGFP signal (Fig. 3C). In contrast, 
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the most prominent co-localization was observed for EGFP-Rab7 with multiple vesicular structures 
showing overlapping M1 and EGFP signals (Fig. 3C). In summary, our ELISA data (Fig. 3A, B) 
together with the colocalization data (Fig. 3C) support that in HEK293 cells constitutively 
internalized TacDAT is sorted primarily to a degradative pathway rather than to recycling. 
To assess whether constitutive internalization and postendocytic sorting was dependent on cell 
type, TacDAT was expressed in the dopaminergic cell line 1Rb3An27 (Adams et al., 1996). Similar 
to our observations in the HEK293 cells, TacDAT internalized constitutively whereas no detectable 
constitutive internalization was observed in cells transfected with Tac (Fig. 4A). Since the 
1Rb3An27 cells are difficult to transfect and because of poor cell adherence we were not able to 
obtain a sufficiently high specific signal to carry out the ELISA internalization assay. Instead we 
performed co-localization experiments like in the HEK293 cells. Similar to our observations in 
these cells, the confocal images indicated that TacDAT had the highest degree of colocalization 
with EGFP-Rab7, partial co-localization with EGFP-Rab4 and the lowest co-localization with 
EGFP-Rab11 (Fig. 4B) (Fig. 4B). Quantification of  the colocalization supported this with EGFP-
Rab7 colocalization being significantly higher than the colocalization with EGFP-Rab11 (one way 
ANOVA, p < 0.01, Bonferroni's Multiple Comparison Test) (Fig. 4D). The intermediate overlap 
with EGFP-Rab4 indicates that TacDAT is also found in an early endosomal compartment as 
expected since we have previously reported that is endycytosed through a dynamin-dependent 
mechanism to early endosomes (Eriksen et al., 2009). 
To verify that the sorting pattern observed for TacDAT was indeed a specific property of the 
transporter and not a pattern that would be seen for any membrane protein, we did parallel 
experiments in which we transiently expressed a FLAG-tagged ß2-adrenergic receptor (β2AR) in 
the 1Rb3An27 cells. The β2AR is internalized upon agonist treatment and the internalized receptor 
is efficiently recycled (Cong et al., 2001, Gage et al., 2001). In contrast to TacDAT, the β2AR 
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transiently expressed in 1Rb3An27 cells did not constitutively internalize to any detectable extent 
(data not shown); however, treatment of the cells with the agonist isopreteronol (10 μM) caused a 
marked time-dependent internalization (Fig. S3). Co-expression with the three EGFP-Rab proteins 
showed for the internalized receptor a pattern markedly different than that seen for internalized 
TacDAT. In the confocal images, the M1 antibody signal overlapped quite prominently with the 
signal from both EGFP-Rab4 and EGFP-Rab11 while rather little overlap was seen with the signal 
from EGFP-Rab7 (Fig. 4D). Quantification of the signals confirmed this by showing significantly 
higher colocalization of the internalized β2AR with EGFP-Rab4 and EGFP-Rab11 than with EGFP-
Rab7 (One way ANOVA, p < 0.001, Bonferroni's Multiple Comparison Test). This pattern of co-
localization is consistent with postendocytic sorting of the β2AR to recyling pathways rather then to 
degradation. Note that the association of the β2AR with both the Rab4 pathway (Yudowski et al., 
2009) and the Rab 11 pathway (Moore et al., 2004) has been described previously.  
 To exclude that TacDAT did not display altered postendocytic sorting as compared to DAT 
without Tac fused to the N-terminus, we performed experiments in 1Rb3An27 cells on non-tagged 
DAT using our previously described rhodamine-coupled cocaine analogue, JHC 1-64. This 
analogue enables fluorescent labelling of surface DAT in live cells with high specificity and was 
recently used to demonstrate constitutive internalization of endogenous DAT in dopaminergic 
neurons (Eriksen et al., 2009). Cells transiently co-expressing DAT and EGFP-tagged Rab4, Rab7 
or 11 were labelled with JHC 1-64 and analyzed by confocal imaging after 1 hour of internalization. 
Again we observed the most pronounced colocalization with EGFP-Rab7 and rather limited co-
localization with EGFP-Rab4 and EGFP-Rab11 (Fig. 5). We also carried out time series 
experiments in the 1Rb3An27 cells expressing both DAT and EGFP-Rab7 showing that DAT 
positive vesicles and EGFP-Rab7 positive vesicles were indeed identical as they co-migrated over 
time (Fig. S4). Moreover, DAT Internalization in cells co-expressing HA-DAT and EGFP-tagged 
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Rab4, Rab7 or 11 was probed with the HA.11 antibody and once again we saw a higher degree of 
colocalization between HA-DAT and EGFP-Rab7 than between HA-DAT and GFP-Rab11 (Fig. 
S5). 
 Finally, we tested whether the same postendocytic sorting pattern was observed for 
endogenous DAT in dopaminergic neurons. As mentioned, we recently demonstrated a marked 
constitutive internalization of DAT in these neurons by labelling DAT with the fluorescent cocaine 
analogue JHC 1-64. To determine the sorting of this constitutively internalized DAT, the 
dopaminergic cultures were transduced at 2-3 DIV (days in vitro) with lentivirus encoding EGFP-
Rab4, -Rab7, or -Rab11. After 10-14 DIV the constitutive DAT internalization was analyzed using 
JHC 1-64 (1 hour of internalization). As in the non-transduced neurons (Eriksen et al., 2009), we 
observed clear constitutive DAT internalization (Fig 6A), and as seen in both tested cell lines the 
most evident co-localization was seen between EGFP-Rab7 and DAT/JHC 1-64 with less apparent 
co-localization between DAT and both EGFP-Rab4 and EGFP-Rab11 (Fig. 6A). To further study 
whether the co-localization of DAT with the late enodosomal marker Rab7 is a reflection of 
constitutively DAT being sorted to a lysosomal degradation pathway, we looked at the constitutive 
DAT internalization in dopaminergic neurons together with the lysosomal marker, Lysotracker 
Green. Substantial colocalization between internalized DAT and the Lysotracker was observed (Fig. 
6B) supporting that constitutively internalized DAT is sorted to a lysosomal degradative pathway. 
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Discussion 
It is well established that DAT undergoes constitutive endocytosis in transfected heterologous cells 
(Chi and Reith, 2003, Loder and Melikian, 2003, Sorkina et al., 2005) and recently it was 
demonstrated that also DAT endogenously expressed in dopaminergic neurons is constitutively 
internalized (Eriksen et al., 2009). However, the postendocytic sorting and fate of the internalized 
transporter has remained uncertain. In the current study, we address this question in both cell lines 
and dopaminergic neurons using a series of different complementary approaches. The predominant 
observation was that constitutively internalized DAT was primarily sorted to a 
lysosomal/degradative pathway. 
DAT sorting was first studied using a new DAT fusion protein with an extra transmembrane 
segment. This TacDAT construct was made by fusing the single transmembrane protein Tac to 
DAT. Tac itself seems to be rather inert in its trafficking properties and several studies have used 
Tac fusion proteins to define trafficking signals in cytosolic domains of membrane proteins 
including DAT (Holton et al., 2005) and other transporters (Kalandadze et al., 2004, Colgan et al., 
2007). However, to our knowledge this is the first time Tac has been used as a ‘silent reporter’ for 
an entire membrane protein. Importantly, TacDAT displayed functional properties similar to DAT 
although maximum uptake was reduced (Fig 1C). Furthermore TacDAT was constitutively 
internalized as well as it internalized in response to PMA and amphetamine stimuli in HEK293 cells 
(Fig. 2C and E) as previously described for DAT in this cell line (Chi and Reith, 2003, Kahlig et al., 
2006, Eriksen et al., 2009) and other systems (Melikian and Buckley, 1999, Sorkina et al., 2003, 
Sorkina et al., 2005). The observed trafficking properties for TacDAT must be related to the DAT 
part of TacDAT since Tac alone, in agreement with previous observations (Holton et al., 2005), did 
not internalize to any detectable degree, neither constitutively nor response to PMA, according to 
microscopic assays (Fig. 2C). 
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Antibodies recognizing extracellular epitopes in membrane proteins are highly desirable for 
dynamic studies of their trafficking properties; however, it has proven notoriously difficult to 
develop an efficient antibody against an endogenous extracellular epitope of the DAT, and with the 
N- and C-termini located intracellularly it has even been difficult to introduce extracellular antibody 
tags in the extracellular domains of the transporter. Nevertheless, Sorkin and coworkers were 
capable of introducing a hemagglutinin tag (HA-tag) in the large second extracellular loop (ECL2) 
and maintain transport activity and wild type expression upon transfection (Sorkina et al., 2006). 
Use of the epitope has already allowed interesting new insight into DAT trafficking using both 
heterologous cells and transfected dopaminergic neurons in culture (Sorkina et al., 2006, Miranda et 
al., 2007, Sorkina et al., 2009). The present TacDAT construct represents an alternative way of 
generating an extracellular antibody epitope and carries several properties that complement already 
existing approaches for studying DAT trafficking. Most importantly, the M1 FLAG antibody 
epitope at the Tac N-terminus harbours several desirable features: 1) It is outside the DAT primary 
sequence and thus unlikely to interfere with DAT function. 2) The M1 antibody bound to the FLAG 
epitope displays an almost 10 times higher signal/DAT molecule than the HA.11 antibody on the 
HA epitope in extracellular loop 2 (Fig. 1E), which makes the FLAG epitope applicable to studies 
of low abundant internalization events. 3) The M1 antibody can be stripped off from the FLAG 
eptitope, which is essential for the quantitative ELISA internalization assays (Fig. 2E) and not 
possible for the HA.11 antibody bound to HA-DAT (Sorkina et al., 2006). 4) Labeling of the 
FLAG-epitope with M1 antibody can be done at 4 °C and thus at a truly trafficking-restricted 
temperature.  This is not the case for labeling of HA-DAT with HA.11, which is only possible at 
18°C or higher (Sorkina et al., 2006). Finally, it interesting to consider extending the use of Tac 
fusion constructs to other transporters in the family. Importantly, fusing SERT and Tac head-to-tail 
results in a TacSERT construct that upon expression in HEK293 cells retains the function and 
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trafficking properties of wild type SERT (Jørgensen and Gether, unpublished observations). Thus, it 
might be possible to use Tac fusion constructs as a general means of tagging transporters thereby 
allowing direct comparisons of trafficking properties between different transporters as well as 
dissection of distinct trafficking signals.  
 Using a quantitative ELISA based internalization assay in HEK293 cells expressing TacDAT, 
we showed that the apparent constitutive intracellular accumulation of TacDAT was increased by 
both inhibitor of lysosomal proteases (leupeptin) and the recycling/degradation inhibitor monensin 
(Fig. 3A). Monensin is a cationophore believed to exert its role on membrane protein trafficking by 
dissipating the pH gradient across the intracellular membranes thereby bringing trafficking between 
intracellular compartments to a hold as this is dependent on differences in pH gradients 
(Mollenhauer et al., 1990). The apparent increase in intracellular accumulation in response 
monensin might accordingly both be an effect of inhibiting sorting to lysosomal degradation and of 
inhibiting recycling back to the plasma membrane. However, according to a surface ELISA assay 
monensin did not affect TacDAT surface expression, which essentially rules out that the increased 
TacDAT accumulation is due to an inhibition of recycling.  TacDAT surface expression was also 
not affected by bafilomycin A1, a H+-ATPase inhibitor that also disrupts vesicular pH-gradients  
(Johnson et al., 1993) (Fig. 3B). Furthermore no effect of monensin or bafilomycin A1 was seen on 
the surface expression of HA-DAT in HEK293 cells (Fig. S1). Previously, it was likewise found in 
DAT expressing PC12 cells that bafilomycin did not affect DAT surface expression (Loder and 
Melikian, 2003). Conversely, the transferrin receptor, a well studied constitutively recycling 
membrane protein, was shown to decrease its surface expression upon bafilomycin A1 treatment 
(Loder and Melikian, 2003). In another study using transfected PAE cells, DAT surface expression 
and function was reduced by monensin as assessed by surface biotinylation and dopamine uptake 
experiments (Sorkina et al., 2005). This might reflect interruption of DAT recycling; however, 
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regarding the uptake experiments it is a caveat, as also noted by the authors, that monensin as a 
sodium ionophore most likely would affect the sodium plasma membrane sodium gradient, which is 
the driving force for dopamine transport, i.e. a reduction in dopamine uptake in response to 
monensin cannot necessarily be attributed to reduced surface expression (Sorkina et al., 2005). 
 In our further strategy to investigate DAT postendocytic sorting, we used Rab proteins fused 
to EGFP in combination with confocal imaging. Co-expression of TacDAT in HEK293 cells with 
EGFP-tagged versions of the endosomal markers Rab4 (early endosomes/recycling), Rab7 (late 
endosomes) or Rab11 (long loop recycling) showed the most pronounced colocalization in a 
vesicular pattern with the late endosomal marker Rab7 (Fig. 3C), whereas little colocalization was 
observed with Rab4 and Rab11. Similarly, in the the dopaminergic cell line 1Rb3An27, we 
observed clear constitutive internalization and when probing the colocalization with the EGFP-
tagged Rab proteins in a quantitative manner, the highest colocalization was observed with Rab7, 
which was significantly higher than with Rab11, but not Rab4 (Fig. 4D). The sorting pattern 
observed was most likely not an artefact of the assay since only cells expressing TacDAT 
internalized M1 antibody (data not shown). In addition, parallel experiments in the 1Rb3An27 cells 
with the ß2-adrenergic receptor exhibited a different colocalization pattern characterized by highest 
colocalization with Rab4 and Rab11 (Fig. 4E), as expected for protein well-known to undergo 
efficient recycling and verifying that the quantification does indeed reflect properties of the 
analysed protein. Furthermore, we observed the same co-localization pattern as for TacDAT when 
using our previously described fluorescent cocaine analogue JHC 1-64 as label to follow 
postendocytic sorting of non-tagged DAT. Finally, we studied sorting of the internalized 
endogenous DAT in dopaminergic primary cultures that were transduced with lentivirus encoding 
EGFP-tagged Rab4, Rab7 or Rab11. Constitutive internalization of endogenous DAT was 
visualized using the cocaine analog JHC 1-64 and, as in the cell lines, DAT primarily colocalized 
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with Rab7 (Fig. 6A). Additionally, we observed a profound colocalization between DAT and 
lysosomal marker Lysotracker further supporting that constitutively internalized DAT is sorted to 
late endosome/degradation in dopaminergic neurons (Fig. 6B).  
 We should note that the quantified co-localization in 1Rb3An27 cells of EGFP-Rab4 indicated 
relatively high co-localization with both internalized TacDAT and ß2-adrenergic receptor. However, 
qualitative differences became apparent by examination of individual images. Only relatively few 
TacDAT positive vesicles showed direct overlap with EGFP-Rab4 whereas examination of images 
of internalized ß2-adrenergic receptor gave the impression of a much higher degree of co-
localization with EGFP-Rab4, i.e. in regions with enriched EGFP signal we observed a 
corresponding marked enrichment in M1 signal, which was never seen for TacDAT (Fig. 4B and 
C).  Together with our data in HEK293 cells, which argue strongly against any major recycling, we 
find it therefore unlikely that TacDAT to any significant extend follows a Rab4 ‘short loop’ 
recycling pathway in the 1Rb3An27 cells. Rather, we find it likely that co-localization with EGFP-
Rab4 simply might reflect presence of TacDAT in early endosomes (Stenmark, 2009).  
 Previous reports have proposed that constitutively internalized DAT is sorted to a recycling 
pathway (Loder and Melikian, 2003, Sorkina et al., 2005, Furman et al., 2009). These previous 
studies were carried out in other cell types than those used in this study and different 
methodological approaches were undertaken but otherwise we have no immediate explanation for 
the apparent discrepancy with the present data. Of note, DAT was suggested to undergo fast 
constitutive recycling in transfected PC12 cells; nonetheless, when treating the cells with 
bafilomcyin no effect was seen on DAT surface expression, whereas a marked effect was seen on 
the well-known recycling membrane protein, the transferrin receptor (Loder and Melikian, 2003). 
Moreover, the conclusion was based on experiments performed 18° C, which was supposed to 
inhibit exocytosis without interfering with endocytosis (Loder and Melikian, 2003); however, this 
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might represent a simplification (Sorkin et al., 1991). In a recent study, it was proposed that DAT  
recycles via a Rab11 dependent pathway because the level of DAT in the plasma membrane DAT 
was increased upon co-expression of constitutively active Rab11 but all experiments were steady 
state experiments and a dominant negative Rab11 mutant did not exhibit any effect compared to a 
GFP control when quantifying DAT surface binding (Furman et al., 2009). 
Summarized, our data suggest that constitutively internalized DAT is sorted to late 
endosomes/lysosomes both in cell lines and dopaminergic neurons. The fact that the sorting pattern 
is the same in three different cellular systems (HEK293 cells, 1Rb3An27 cells and cultured 
dopaminergic neurons) suggest that the constitutive internalization depends on general cellular 
factors as opposed to the PKC-mediated DAT internalization where the cellular environment seems 
to affect the PKC stimulation to a high degree (Mortensen et al., 2008, Eriksen et al., 2009). The 
sorting of DAT directly to degradation rather than to recycling challenges previous suggestions of a 
continuously cycling intracellular pool of transporter that might be rapidly recruited to meet 
immediate changes in the need for neurotransmitter reuptake from the extracellular space (Melikian 
and Buckley, 1999, Johnson et al., 2005). In the future it should therefore be highly interesting to 
investigate to what degree postendocytic sorting might be subject to regulation and redirection by 
yet unknown mechanisms with putative impact on the overall regulation of dopaminergic 
signalling.  
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Figure Legends 
 
Figure 1: TacDAT is a 13 transmembrane segment fusion protein with a high-affinity FLAG 
epitope and that is functionally expressed at the plasma membrane in HEK293 cells. A) TacDAT is 
a head-to-tail fusion of hDAT (blue) and Tac (green) with an N-terminal FLAG-epitope, 
DYKDDDDK. B) Non-permeabilizing immunostaining of HEK293 cells transfected with TacDAT 
using an M1 antibody recognizing the FLAG-epitope reveals that TacDAT is expressed at the 
plasma membrane of HEK293 cells and that the FLAG-epitope is exposed on the extracellular side 
of the plasma membrane. Scale bar is 10 μm. C) Dopamine uptake in HEK293 cells transfected 
with TacDAT or hDAT shows that TacDAT is functional at the plasma membrane with a Km 0.40 
μM [SE interval (0.36 - 0.47 μM), n=3] similar to hDAT 0.92 μM [SE interval (0.62 - 1.4 μM), 
n=3], (p>0.05, student’s t-test n=3). However the Vmax of TacDAT; 511 +/- 104 fmol/min/105 cells 
was significantly lower than the Vmax of DAT, 2486 +/- 236 fmol/min/105 cells (p = 0.011, paired t-
test n=3). D) Preincubating HEK293 cells expressing TacDAT or hDAT for 30 mins at 4° C with 
M1 antibody does not impair dopamine uptake suggesting that antibody binding does not affect 
TacDAT function. E) The surface ELISA signal from the M1 antibody of cells expressing TacDAT 
with an HA-tag in the extracellular loop 2 was almost 10-fold higher pr molecule than the signal 
from the HA.11 antibody. 
 
Figure 2: Visualizing TacDAT internalization using an M1 antibody-based internalization assay. 
A) To be able to detect TacDAT internalization we set up a conventional antibody internalization 
assay, in which we first labelled the cells with M1 at 4 °C, to label surface TacDAT at a trafficking 
blocked temperature. Then the cells were incubated at 37 °C in new media to allow internalization 
of TacDAT, followed by a fixation to stop the process. Finally the cells were permeabilized and 
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incubated with a secondary fluorophore-conjugated antibody that recognizes M1 as a preparation 
for immuno-fluorescence microscopy. B) Confocal images of HEK293 cells expressing Tac assayed 
as just described. Only surface staining was observed whether the internalization was carried out at 
4 °C or 37 °C indicating that Tac resides in the plasma membrane and does not undergo any visible 
internalization within 30 minutes. C) The same assay with HEK293 cells expressing TacDAT. No 
intracellular accumulation is observed when internalizing at 4 °C, however at 37 °C an intracellular 
accumulation of TacDAT is observed suggesting a constitutive internalization of TacDAT, and the 
internalization is intensified when incubating with the PKC activator PMA (1 μM). D) Brief 
description of the ELISA-based internalization assay. The analysed cells were first labeled with M1 
at 4 °C and then either incubated at 4° C for surface detection or incubated at 37° C for various 
periods to allow internalization. After the internalization period the cells were placed on ice and the 
surface antibody was stripped off using an acid strip buffer. After fixation the cells were 
permeabilized and the intracellular accumulated antibody was detected with a horseradish 
peroxidase-conjugated secondary antibody. The internalization signal was expressed as the 
proportion of the start surface signal. E) Using the cell-based ELISA assay it was possible to 
quantify the amount of internalized Tac and TacDAT relative to the surface fraction in HEK293 
cells. A time dependent intracellular accumulation of TacDAT was observed and this internalization 
was significantly larger than for Tac. TacDAT internalization was further accelerated when 
stimulating with PMA (1μM) or amphetamine (10μM). F) Amphetamine and PMA had no 
significant effect on Tac after 1h of internalization whereas a significant effect was seen on 
TacDAT for both compounds and TacDAT control was significantly higher than Tac (One way 
ANOVA with Bonferroni's Multiple Comparison Test, ** p < 0.01 and *** p < 0.001). 
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Figure 3: Monensin and leupetin increase intracellular TacDAT accumulation and TacDAT 
colocalize with the late endosomal marker Rab7 in HEK293 cells. A) In HEK293 cells transfected 
with TacDAT the intracellular accumulation of TacDAT after 1 hour of internalization was 
increased significantly upon incubation with either the protease inhibitor leupeptin (100 µg/ml) or 
the recycling inhibitor monensin (25 µM) (One way ANOVA, Dunnett’s Multiple Comparison test, 
* p < 0.05, ** p < 0.01, n=4).  B) TacDAT surface expression after treatment with monensin (25 
µM) or bafilomycin (XXXX) for 1 hour was determined in an ELISA assay. Neither monensin (p > 
0.05, paired t-test, n=5) nor bafilomycin (p > 0.05, paired t-test, n=3) had any significant effect on 
TacDAT surface expression. C) Confocal microscopy images of colocalization between TacDAT 
and EGFP-tagged Rab4, Rab7 and Rab11 after 1 hour of AlexaFluor 568-conjugated M1 antibody 
internalization in HEK293 cells. TacDAT exhibited the most prominent colocalization with the late 
endosomal marker Rab7. Data are representative of at least three independent experiments. Scale 
bar 10 μm. 
 
Figure 4: TacDAT is constitutively internalized in the dopaminergic cell line 1Rb3An27 and 
colocalize primarily with EGFP-Rab7. A) Experiment as in Fig. 2A. No detectable constitutive 
internalization was observed after 1 hour in 1Rb3An27 cells expressing Tac, whereas in cells 
expressing TacDAT, internalization was evident as analyzed by confocal microscopy. Pictures are 
representative of several experiments. B) Quantification of fluorescence colocalization between 
internalized TacDAT and the EGFP-tagged endosomal markers Rab4, Rab7 and Rab11 after 1 hour 
of M1 internalization. TacDAT exhibited the highest level of colocalization with EGFP-Rab7 which 
was significantly different from colocalization with the ‘long loop’ recycling marker EGFP-Rab11 
(p < 0.01, One way ANOVA, Bonferroni's Multiple Comparison Test). The colocalization with the 
‘short loop’ recycling marker Rab4 was intermediate and did not differ significantly from either 
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Rab7 or Rab11. C) Colocalization quantification of a FLAG-tagged ß2-adrenergic receptor (ß2AR) 
with EGFP-Rab4, 7 and 11 after 1 hour of isoproterenol (10 μM) stimulation was carried out as a 
control for specificity of the sorting pattern found in B). As expected the ß2-adrenergic receptor, a 
bona fide recycling membrane protein, showed a higher degree of colocalization with the recycling 
markers Rab4 and Rab11 than with the late endosomal marker Rab7 (One way ANOVA, p < 0.001, 
Bonferroni's Multiple Comparison Test). Representative pictures from the colocalization analysis 
are shown for TacDAT (D) the ß2-adrenergic receptor (E). Colocalization data was analysed from 
30 images from each condition. Scale bars 10μm. 
 
Figure 5: Visualization of constitutive DAT internalization in live 1Rb3An27 cells with the cocaine 
analog, JHC 1-64, reveals a predominant colocalization with EGFP-Rab7. 1Rb3An27 cells 
expressing DAT together with EGFP-Rab4, -Rab7 or -Rab11 were incubated with the cocaine 
analog JHC 1-64 (5 nM) at 4 °C to label surface DAT and subsequently incubated at 37 °C to drive 
internalization of DAT. After internalization the live cells were imaged using confocal microscopy, 
and a predominant colocalization with the late endosomal marker EGFP-Rab7 was observed. 
Images are representative of three independent experiments. 
 
Figure 6: Constitutive DAT internalization in cultured dopaminergic neurons is sorted to a late 
endosomal/lysosomal pathway. A) Postnatal mesencephalic primary cultures from rat pups were 
transduced with lentivirus encoding EGFP-Rab4, -Rab7 or –Rab11 at day 2-3 in vitro. At day 10-14 
in vitro the cultures were used for constitutive DAT sorting experiments by incubating the cultures 
with 5 nM JHC 1-64 at 4 °C to label surface DAT then the cells were incubated at 37 °C for 1 hour 
to drive the constitutive internalization. Subsequently the live cells were imaged at room 
temperature using confocal microscopy. As for the cell lines the most apparent colocalization was 
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observed between DAT/JHC 1-64 and the late endosomal marker EGFP-Rab7 in the soma of the 
dopaminergic neurons, whereas for Rab 4 and Rab 11 the colocalization was not noticeable. B) 
With an experiment parallel to A) we observed a prominent colocalization between the lysosomal 
marker lysotracker and constitutive internalized DAT in the dopaminergic neurons. Lysotracker 
Green (100 nM) was added in the last 10 minutes of incubation before imaging. Images are 
representative of at least 3 batches of neuronal cultures and three transductions. Scale bar 10 μm. 
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Figure S1: HEK293 cells expressing HA-DAT were treated with monensin (25 μM) or bafilomycin 
(1 μM) for 60 minutes before quantification of HA-DAT surface expression by ELISA. No effect of 
monensin (p > 0.05, paired t-test, n=5) or bafilomycin (p > 0.05, paired t-test, n=3) was observed. 
 
 
 
 
 
 
  
 
 
 
 
 
Figure S2: Surface expression in HEK293 cells expressing HA-DAT together with either EGFP-
tagged Rab4 WT, Rab4 D.N. (S22N), Rab11 or Rab11 D.N. (S25N) by cell surface ELISA. The 
surface expression was calculated as the ratio between the surface expression of Rab4 D.N. and 
Rab4 WT and as the ratio between Rab11 D.N. and Rab11 WT. No significant difference was 
observed between cells expressing HA-DAT + Rab 4WT and cells expressing HA-DAT Rab4 D.N 
(p > 0.05, paired t-test, n=3). Likewise no difference was observed in the surface expression 
between cells expressing HA-DAT + Rab 4WT and cells expressing HA-DAT Rab4 D.N (p > 0.05, 
paired t-test, n=3). 
 
 
  
 
 
 
 
 
 
 
 
 
Figure S3: 1Rb3An27 cells expressing FLAG-tagged ß2-adrenergic receptor was labelled with M1 
antibody and 4 °C, and then incubated with agonist isoproterenol (10 μM) for 0, 10 or 30 minutes. 
Scale bar 10μm. 
  
 
Figure S4: 1Rb3An27 cell expressing DAT and EGFP-Rab7 was labelled with JHC 1-64 as 
described in materials and methods and DAT was allowed to internalize for 1 hour before imaging. 
Imaging was done at room temperature and each picture repsents a time increment of 8 seconds. 
Arrow indicates moving vesicle that is both positive for DAT/JHC 1-64 (red channel) and EGFP-
Rab7 (green channel). 
  
 
 
 
 
 
Figure S5: 1Rb3An27 cells expressing HA-DAT and EGFP-Rab7 or -Rab11 were incubated 
HA.11 antibody at 18 °C for 30 minutes to label surface HA-DAT. After labelling the media was 
replaced and the cells incubated at 37 °C for 1 hour to allow internalization. HA-DAT showed the 
most colocalization with EGFP-Rab7. 
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The PSD-95/Discs-large/ZO-1 homology (PDZ) domain
protein, protein interacting with C kinase 1 (PICK1) con-
tains a C-terminal Bin/amphiphysin/Rvs (BAR) domain
mediating recognition of curved membranes; however,
the molecular mechanisms controlling the activity of this
domain are poorly understood. In agreement with nega-
tive regulation of the BAR domain by the N-terminal PDZ
domain, PICK1 distributed evenly in the cytoplasm,
whereas truncation of the PDZ domain caused BAR
domain-dependent redistribution to clusters colocalizing
with markers of recycling endosomal compartments. A
similar clustering was observed both upon truncation of
a short putative a-helical segment in the linker between
the PDZ and the BAR domains and upon coexpression of
PICK1 with a transmembrane PDZ ligand, including the
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) receptor GluR2 subunit, the GluR2 C-terminus
transferred to the single transmembrane protein Tac or
the dopamine transporter C-terminus transferred to Tac.
In contrast, transfer of the GluR2 C-terminus to cyan
fluorescent protein, a cytosolic protein, did not elicit
BAR domain-dependent clustering. Instead, localizing
PICK1 to the membrane by introducing an N-terminal
myristoylation site produced BAR domain-dependent,
but ligand-independent, PICK1 clustering. The data sup-
port that in the absence of PDZ ligand, the PICK1 BAR
domain is inhibited through a PDZ domain-dependent
and linker-dependent mechanism. Moreover, they sug-
gest that unmasking of the BAR domain’s membrane-
binding capacity is not a consequence of ligand binding
to the PDZ domain per se but results from, and coincides
with, recruitment of PICK1 to a membrane compartment.
Key words: BAR domains, PDZ domains, protein–lipid
interactions, receptors, transporters
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Protein interacting with C kinase 1 (PICK1) is a dimeric
scaffolding protein widely distributed in the central ner-
vous system (CNS) (1). Each protomer in the PICK1 dimer
contains a single N-terminal PSD-95/Discs-large/ZO-1
homology (PDZ) domain that was originally found to bind
the extreme C-terminus of protein kinase Ca (PKCa) (2) but
later was shown to bind also the C-termini of several other
proteins (1,3). These include receptor and transporter
proteins expressed in the CNS [see data in PDZbase (4)],
such as the GluR2/3 subunits of alpha-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA)-type ionotropic
glutamate receptors (AMPA receptors), the metabotropic
glutamate receptor mGluR7 and various neurotransmitter
transporters including the dopamine transporter (DAT), the
norepinephrine transporter and the Glt1b glutamate trans-
porter (1,3,5–7). In concordance with these interactions,
there is compelling evidence for a critical function of PICK1
in regulation of neuronal signalling (8). A central role for
PICK1 in severe psychiatric disorders such as schizophre-
nia has also been suggested (8). The interaction between
PICK1 and AMPA receptors has been demonstrated to be
essential for induction of synaptic long-term depression
(LTD) (9,10) as well as for a new form of cerebellar synaptic
plasticity termed calcium-permeable AMPA receptor plas-
ticity (11). Moreover, induction of neuropathic pain, as well
as cocaine sensitization, can be reversed by PICK1-specific
peptides, conceivably through disruption of the PICK1/
AMPA receptor interaction (12,13).
It is believed that PICK1 fulfils its biological role either by
regulating trafficking of its binding partners (5,11,14) or in
some cases by recruiting PKCa to facilitate their phosphor-
ylation (6,15,16). For the AMPA receptor, it has been
suggested that PICK1 enhances AMPA receptor endo-
cytosis and thereby maintains an intracellular pool of the
receptor (14). Observations in mice with targeted disruption
of the PICK1 gene suggest that PICK1 might be critical not
only for stabilizing an intracellular pool of AMPA receptors
but also for mediating the recycling of AMPA receptors back
to the plasma membrane – at least in cerebellar stellate cells
(11). However, recent results suggest that PICK1 restricts
AMPA receptor recycling in hippocampal neurons (17). For
other interaction partners such as DAT, PICK1 is unlikely to
promote endocytosis but rather seems to stabilize the
expression of the binding partner at the cell surface (7,18).
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The recent identification of a Bin/amphiphysin/Rvs (BAR)
domain in the C-terminal half of PICK1 might shed light on
the complex molecular functions of PICK1. BAR domains
are homodimeric modules that mediate curvature-dependent
recognition and/or tubulation of lipid membranes (19,20).
They are present in many proteins involved in cellular
trafficking processes and are believed to play a key role
as membrane curvature-sensing and curvature-generating
modules (19,20). The interaction with lipids has been
suggested to be mediated by electrostatic attraction
between positive charges on the concave side of the
crescent-shaped BAR domain and negative charges on
the lipid head groups (19,20). The strongest evidence
for a role of the BAR domain in PICK1 function is the
demonstration that transfection of wild-type (wt) PICK1
into cerebellar Purkinje cells derived from PICK1 knock-out
mice can restore LTD, which was not observed for a PICK1
mutant containing a mutant BAR domain deficient in lipid
vesicle binding (21).
Interestingly, the activity of the PICK1 BAR domain has
been suggested to be negatively regulated by the PDZ
domain, and the lipid-binding capacity was proposed to be
activated upon binding of an interaction partner to the
N-terminal PDZ domain (22). Such a regulation functionally
distinguishes PICK1 from other BAR domain-containing
proteins characterized to date. In this study, we have
investigated the molecular mechanisms underlying this
negative regulation of the PICK1 BAR domain. Our data
suggest that the BAR domain activity is indeed inhibited in
the absence of PDZ ligand; however, they also support
a model in which unmasking of the PICK1 BAR domain
activity is not caused by ligand binding to the PDZ domain
per se but rather by recruitment of PICK1 to a membrane
compartment by the interaction partner. We propose that
this regulatory mechanism prevents improper BAR
domain activity and ensures tight spatial and temporal
control of PICK1 function in relation to its several interac-
tion partners.
Results
The PICK1 BAR domain is negatively regulated
by the PDZ domain
It was recently shown that the coiled-coil domain in
arfaptin2 is a membrane curvature-recognizing BAR
domain (19). This domain is homologous to the coiled-coil
domain predicted to be present in PICK1, suggesting that
PICK1 also contains a membrane curvature-recognizing
BAR domain (19). For arfaptin, the BAR domain was
responsible for a characteristic juxtanuclear tubular locali-
zation of the protein upon overexpression in heterologous
cells such as COS7 cells (19). In contrast to arfaptin2,
PICK1 was evenly distributed throughout the cytosol when
heterologously expressed in COS7 cells (Figure 1A). Trun-
cation of the N-terminal PDZ domain (PICK1 D1–101)
caused, however, a significant redistribution of the protein
characterized by the presence of multiple distinct vesicle-
like clusters (Figure 1A). Truncation of not only the PDZ
domain but also the linker between the PDZ domain and
the predicted BAR domain (PICK1 D1–135) increased the
protein clustering at juxtanuclear sites (Figure 1A). Note
that the cells expressing PICK1 D1–135 actually display
a spectrum of clustering phenotypes illustrated in Figure
1B. The cell shown to the right in Figure 1B represents
a frequent extreme.
An intriguing explanation for these observations would be
that the activity of the BAR domain, as reflected by relo-
calization to clusters, is inhibited in full-length PICK1 and
that removal of the N-terminal PDZ domain allows ‘activa-
tion’ of the BAR domain and thereby clustering. A strikingly
similar clustering is seen for full-length BAR domain pro-
tein islet cell autoantigen 1, 69 kDa (ICA69) which is very
closely related to PICK1 (23). Previous findings by Ziff and
coworkers, suggesting a direct interaction between the
PDZ domain and the BAR domain of PICK1 that might be
responsible for the negative regulation of the BAR domain
(22), are in agreement with such a hypothesis.
To interpret the phenotypes observed for the two PICK1
truncations (PICK1 D1–135 and PICK1 D1–101) in a struc-
tural context, we modelled the PICK1 BAR domain-like
sequence using the co-ordinates from the crystal struc-
tures of known BAR domains, including arfaptin2, amphi-
physin and endophilin (Figure 1). In the molecular model,
the PICK1 BAR domain exhibited a strong concentration of
positive electrostatic potential on the concave side of the
crescent shape, similar to that observed for the crystal
structure of the BAR domain from Arfaptin2 (19). Positively
charged residues generating this potential on the concave
side of the BAR domain have been suggested to mediate
the electrostatic interaction with negatively charged
curved membranes (19). To disrupt the electrostatic inter-
action, we substituted either three positively charged
residues on the concave side of each subunit of the BAR
domain (K251E, K252E and K257E; termed 3KE) or two
residues (K266E and K268E; termed 2KE) (Figure 1). As
shown in Figure 1A, reversing the charges on the concave
side of the crescent shape reversed the clustering of both
truncated proteins. This observation parallels findings
by Lu and Ziff who studied a similar truncation of PICK1
(22). No change in localization was observed when the
2KE and 3KE mutations were introduced in full-length
PICK1 (data not shown).
To further substantiate our findings obtained with immuno-
cytochemistry, we employed a biochemical assay in
which we separated cytosolic and particulate fractions.
PICK1 was distributed equally between the two fractions,
suggesting some constitutive membrane association of
full-length PICK1 that was not apparent from the confocal
imaging. Because the 3KE mutation only slightly reduced
association to the particulate fraction, this association was
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independent of the presence of the positively charged
residues on the concave side of the BAR domain. It might,
therefore, at least in part reflect the recently reported
membrane-interacting capacity of the PDZ domain itself
(24).
Importantly, our two deletion mutants (D1–101 and D1–
135) associated to a markedly higher degree to the
particulate fraction than to the cytosolic fraction (Figure 2).
In agreement with a BAR domain-mediated effect and the
confocal imaging data, we found that reversing the charge
of lysines 251, 252 and 257 (3KE) in the BAR domain
decreased the association with the particulate fraction to
the same level as that seen for PICK1 and PICK1 3KE
(Figure 2). It should be noted, however, that even though
PICK1 and the deletion mutants containing the 3KE
mutations display the same degree of association to the
particulate fraction, it could very well involve different
Figure 1: Activity of the PICK1 BAR domain is inhibited by the N-terminal PDZ domain and the PDZ-BAR linker sequence. A) COS-
7 cells were transiently transfected with indicated myc-tagged PICK1 constructs, immunostained and analysed by confocal microscopy.
The diagrams on the left indicate the N-terminal truncations. Left picture panel: representative cells expressing from top mycPICK1,
mycPICK1 D1–101 or mycPICK1 D1–135; middle picture panel: representative cells expressing mycPICK1 D1–101 3KE or mycPICK1 D1–
135 3KE and right picture panel: representative cells expressing mycPICK1 D1–101 2KE or mycPICK1 D1–135 2KE. The 3KE and 2KE refer
to charge-reversing mutations in the BAR domain (3KE, K251E, K252E and K257E) and (2KE, K266E and K268E). Models of the predicted
effects of these mutations on the surface charge of the concave side of the PICK1 BAR domain are shown below the pictures (blue,
positive and red, negative). B) Four different cells expressing mycPICK1 D1–135 and covering the range of phenotypes observed. All white
bars ¼ 10 mm. The data shown are representative of more than five similar experiments.
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mechanisms, that is, while the PDZ domain might play
a role in full-length PICK1, it is possible that in the
truncations, the 3KE mutation is insufficient to completely
abolish the lipid-binding capacity of the activated BAR
domain and thereby association to the particulate fraction.
BAR domain-dependent clustering is observed in
a neuronal cell line and in hippocampal neurons
In addition to the immunostainings shown above, we
analysed PICK1 fusion constructs with yellow fluorescent
protein (YFP). This allowed visualization of the different
constructs without antibody staining and cell permeabiliza-
tion. In both COS7 cells (data not shown) and in 1Rb27AN3
cells (Figure 3), an immortalized dopaminergic cell line
(25), we observed results corresponding to those obtained
in the immunostainings. However, the clusters seen in the
living cells appeared more like distinct vesicles containing
enhanced yellow fluorescent protein (eYFP)-tagged PICK1
D1–135 or eYFP-tagged PICK1 D1–101 (Figure 3A).
We could also reproduce the result in transfected hippo-
campal neurons [6 days in vitro (DIV)] with clear clustering
of eYFP-tagged PICK1 D1–135 and eYFP-tagged PICK1 D1–
101 but not of the corresponding 3KE mutations (Figure 3B).
Coexpression of PICK1 with membrane-associated
PDZ ligands causes clustering
The BAR domain-dependent vesicular and juxtanuclear
clustering of truncated PICK1 strongly resembles the
redistribution of PICK1, which was previously reported to
occur upon coexpression of full-length PICK1 with trans-
membrane proteins that bind to the PICK1 PDZ domain
(5,26,27). Congruent with these findings, coexpression of
the GluR2 subunit of the AMPA receptor with eYFP–PICK1
caused a marked coclustering of both proteins (Figure 4).
However, when GluR2 was coexpressed with eYFP–
PICK1 3KE, we did not see this redistribution (Figure 4).
The BAR domain-dependent clustering of PICK1 upon
coexpression with a PDZ ligand (GluR2) is consistent with
the release of an inhibition of the BAR domain by the
binding of an interaction partner to the PDZ domain. To
examine whether the C-terminal tail of GluR2, which
binds to PICK1, was sufficient to promote clustering,
we transferred the 50 C-terminal residues of GluR2 to the
single transmembrane protein Tac (the a subunit of
interleukin-2 receptor) that has been used previously to
study autonomous signal sequences in protein trafficking
(28,29). Tac was tagged at the N-terminus with the
FLAG tag to obtain FLAG–TacGluR2 C50, which, by itself,
localized predominantly to the plasma membrane with
some intracellular, vesicular accumulation (Figure 5A).
However, upon cotransfection with PICK1, we observed
a major relocalization of FLAG–TacGluR2 C50 to clusters
where it colocalized with PICK1. This localization mostly
resembles the localization of the D1–135 PICK1, whereas
full-length GluR2 causes a clustering more resembling the
D1–101 PICK1 or at least the less extreme D1–135 PICK1.
Importantly, like for full-length GluR2, this clustering was
BAR domain dependent because it was abolished by the
3KE mutation (PICK1 3KE) (Figure 5A). We subsequently
fused only the 29 C-terminal residues of GluR2 to the
C-terminus of Tac. As shown in Figure 5B, this was also
sufficient for BAR domain-dependent clustering when
PICK1, but not PICK1 3KE, was coexpressed with the
ligand (GluR2 C29). This experiment excludes the need
for the sequence 843–852 in the GluR2 tail, which was
shown previously to mediate direct interaction with the
PICK1 BAR domain (30), in forming the clustering pheno-
type. We also coexpressed FLAG–TacGluR2 C29 with
YFP–PICK1 in the neuronally derived 1Rb27AN3 cells and
observed clustering similar to that seen in the COS7 cells
(data not shown).
Finally, to test whether the clustering was specific to the
GluR2 C-terminal sequence, we turned to another interac-
tion partner for PICK1 – the DAT (3). We transferred the
C-terminal 24 residues downstream from the putative
internalization motif in the DAT C-terminus to Tac. Coex-
pression of this construct (FLAG–TacDAT C24) with PICK1
Figure 2: Association of the PICK1 BAR domain with the
particulate fraction is increased in a manner that depends
on positively charged residues on the concave side of the
domain. A) Representative immunoblot illustrating distribution of
PICK1, PICK1 D1–101, PICK1 D1–135, PICK1 3KE, PICK1 D1–101
3KE and PICK1 D1–135 3KE between the cytosolic (C) and the
particulate (P) fractions of transiently transfected COS7 cells. B)
Densitometry analysis of immunoblots. Data are expressed as
percent of total in the particulate fraction for the indicated
constructs (mean  SEM, **p < 0.01 compared with PICK1
WT, n ¼ 3).
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induced BAR-dependent clustering just as efficiently as
FLAG–TacGluR2 C29 (Figure 5C).
Clustering is also seen with partial truncation of the
linker between the PDZ domain and the BAR domain
Our data are consistent with a model in which the PDZ
domain in the absence of PDZ ligand is capable of
preventing BAR domain-dependent redistribution of PICK1
to clusters. A region that could play a role in this inhibition
is the linker between the two domains (residues 105 and
135). According to a secondary structure prediction of
the PICK1 protein, a putative a-helical region was sug-
gested from Ser113 to Val121, whereas the C-terminal half
of the linker region was suggested to have little secondary
structure. We decided, therefore, to generate two discrete
truncation mutations in the linker sequence; one mutation
with deletion of the predicted a-helical segment (PICK1
D113–121) and another with deletion of the C-terminal part
of the linker (PICK1 D125–135) (Figure 6A). Interestingly,
deletion of the putative a-helical segment (PICK1 D113–
121) resulted in clustering similar to that seen by expressing
the BAR domain alone or together with a transmembrane
PDZ ligand (Figure 6B). The PDZ ligand-binding capacity
was preserved in the mutant as reflected by relocalization
of coexpressed FLAG–TacGluR2 C29 to clusters (Figure
6B). In contrast, PICK1 D125–135 did not show constitu-
tive clustering but rather displayed a phenotype similar to
PICK1 wt with cytoplasmic distribution in the absence of
PDZ ligand and clustering upon coexpression with PDZ
ligand (Figure 6).
The BAR domain is not activated by a
cytosolic ligand
It was our original hypothesis that ligand binding per se to
the PDZ domain would unmask the BAR domain activity
Figure 3: The BAR domain-dependent
clustering is observed in live immor-
talized dopaminergic neurons and in
hippocampal neurons. A) Immortalized
dopaminergic neurons (1Rb27AN3 cells)
and B) cultured hippocampal neurons tran-
siently (6 DIV) expressing eYFP–PICK1
D1–101, eYFP–PICK1 D1–101 3KE, eYFP–
PICK1, eYFP–PICK1 D1–135 or eYFP–PICK1
D1–135 3KE. The transfected cells were
analysed by confocal live imaging at 378C.
The data shown are representative of three
identical experiments.
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and thus would not require binding to a transmembrane
protein. To test this hypothesis, we transferred the 29
C-terminal residues of GluR2 onto enhanced cyan fluor-
escent protein (eCFP). This construct localized evenly
throughout the cytosol with some tendency to accumulate
within the nucleus (Figure 7A), which has previously been
reported for enhanced green fluorescent protein (eGFP)
itself (31). Upon cotransfection of eCFP–GluR2 C29 with
eYFP–PICK1, we observed an entirely even distribution of
PICK1 within all cells, suggesting that this cytosolic ligand
was unable to cause BAR domain-mediated clustering of
PICK1 (Figure 7A). To verify that the eCFP–GluR2 con-
struct was actually bound by the PICK1 PDZ domain, we
performed fluorescence resonance energy transfer (FRET)
experiments using live cell imaging in an epifluorescence
microscopy set up (Figure 7B). In control experiments, we
observed substantial energy transfer in an eCFP–YFP
fusion protein and we did not see any significant energy
transfer when eCPF was coexpressed with YFP–PICK1
(Figure 7C). Importantly, we observed significant energy
transfer from eCFP–GluR2 C29 to eYFP–PICK1, and this
transfer was essentially abolished by addition of an alanine
to the GluR2 C29 sequence (Figure 7C), which is predicted
to interfere with the PDZ binding (18). Note that the FRET
signal generated by the interaction of eCFP–GluR2 C29
with eYFP–PICK1 was localized evenly throughout the
cytosol (Figure 7D), suggesting that the FRET signal is
unlikely the result of a small pool of interacting proteins
whose membrane localization may not be easily detect-
able on the background of diffusely localized non-interact-
ing proteins. Note also that eCFP–GluR2 C29 was
expressed at markedly higher levels than FLAG–TacGluR2
C29 as estimated from western blots using an antibody
directed against the GluR2 C-terminus (Figure 7E). This
strongly suggests that the lack of clustering despite
significant FRET signal is not the result of reduced expres-
sion of ligand (eCFP–GluR2 C29).
To further substantiate that eCFP–GluR2 C29 and PICK1
interact in the cytosol, we performed coimmunopre-
cipitation experiments. As shown in Figure 7F, PICK1
coimmunoprecipitated with eCFP–GluR2 C29 but not with
eCFP–GluR2 C29 þ Ala in agreement with the FRET
measurements and a PDZ domain-dependent interaction
between the two proteins. We used myc-tagged PICK1 in
these experiments to have an optimal antibody for the
immunoblotting procedure. Of note, myc antibody staining
of cells coexpressing eCFP–GluR2 C29 þ Ala and myc-
tagged PICK1 showed uniform distribution of both proteins
in the cytosol identical to that seen for cells coexpressing
eCFP–GluR2 C29 and eYFP–PICK1 (data not shown).
Summarized, our FRET and coimmunoprecipitation data
provide strong evidence that indeed eCFP–GluR2 C29 and
Figure 4: Coexpression of Myc-
tagged GluR2 with eYFP–PICK1
causes BAR domain-dependent co-
clustering. Myc-tagged GluR2 was
transiently expressed in COS7 cells
alone (upper row), together with
eYFP–PICK1 wt (middle row) or to-
gether with eYFP–PICK1 3KE (bottom
row). Cells were fixed, permeabilized
and stained with anti-myc for confocal
microscopy. eYFP was visualized by
YFP fluorescence. MycGluR2 is shown
in red (left column) and eYFP–PICK1 in
green (middle column). Right column
shows the merged pictures. White
bar ¼ 10 mm. The data shown are rep-
resentative of four experiments.
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eYFP–PICK1 interact, and given that both the PICK1 and
the FRET signals are evenly distributed in the cytosol, this
suggests that binding of a cytosolic PICK1 ligand does not
result in BAR domain activation.
The BAR domain is activated by membrane
association independent of ligand binding
to the PDZ domain
The inability of a PDZ ligand by itself to activate the BAR
domain opened the possibility that activation of BAR
domain function in the full-length PICK1 might depend on
recruitment of PICK1 to a membrane compartment. To
test this hypothesis further, we introduced an N-terminal
myristoylation site from the chicken myc protein because
N-myristoylation has previously been shown to mediate
a relatively weak and reversible plasma membrane local-
ization of numerous proteins (32). The myristoylated PICK1
localized to the plasma membrane as well as to intracel-
lular clusters in COS7 cells (Figure 8A), which resembled
the clustering observed for truncated PICK1 and upon
cotransfection of PICK1 with transmembrane ligands for
the PDZ domain. The clustering appeared to be markedly
reduced in the corresponding 3KE mutant (Figure 8A).
However, because the effect of the 3KE mutation was
less pronounced than the effect seen for truncated PICK1
and PICK1 cotransfected with a transmembrane ligand, we
performed a quantification of the clustering. The quantifi-
cation was done by determining the standard deviation of
a line scan through the cells as a measure of clustering
(a representative example is shown in Figure 8A). Using
8-bit pixel depth (256 graytones), we observed a mean
standard deviation of MyriPICK1 wt profiles of 54.7  1.5
(n ¼ 64), whereas the mean standard deviation results for
MyriPICK1 3KE profiles was 30.1  1.7 (n ¼ 63) (mean 
SEM, p < 0.0001, unpaired t-test). This is consistent with
a significantly higher degree of clustering of MyriPICK1
compared with MyriPICK1 3KE and thus that a part of the
clustering phenotype is indeed BAR domain dependent
(Figure 8A).
In principle, the observed activation of the BAR domain in
MyriPICK1 could be the result of myristoyl-dependent
localization of PICK1 to a membrane domain that contains
a high concentration of an endogenous PDZ-binding
Figure 5: The C-termini of GluR2 and of DAT fused to the
single transmembrane protein Tac are sufficient for BAR
domain-dependent coclustering with PICK1. A) FLAG–Tac-
GluR2 C50 and B) FLAG–TacGluR2 C29 transiently expressed in
COS7 cells alone (upper row), together with mycPICK1 wt (middle
row) or together with mycPICK1 3KE (lower row). C) FLAG–
TacDAT C24 transiently expressed in COS7 cells alone (upper
row), together with mycPICK1 wt (middle row) or together with
mycPICK1 3KE (lower row). Cells were fixed, permeabilized and
stained with anti-FLAG and anti-Myc for confocal microscopy. The
C-terminal FLAG–Tac fusions are shown in green (left column)
and mycPICK1 in red (middle column). Right column shows the
merged pictures. White bar ¼ 10 mm. The data shown are
representative of four experiments.
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partner of PICK1, leading to BAR activation through ligand
binding to the PDZ domain. Therefore, we introduced
a mutation (A87L) in the binding pocket of the myristoy-
lated PICK1, which we have shown previously to eliminate
binding to all tested ligands in vitro without compromising
the structural integrity of the PDZ domain (3). This mutant
of MyriPICK1 displayed the same clustering as observed
for MyriPICK1 itself even though the ligand-binding capa-
city of the PDZ domain was eliminated (Figure 8B). Finally,
we wanted to confirm that activation of the PICK1 BAR
domain by introduction of the myristoylation site from
chicken myc was because of addition of the acyl chain and
not an artifact of introducing the sequence itself. Figure 8B
shows that mutation of the glycine in position 2 of the
chimeric protein, which is the residue modified with the
acyl chain, into an alanine completely abolished clustering
of the protein.
The clusters originate from the plasma membrane
It is tempting to speculate that the clustering seen upon
coexpression of PICK1 with a transmembrane ligand
directly reflects the suggested ability of PICK1 to regulate
trafficking of its interaction partners. Specifically, the
clusters might reflect the suggested ability of PICK1 to
generate an intracellular pool of AMPA receptors, which is
believed to be essential for induction of LTD (9,10,14).
Figure 6: Deletion of a predicted
a-helical region (residues 113–
121) in the linker region between
the PDZ and the BAR domains
causes redistribution of PICK1
to juxtanuclear clusters. A) Sche-
matic diagram of PICK1 highlighting
the linker sequence between the
PDZ domain and the BAR domain.
According to a secondary structure
prediction of the PICK1 protein, the
short sequence between residues
113 and 121 was suggested to form
an a-helical segment. In contrast,
the C-terminal half of the linker
was predicted to have a less well-
defined structure. To investigate the
putative role of the linker in regula-
tion of BAR domain activity, we
generated two deletion mutants,
one corresponding to residues
113–121 and thus the putative
a-helical segment and one corres-
ponding to residues 125–135. B)
Expression of myc-tagged PICK1
D113–121 alone (upper panel) or
together with a PDZ ligand (FLAG–
TacGluR2 C29) (lower panels).
PICK1 D113–121 is shown in red
(left picture) and FLAG–TacGluR2
C29 in green (middle picture). The
merged pictures are shown on the
right. C) Expression of myc-tagged
PICK1D125–135 alone (upper panel)
or together with a PDZ ligand
(FLAG–TacGluR2 C29) (lower pan-
els). PICK1 D125–135 is shown in
red (left picture) and FLAG–Tac-
GluR2 C29 in green (middle picture).
The merged pictures are shown on
the right.
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If the clusters are representative of such an intracellular
pool, it would be expected that a transmembrane PDZ
ligand coexpressed with PICK1 would be continuously
internalized to the observed clusters. To test this, we
performed an antibody feeding experiment using FLAG–
TacGluR2 C29 as our ‘model’ construct. Cells expressing
FLAG–TacGluR2 C29 with PICK1 were incubated with the
M1 antibody at 378C for 90 min followed by fixation and
staining with secondary fluorescent antibody. In agree-
ment with our prediction, we observed clusters containing
both PICK1 and FLAG–TacGluR2 C29 (Figure 9). Thus,
FLAG–TacGluR2 C29 from the surface was dynamically
accumulated in the juxtanuclear clusters. This process was
also BAR domain dependent because coexpression of
FLAG–TacGluR2 C29 with the PICK1 3KE mutant did not
result in accumulation of the two proteins in intracellular
clusters (Figure 9).
The juxtanuclear clusters represent Rab11-positive
endocytic compartments
We next wanted to investigate the more precise nature of
the juxtanuclear clusters. Given that FLAG–TacGluR2 C29
was internalized from the surface, we investigated
whether the PICK1 clusters it generated colocalized with
any of the small guanosine triphosphatase (GTPase) Rab
proteins that characterize distinct endocytic compart-
ments (33–35). Accordingly, FLAG–TacGluR2 C29 and
PICK1 were expressed together with eGFP-tagged Rab5,
Rab7 or Rab11. As shown in Figure 10A and as expected,
the eGFP-tagged Rab proteins displayed distinct expres-
sion patterns consistent with localization to different
endocytic compartments. The PICK1 clusters generated
by FLAG–TacGluR2 C29 showed most prominent colo-
calization with eGFP–Rab11, a marker of recycling endo-
somes (33–35), that is, there was a marked overlap
between the eGFP–Rab11-positive vesicles and the
PICK1-positive juxtanuclear clusters (Figure 10B). This
was supported by the quantification of colocalization
shown in Figure 10D, showing 60% colocalization of
PICK1 with eGFP–Rab11. For eGFP–Rab5, which is
a marker of the early endosomal compartments (33–35),
we also observed overlap, although lower than that with
the eGFP–Rab11-positive clusters (30%) (Figure 10B,D).
In contrast, essentially, no colocalization was observed
with eGFP–Rab7, a marker of late endosomes (Figure
10B,D). Finally, we tested the subcellular localization of
the PICK1 BAR domain alone (D1–135). As seen in Figure
10C,D, we observed clear colocalization with eGFP–Rab11
(60%) but very little with eGFP–Rab5 and eGFP–Rab7
(<10%) (Figure 10C,D).
Discussion
PICK1 is the only protein known to contain a PDZ domain in
combination with a BAR domain. Thus, PICK1 has the
unique property of having a PDZ domain capable of binding
the extreme C-termini of a broad range of proteins critical
for neuronal signalling and a BAR domain that can connect
these proteins to distinct curved membranes within the
cell. Recent studies have documented the critical physio-
logical roles of both domains in PICK1 (21). In this study,
we present data providing new insight into the molecular
mechanisms controlling the activity of the PICK1 BAR
domain and how this might regulate trafficking of trans-
membrane interaction partners of the PDZ domain.
The presence of a membrane curvature-recognizing BAR
domain in PICK1 is a relatively recent insight. PICK1 has
long been known to have high sequence identity to the
arfaptin2, but it was not until the structure of arfaptin2 was
shown to be recapitulated in the BAR domain of amphi-
physin that this sequence was realized to be a BAR domain
(19). In vitro membrane vesicle-binding assays have indi-
cated that the PICK1 BAR domain is indeed capable of
binding lipids (21). As shown by Lu and Ziff (22) and in this
Figure 7: The interaction of PICK1 with a cytosolic ligand does not cause clustering of PICK1. A) COS7 cells transiently
coexpressing eCPF–GluR2 C29 (eCFP with the 29 C-terminal residues of GluR2 fused to the C-terminus) and mycPICK1. Cells were
fixed, permeabilized and stained with anti-Myc. eCFP was visualized by CFP fluorescence. eCFP–GluR2 C29 is shown in blue (left column)
and mycPICK1 in red (middle column). Right column shows the merged pictures. White bar ¼ 10 mm. The data shown are representative
of three experiments. B) COS7 cells expressing eCPF–GluR2 C29 and eYFP–PICK1, eCPF–GluR2 C29 þ Ala (non-binding control) and
eYFP–PICK1 or eCFP and eYFP–PICK1. The first and second columns from the left show the images obtained with CFP and YFP filter sets,
while the third column represents a merged image of CFP and YFP. The fourth column shows line scan histograms illustrating cellular
colocalization. The images shown are representative of three independent experiments. C) Normalized FRET efficiency is given for eCFP–
GluR2 C29 and eYFP–PICK1 (n ¼ 29), eCFP–GluR2 C29 þ Ala and YFP–PICK1 (n ¼ 28) and eCFP cotransfected with YFP–PICK1 (n ¼ 22);
as controls, we used CYFP (a covalent fusion of CFP and YFP) (n ¼ 22) and cotransfection of CFP and YFP vectors (n ¼ 20). All bars
represent data from three experimental days (mean  SEM). Statistical analysis was done using ANOVA, post hoc Bonferroni’s test for
multiple comparisons (***p < 0.001). D) Distribution of the FRET signal corrected for bleed-through in COS7 cells expressing eCFP–GluR2
C29 and eYFP–PICK1. E) Western blot of eCFP–GluR2 C29 and FLAG–TacGluR2 C29 transfected in parallel. The two proteins were
visualized with an antibody against the C-terminal 20 residues of GluR2 (Santa Cruz). F) Coimmunoprecipitation of myc-tagged PICK1 with
eCFP–GluR2 C29 but not with eCFP–GluR2 C29 þ Ala in agreement with the FRET measurements and a significant interaction. The
experiments were carried out using lysates from COS-7 cells transiently expressing mycPICK1, eCFP–GluR2 C29, eCFP–GluR2 C29 þ Ala,
eCFP–GluR2 C29 together with mycPICK1 or eCFP–GluR2 C29 þ Ala together with mycPICK1. The immunoprecipitations were done with
a mouse monoclonal anti-green fluorescent protein antibody and immunoblotting with a rabbit anti-myc antibody. No antibody refers to no
antibody in the immunoprecipitate.
1336 Traffic 2008; 9: 1327–1343
Madsen et al.
study, heterologous expression of the PICK1 BAR domain
results in a characteristic clustering that is likely to reflect
the vesicle-binding capacity of this type of domain. This
juxtanuclear clustering strongly resembles the localization
observed for full-length endogenous ICA69 – a closely
related BAR domain protein (23).
In a recent study, a series of PICK1 truncation mutants
were analysed in an in vitro membrane vesicle-binding
assay (36). The data suggested that N-terminal deletions
decreased vesicle binding, which is in disagreement with
both our cellular confocal microscopy data and our data
obtained in the cellular fractionation assay. To address this
discrepancy, we performed a series of experiments in
which we employed a vesicle-binding assay similar to that
of Jin et al. (36) using purified PICK1 (Figure S1). In contrast
to Jin et al., but in full agreement with our other data, we
observed a marked increase in liposome binding upon
truncation of the N-terminal PDZ domain (D1–135 PICK1).
In further agreement with our hypothesis, we did not
observe any effect on vesicle binding upon incubation with
a peptide ligand (GluR2) (Figure S1). Moreover, we find it
reasonable to emphasize that our findings in the vesicle-
binding assay are consistent with the results from both our
confocal microscopy assays and our cellular fractionation
assay. Additionally, the findings by Jin et al. on the PICK1
truncation mutants were not supported by parallel experi-
ments in a cellular system (36).
We have no explanation for the apparent discrepancy
between our vesicle-binding data and those of Jin et al.
(36). One possibility is that it relates to putative weak-
nesses and variability of the assay because of the rather
high protein concentrations required to perform it; hence,
we have reasons to believe based on preliminary experi-
ments that purified PICK1 and D1–135 PICK1 are capable
not only of binding but also of disrupting liposomes at
the concentrations used in the assay (unpublished data).
This might affect the results obtained with different
PICK1 constructs and thereby potentially contribute to
Figure 8: Evidence for BAR domain activation in PICK1 by
membrane localization. A) COS-7 cells were transiently trans-
fected with PICK1 containing an artificial N-terminal myristoylation
site (MyriPICK1) (top left panels) or MyriPICK1 3KE to disrupt the
function of the BAR domain (top right panels). The constructs are
schematically illustrated above the confocal microscopy pictures
of representative cells. The clustering was quantified by deter-
mining the standard deviation (SD) of a line scan through the cells
as a measure of clustering. Representative line scan along
indicated green line is shown below the confocal pictures. The
SD for the shown scans were 59.0 for MyriPICK1 and 35.7 for
MyriPICK1 3KE. The SD values for 64 cells expressing MyriPICK1
and for 63 cells expressing myriPICK1 3KE are indicated in
the lower panel. Mean SD was 54.7  1.5 for myriPICK1 and
30.1  1.7 for myriPICK1 3KE. These values were significantly
different (p < 0.0001, unpaired t-test). B) COS-7 cells expressing
MyriPICK1 G2A to prevent myristoylation (left panel) or MyriPICK1
A87L to prevent ligand binding to the PDZ domain (right panel).
The mutations are schematically illustrated above the images.
Cells were fixed, permeabilized and stained with a C-terminal
PICK1 antibody for confocal microscopy. White bar ¼ 10 mm. The
PDZ domain is shown in red and the BAR domain in blue. The black
bar illustrates the artificial myristoylation sequence, whereas the
purple tilde illustrates the myristoyl chain. The stars indicate
where mutations are introduced, and the orientation of the BAR
domain relative to the PDZ domain suggests whether the BAR
domain is activated or not.
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the discrepancy. It is also possible that, although we both
used 100 nm lipid vesicles derived from the brain, even
minor differences in the method of preparation could po-
tentially impact the results of the experiments and con-
tribute to differences. An interesting difference between
our procedure and that of Jin et al. is that their constructs
had glutathione S-transferase (GST) fused to the N-termini
of PICK1 and the PICK1 mutants when analysed in the
assay, whereas we enzymatically removed the GST before
performing the experiments. It is possible that this differ-
ence also might affect the results of the experiments.
We were able to cause juxtanuclear clustering of PICK1
not only by deletion of the PDZ domain but also by discrete
deletion of a short putative a-helical segment in the linker.
This suggests that the linker may also play a critical role in
negative regulation of BAR domain activity. The somewhat
more pronounced juxtanuclear clustering observed in
D1–135 PICK1 compared with that of the D1–101-PICK1
construct that contains the linker provides additional
support for such a functional role. However, it is intriguing
to consider as well the data in the context of the suggested
direct interaction between the PDZ domain and the BAR
domain that was proposed to negatively regulate BAR
domain activity (22). Hence, it could be envisioned that the
linker is critical for appropriate positioning of the PDZ
domains relative to the BAR domain. Notably, in this case,
the role of the linker is not a mere consequence of its
length because only deletion of the putative a-helical
segment (residues 113–121), and not of residues 125–
135, resulted in cellular redistribution of the protein.
Initially, we hypothesized that simple ligand binding to the
PICK1 PDZ domain was capable of triggering BAR domain
activation through conformational changes. Nevertheless,
we did not see any sign of BAR domain activation when
the interaction took place in the cytosol, that is, when the
29 C-terminal residues of GluR2 were fused to eCFP and
coexpressed with PICK1. Conversely, simple membrane
recruitment of PICK1 by introduction of an N-terminal
myristoyl signal redistributed PICK1 in a BAR domain-
dependent manner, suggestive of BAR domain activation.
These findings indicate that unmasking of the lipid-binding
capacity is not directly elicited by the PDZ ligand but
dependent on recruitment of PICK1 to selected membrane
compartments.
Certain proteins [e.g. sorting nexin-1 (SNX-1), oligophrenin
and centaurin] contain, in addition to a BAR domain, yet
another phospholipid-binding domain, such as a pleckstrin
homology or a Phox homology (PX) domain (19,37). For
SNX-1, mutagenesis studies have shown that the BAR and
Figure 9: The transmembrane ligand
for PICK1 that coclusters with
PICK1 intracellularly originates
from the plasma membrane. Feed-
ing experiments were performed by
incubating cells with FLAG-M1 anti-
body in DMEM for 90 min at 378C
before fixing, permeabilization and
staining. FLAG–TacGluR2 C29 tran-
siently expressed with mycPICK1
wt; right column shows the merged
pictures. The data shown are repre-
sentative of four similar experiments.
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the PX domains alone were incapable of mediating lipid
membrane association. Thus, membrane association
required the combined presence of the BAR domain and
the intact PX domain (38). This suggests a ‘coincidence
detection’ mechanism in which membrane curvature
recognition by the BAR domain coincides with recognition
of lipid composition, for example, phosphatidylinositol
bisphosphate by the PX domains. Such coincidence detec-
tion would be expected to play a critical role in achieving
a more precise localization to a given membrane microen-
vironment with defined curvature and defined lipid com-
position (20). We note the possibility that while the
situation in PICK1 is somewhat different, the mechanism
may be analogous. Thus, in PICK1, the BAR domain
coexists with a PDZ domain that by virtue of its binding
to the C-termini of integral membrane proteins is likely to
be brought near the membrane. This would suggest that
the PDZ domain may work in conjunction with the BAR
domain to ensure localization of the protein complex to the
proper microenvironment determined by (i) putative target-
ing signals inherent to the binding partner of the PDZ
domain and (ii) the ability of the BAR domain to recognize
specific membrane curvatures. Note, however, that PICK1
differs from SNX by the ability of the BAR domain by itself
to mediate lipid membrane binding (19,21,36). Unlike
a membrane-binding protein, any uncontrolled binding of
the BAR domain is prevented by negative regulation in
the full-length molecule. Consequently, it is tempting to
Figure 10: The juxtanuclear PICK1-positive clusters colocalize primarily with eGFP–Rab11. A) eGFP-tagged Rab5, Rab7 or Rab11
expressed in COS7 cells as indicated. Cells were fixed before visualization by confocal microscopy. eGFP–Rabs are visualized by eGFP
fluorescence. B) Coexpression in COS7 cells of mycPICK1 and FLAG–TacGluR2 C29 with eGFP-tagged Rab5, Rab7 or Rab11 as indicated.
Cells were fixed, permeabilized and stained with anti-myc antibody before visualization by confocal microscopy. Staining for mycPICK1 is
shown in red (upper row), and eGFP fluorescence is shown in green (middle row). The merged pictures are shown in the lower row.
C) Coexpression in COS7 cells of mycPICK1 D1–135 with eGFP-tagged Rab5, Rab7 or Rab11 as indicated. Cells were fixed, permeabilized
and stained with anti-myc antibody before visualization by confocal microscopy. Staining for mycPICK1 D1–135 is shown in red (upper
row), and eGFP fluorescence is shown in green (middle row). The merged pictures are shown in the lower row. D) Quantification of
colocalization between PICK1 and indicated Rab proteins. The data show percentage of colocalization with data points plotted for all tested
cells (a total of>15 cells from three independent experiments for each of the Rab proteins). The quantification was performed according to
previously published procedures (46,47).
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propose for PICK1 a mechanism in which initial recruit-
ment to a specific membrane compartment by the PDZ
ligand leads to subsequent unmasking of the BAR domain
activity. This unmasking would be facilitated by the avidity
generated by the mere proximity of the PICK1 molecule to
a lipid membrane and occur when an optimal membrane
curvature is available.
Of interest, a recent study has suggested a lipid-binding
capacity also for the PDZ domain (24). Specifically, muta-
tion of a ‘Cys-Pro-Cys’ motif in the PDZ domain diminished
coclustering of PICK1 with GluR2 in transfected cells. It is
tempting to speculate that this lipid-binding capacity of
the PDZ domain might operate in conjunction with that of
the activated BAR domain, thereby further enhancing the
avidity of the interaction.
It is important, nevertheless, also to note that unmasking
of the phospholipid-binding capacity of the BAR domain
might involve as well an as yet unknown membrane-
localized protein. For example, the BAR domain of arfap-
tin2, which has the highest homology to the PICK1 BAR
domain, was crystallized with a small GTPase in the
concavity (39). Additional experiments are required in the
future to address these questions; however, the present
data clearly support the importance of negatively regulated
BAR domain in PICK1 that both might prevent improper
BAR domain activity and ensure tight spatial and temporal
control of PICK1 function in relation to its interaction
partners in the endocytic pathway.
Interestingly, antibody-feeding experiments suggested
that transmembrane PDZ ligands coexpressed with PICK1
were internalized from the cell surface to the juxtanuclear
clusters within a time frame of <90 min in a BAR domain-
dependent manner. This supports the notion that the
clusters are not static, but highly dynamic entities, and is
consistent with a role of PICK1 in regulating trafficking of
its transmembrane interaction partners, for example by
promoting formation of an intracellular pool of such part-
ners – a possibility that is particularly relevant for the
AMPA receptors (9,10,14). A possible weakness of the
data could be that the observed clusters represent an
artefact resulting from overexpression of PICK1 and that
their formation results in general trafficking defects in the
cells. To exclude this possibility, we tested internalization
and recycling of FLAG-tagged b2 adrenergic receptor in
COS7 cells expressing PICK1 D135 or PICK1 and GluR2. Our
assay followed the principles described by Gage et al. (40)
except that we estimated surface expression by enzyme-
linked immunosorbent assay instead of by flow cytometry.
Importantly, we were unable to detect any significant
changes in agonist-induced internalization and subsequent
recycling of the receptor when comparing cells expressing
the receptor alone and cells expressing the receptor
together with either PICK1 D135 or PICK1 and GluR2 (data
not shown). Thus, PICK1 overexpression together with
ligand or overexpression of truncated PICK1 does not
cause general trafficking defects despite formation of
clusters.
Of further interest is the result of coexpression with eGFP-
tagged Rab GTPases, which revealed marked colocalization
of the juxtanuclear clusters especially with eGFP–Rab11,
and for the FLAG–TacGluR2/PICK1 clusters also with Rab5.
Rab5 and Rab11 are associated with early and recycling
endosomes, respectively (33–35), and clustered PICK1 has
previously been shown to colocalize with Rab5 (41). It is
accordingly tempting to suggest that PICK1 associates with
its interaction partners during the early stages of the
endocytic process conceivably through the combined avid-
ity of the PDZ domain interaction and membrane recogni-
tion by the BAR domain. It might even be speculated that
the BAR domain is capable of recognizing the high curvature
membranes generated during vesicle budding. Given that
clustered D1–135 PICK1 showed colocalization only with
Rab11-positive compartments, it is furthermore tantalizing
to propose a role of PICK1 and its BAR domain in the sorting
and recycling stages of the endocytic pathways rather
than directly in the endocytosis process. This could in-
volve sorting between distinct pathways as suggested for
another BAR domain-containing protein, SNX1 (38), or
retention of the PDZ domain interaction partner by delaying
its recycling as recently suggested for the AMPA receptor
(17). Future experimental efforts are required to further
address this important issue.
Materials and Methods
Molecular biology
MycPICK1, mycPICK1 D1–101 and mycPICK1 D1–135 were amplified by
polymerase chain reaction (PCR) of the complementary DNA (cDNA)
encoding mPICK1 and inserted into the pCMV vector. The 2KE (K266E
and K268E) and 3KE (K251E, K252E and K257E) mutants were made using
two-step PCR. The deletions PICK1 D112–120 and PICK1 D124–134 were
generated by using the Quick-Change strategy (Stratagene). To generate
eYFP–PICK1, the cDNA encoding PICK1 was fused at its 50-end to eYFP in
peYFP-C1 (Clontech) by subcloning the entire encoding sequence of rat
PICK1 (rPICK1) from eGFP rPICK1 (a kind gift from Dr K. Dev, Switzerland).
The eYFP–PICK1 D1–101 and eYFP–PICK1 D1–135 constructs as well as
the corresponding 3KE constructs were obtained by amplification from
mycPICK1 and mycPICK1 3KE and ligation into the peYFP-C1 vector. The
cDNA encoding Tac was subcloned from a modified pCDM8 vector (kind
gift from Dr M. D. Ehlers, North Carolina) into the mammalian expression
vector pcDNA3 (Invitrogen). A HindIII site was removed from pcDNA3, and
an N-terminal FLAG tag was introduced downstream from the predicted
N-terminal signal sequence of Tac using two-step PCR resulting in pcDNA
FLAG-tac. The DNA sequence encoding the C-terminal 50 and 29 residues
of hGluR2 as well as the 24 C-terminal residues of the human dopamine
transporter were amplified by PCR and ligated in-frame into 30 of pcDNA
FLAG-Tac. To generate eCFP–GluR2 C29, the HindIII/XbaI fragment from
FLAG–TacGluR2 C29 was subcloned into peCFP-C1 (Clontech). A
C-terminal alanine was introduced using an antisense primer encoding
the alanine preceding the stop codon. The peCFP-C1 and peYFP-C1 vectors
were used for expressing eCFP and eYFP, respectively, as well as
a covalent fusion of the two previously described (42). An N-terminal
myristoylation site was introduced into PICK1 (MyriPICK1) using an
N-terminal primer encoding the 17 N-terminal residues from chicken c-myc
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(43) and a C-terminal primer to amplify mPICK1 (2–416). The PCR product
was ligated into pcDNA3.1. MyriPICK1 G2A, 3KE and A87L were made by
conventional site-directed mutagenesis. The MycGluR2 was a kind gift from
Jonathan Hanley, MRC, Bristol, UK. The eGFP-tagged Rab constructs
(pEGFP-C1 Rab5, pEGFP-C1 Rab7, pEGFP-C1 Rab9 and pEGFP-C1 Rab11)
were a kind gift from Dr Juan Bonifacino, National Institute of Child Health
and Human Development, National Institutes of Health, Bethesda, MD, USA.
Cell culture
COS-7 and 1Rb27AN3 cells were maintained in DMEM 1965 with Glutamax
(L-alanyl-L-glutamine) containing 10% foetal calf serum and 0.01 mg/mL
gentamicin (Invitrogen) at 378C in a humified 5% CO2 atmosphere. Cells
were transfected using Lipofectamine 2000 (Invitrogen) and used for
experiments after 2 days.
Preparation and transfection of hippocampal neurons
Hippocampal neurons were prepared from embryonic day (E) 19 Wistar
rat embryos as described (44). In short, after a pregnant rat was
sacrificed, the hippocampal tissue of the foetuses was dissected in ice-
cold modified Krebs–Ringer solution and cleared of blood vessels and
meninges. The neurons were crudely homogenized by chopping before
trypsin treatment and then washed in the presence of soybean trypsin
inhibitor and DNAse 1 (both from Sigma) before plating in Neurobasal
medium supplemented with 2% (v/v) B27, 0.4% (w/v) BSA, 20 mM
HEPES, 1% (v/v) glutamax, 100 U/mL penicillin and 100 g/mL strepto-
mycin (Invitrogen) (45). Neurons were seeded at a density of 100 000
cells/cm2 in two-well Lab-Tek tissue culture chambers with a growth
surface of Permanox plastic (NUNC). For transfection, the neurons were
electroporated before plating using a Nucleofector device and a Rat
Neuron Nucleofector Kit (Amaxa Inc.) according to the manufacturer’s
recommendations using program G-13.
Immunocytochemistry and confocal microscopy
The cells were washed two times in PBS, fixed in 4% paraformaldehyde for
20 min, washed 3 in PBS and permeabilized by incubation for 20 min in
PBS containing 5% goat serum and 0.1% Triton-X-100. Primary antibodies
rabbit anti-myc 1:1000 (Upstate), mouse anti-haemagglutinin 1:1000 (Nor-
dic Biosite AB), mouse anti-FLAG-M1 1:1000 (Sigma) or chicken anti-PICK1
1:500 (a kind gift from Paul Rosenberg) were added for 1 h followed by
incubation with Alexa-conjugated secondary antibodies (1:500) (Molecular
Probes) for 30 min prior to mounting. In antibody feeding experiments, M1
anti-FLAG antibody (1:5000) was added to prewarmed serum-free medium
and incubated for 90 min at 378C to allow internalization. The staining
procedure was performed as described above except that the primary anti-
FLAG antibody was left out from the staining procedure. The stained cells
were visualized using a Zeiss LSM 510 confocal laser-scanning microscope
using an oil immersion 63 objective. The Alexa Fluor 488 dye and eYFP
were excited with the 488 nm laser line from an argon–krypton laser, and
the emitted light was detected using a 505–550 nm bandpass filter,
whereas the Alexa Fluor 568 dye was excited at 543 nm with a helium–
neon laser, and the emitted light was detected using a 585 nm long-pass
filter. The resulting images were combined using IMAGEJ software. Quanti-
fication of intracellular clustering of transfected constructs was performed
by determining the standard deviation of the pixel intensity of a profile
through individual cells (avoiding the nucleus). The profiles were generated
using the Zeiss LSM software. Quantification of colocalization with eGPP-
tagged Rab5, Rab7 and Rab11 was done using the RG2B colocalization
plug-in to IMAGEJ (Rasband W. S., ImageJ, U. S. National Institutes of Health,
Bethesda, MD, USA, http://rsb.info.nih.gov/ij/, 1997–2006) as described
(46,47). Single cells were defined as regions of interest to avoid noise from
untransfected cells and non-specific staining. A minimum threshold pixel
intensity of 100 was set for each channel in the 8-bit pictures to focus on
clustering, and the minimum ratio for pixel intensity between the two
channels was set to 0.5. Results are displayed as percent colocalization as
determined by dividing the area of colocalization pixels by the total area over
the threshold of the 543 channel reporting PICK1 localization. About 15–16
cells were used for quantification in each condition.
Molecular modelling
A secondary structure prediction for the PICK1 protein was made using
JPRED, a consensus secondary structure prediction server (48). The homol-
ogy model of a monomer of the PICK1 wt BAR domain (N146–N346) was
constructed with MODELLER 8.1 (49) using the sequences and structures of
arfaptin2 (1I49), amphiphysin (1URU) and endophilin (1ZWW). An initial
model of the PICK1 dimer complex was then obtained by alignment of the
monomer on the arfaptin dimer. For refinement, this dimer structure was
subjected to a Monte Carlo-minimization scheme in ROSETTADOCK where one
of the monomers underwent rigid body displacements, while the side-chain
orientations from both monomers were simultaneously optimized (50). The
lowest energy structure was then saved as the final dimer complex model.
The mutant constructs were obtained by residue replacement and applica-
tion of SCRWL 3.0, a fast side-chain conformation prediction program (51).
The electrostatic potential surfaces were calculated with the program GRASP
(52) using the linear Poisson–Boltzmann equation and a probe radius of
2.0 A˚.
Cellular fractionation and western blotting
Cells were fractionated into cytosolic and particulate fractions as previously
described with slight modifications (53). Briefly, 1  106 transiently trans-
fected COS7 cells were lysed using 1 mL of hypotonic lysis buffer [20 mM
Tris–HCl (pH 7.4), 10 mM potassium acetate, 1.5 mM MgCl2 and protease
inhibitor cocktail (Roche)] and douncing (35 strokes). Cell debris and nuclei
were pelleted by centrifugation (16 100  g for 20 min). The supernatants
(the cytosolic fractions) were removed, and the pellet was resuspended in
1.0 mL of the hypotonic buffer described above containing 1% Nonidet
P-40 and rotated for 1.5 h at 48C. The solubilisates were centrifuged
16 100  g for 20 min and supernatants (particulate fraction) removed.
Equal volumes of cytosolic and particulate fractions were subjected to
SDS–PAGE and immunoblotting using primary mouse anti-myc antibody
(1:1000) (Sigma) and a secondary horseradish peroxidase (HRP)-conjugated
goat a mouse antibody (Pierce). For immunoblotting of Tac–GluR2 and
eCFP–GluR2, we used a primary antibody directed towards the 20
C-terminal residues of GluR2 (Santa Cruz) and a secondary HRP-conjugated
donkey a goat antibody (Pierce). Quantification was done using QUANTITY ONE
(Bio Rad) and GRAPHPAD PRISM 4 (Graphpad Software) for data treatment.
Coimmunoprecipitations
Lysates from COS7 cells transiently expressing eCFP–GluR2 C29, eCFP–
GluR2 C29 þ Ala and eYFP–PICK1 alone or in combination were prepared
in tris buffered salt (TBS) containing 1% (v/v) Triton-X-100, 5 mM n-ethyl-
maleimide and a protease inhibitor cocktail (Roche Diagnostics). After
30 min of solubilization, insoluble material was removed by centrifugation
at 16 000  g for 10 min, and the supernatant (100 mg protein) was diluted
to 0.5 mL and precleared for 1 h with 25 mL protein G–agarose (Roche
Diagnostics) at 48C during constant rotation. The supernatant was incu-
bated with rabbit green fluorescent protein antibody (Abcam) for 1 h at 48C
during constant rotation. As controls, samples with only one construct or
without antibody were performed in parallel. The mixtures were sub-
sequently centrifuged at 16 000  g for 10 min to remove any precipitates
before incubation with 25 mL protein A–agarose (Roche Diagnostics) for
60 min at 48C. The beads were washed three times with TBS containing
0.1% (v/v) Triton-X-100. The bound material was eluted by addition of
loading buffer and separated by SDS–PAGE. Precipitated mycPICK1 was
detected by immunoblotting using mouse Myc antibody (9E10; Sigma).
Fluorescence resonance energy transfer
FRET (54) was measured with an epifluorescence microscope (Carl Zeiss
TM210) using the ‘three-filter method’ according to Xia and Liu (55). COS7
cells (3  105 cells/well) were seeded on to poly-D-lysine-coated glass
coverslips (24 mm diameter). Cells were transiently transfected using the
calcium phosphate precipitation method. The next day, media were
replaced by Krebs–HBS buffer (10 mM HEPES, 120 mM NaCl, 3 mM KCl,
2 mM CaCl2 and 2 mM MgCl2), and images were taken using a 63 oil
objective and a Ludl filter wheel that allows for rapid exchange of filters
(less than 100 milliseconds). The system was equipped with the following
fluorescence filters: CFP filter (ICFP; excitation: 436 nm, dichroic mirror:
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455 nm and emission: 480 nm), YFP filter (IYFP; excitation: 500 nm, dichroic
mirror: 515 nm and emission: 535 nm) and FRET filter (IFRET: excitation
¼ 436 nm, dichroic mirror ¼ 455 nm and emission ¼ 535 nm). The acqui-
sition of the images was done with METAMORPH (Meta Imaging; Universal
Imaging Corporation, version 4.6). Background fluorescence was sub-
tracted from all images, and fluorescence intensity was measured in
cytosolic regions in all images. To calculate a normalized FRET signal
(NFRET), we used the following equation:
NFRET ¼ IFRET  aIYFP  bICFPﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
IYFPICFP;
p
where a and b represents the bleed-through values for YFP and CFP,
respectively.
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Protein purification (19)
Liposome pull-down assay
Figure S1: Liposome pull down of PICK1. A) Representative liposome
pull-down assay showing stronger pelleting of PICK1 D135 than of PICK wt.
Both constructs show some unspecific pelleting. B) Quantification of the
specific pull down from six independent experiments. C) Representative
experiment showing the effect of four different peptides on the PICK1 pull
down. Peptides are used in a concentration where they have been shown
to bind more than 90% of the PICK1 protein. P, pellet; S, supernatant.
Supplemental materials are available as part of the online article at http://
www.blackwell-synergy.com
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Supplementary Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S1: Liposome pull-down of PICK1. (A) Representative liposome pull-down assay showing stronger 
pelleting of PICK1 Δ135 than of PICK wt. Both constructs show some unspecific pelleting. (B)  Quantification 
of the specific pull down from 6 independent experiments. (C)   Representative experiment showing the 
effect of 4 different peptides on the PICK1 pull-down. Peptides are used in a concentration where they have 
been shown to bind more than 90% of the PICK1 protein. (P) Pellet, (S) Supernantant. 
 
 
 
Supplementary Material and Methods:  
 
Protein purification:  
Relevant constructs were inoculated overnight in 50 ml of LB media, diluted into 1 liter of LB 
media, and grown to A600 1.0 (2–3 h). Expression of the fusion protein was induced with 
isopropyl-D-thiogalactopyranoside (100 µM) for 3 h at 30°C. Cells were harvested and frozen at -
80°C until purification. The pellets were thawed and resuspended in buffer A (50 mM Tris, pH 7.4, 
125 mM NaCl, 1%triton X 100, 20 µg/ml DNase I, 1 mM dithiothreitol) and 1x bacterial protease 
inhibitor mixture (Sigma). The lysate was frozen at -80 °C, thawed and thoroughly triturated to 
reduce viscosity. The lysate was clarified by centrifugation (rotor SS-34, 18,000 rpm, 48,000 x g, 
30 min). The supernatant was incubated with glutathione-Sepharose beads (Amersham 
Biosciences AB, Uppsala, Sweden) under slow rotation for 90 min at 4 °C. The beads were 
pelleted at 1,000 x g for 10 min and washed in buffer B (50 mM Tris, pH 7.4, 125 mM NaCl, 0.01% 
Triton X-100, 1 mM dithiothreitol) by three batch washes. The protein was separated from the GST 
domain by cleavage with thrombin protease (Novagen) in buffer B. The protein was eluted on ice 
until use (usually the same day). Samples of 25 µl were taken from the protein solution for 
determination of protein concentration and SDS-PAGE. Protein determination was carried out 
using the BCA Protein Assay Reagent kit (Pierce, Rockford, IL) according to the manufacturer’s 
protocol using bovine serum albumin as standard. Gels were stained with GelCode Blue Stain 
Reagent (Pierce) to inspect size, integrity, and purity of the protein. 
 
Liposome Pull Down assay 
The liposome pull-down assay was performed generally as described. Briefly, protein in a final 
concentration of 5μM in 0.005% TX-100 was incubated with 0.6 mg/ml brain liposomes  (Folch 
fraction I, B1502 from Sigma) extruded 10 times through 100 nm membranes in a total of 100μl for 
10 minutes before sedimentation in a Beckmann Airfuge (120,000g) for 15 minutes at 4ºC. 
Supernatant and pellet was separated and the pellet resuspended in 100μl buffer, before the 
protein was subjected to SDS-PAGE, Coomassie stained and quantified using the Bio-Rad 
Quantity One system.  
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Abstract 
 
The dopamine D2 receptor (D2R) is the primary target for anti-psychotic treatment. D2R is among 
other places expressed as an autoreceptor in dopaminergic neurons where it regulates dopamine 
release through a negative feedback. Previously it has been shown that D2R directly interacts with 
the dopamine transporter (DAT). Activation of D2R can upregulate DAT, thereby increasing 
cellular dopamine uptake capacity and possibly shaping locomotor activity in mice. Here we 
investigated the effect of DAT as a regulator of D2R signalling. We found that transient over-
expression of DAT with D2R in HEK293 cells reduced surface expression of D2R while DAT 
surface levels remained unaffected. Furthermore ß-Arrestin2 recruitment to D2R was compromised 
and D2R-mediated inhibition of cAMP accumulation was reduced as a consequence of the reduced 
surface level expression of D2R. The effects of DAT on D2R surface expression and signalling was 
not unique for DAT and D2R. Thus, transient co-expression of ß2AR with DAT resulted in reduced 
surface levels of ß2AR. In addition, co-expression of the serotonin transporter with D2R appeared to 
modulate the ß-Arrestin2 recruitment to D2R and the D2R-mediated inhibition of cAMP 
accumulation in a manner similar to co-expression of DAT. 
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Introduction 
The pre-synaptically expressed dopamine transporter (DAT) and dopamine D2 receptor (D2R) are 
both expressed in the dopaminergic neurons and both serve to restrain extracellular dopamine 
signalling (Geracitano et al. 2006). Alterations in dopamine signaling is coupled to neurological and 
psychiatric diseases including schizophrenia, bipolar disorder, ADHD (attention-deficit 
hyperactivity disorder) and Parkinson’s disease (Iversen and Iversen 2007).  
 
DAT exerts its effect by transporting dopamine released to the synapse back into the presynaptic 
neuron – thereby restricting DA signalling and facilitating the recycling of dopamine. DAT is also 
the principle target for widely abused psychostimulants, such as cocaine and amphetamine. The 
transporter belongs to the family of Na+/Cl- coupled neurotransmitter transporters (SLC6 gene 
family) that are characterized by the use of the transmembrane Na+ gradient as a driving force for 
transport of substrate and co-transport of Cl- (Torres and Amara 2007; Gether et al. 2006; Chen et 
al. 2004). 
 
In the pre-synapse the short splice variant of D2R complements DAT function by acting as a pre-
synaptic autoinhibitory receptor that inhibits further dopamine release and increases re-uptake of 
dopamine (Lee et al. 2007; Usiello et al. 2000). DAT and D2R were recently reported to interact 
and that the presence of D2R increased DAT expression in the plasma membrane (Bolan et al. 
2007; Lee et al. 2007). Furthermore the DAT/D2R interaction was proposed to regulate locomotor 
activity in mice (Lee et al. 2007) and recently the interaction has been suggested to be linked to 
schizophrenia (Lee et al. 2009).  
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It has previously been shown that D2R signalling function can be modulated by other interacting 
membrane proteins. Expressing D2R with the dopamine D1 receptor that in itself couples to Gs 
proteins results in a receptor complex that show enlarged Gq/11 mediated increase in intracellular 
calcium upon dopamine activation (Rashid et al. 2007). D2R can also directly interact with the 
Adenosine A2 receptor (Canals et al. 2003) and A2 agonist treatment of striatal membranes 
decreased agonist affinity for striatal D2R (Ferre et al. 1991). Many other GPCR’s have been 
shown to exist in both heteromeric and homomeric complexes and some of these complexes have 
been shown to alter GPCR signalling (Ferre et al. 2007; Fuxe et al. 2008; Szidonya et al. 2008). An 
interaction between mGluR2 and 5-HT2A have been shown exist in the rodent cortex in which 
ligand activation of mGluR2 positively regulates agonist affinity for 5-HT2A while ligand activation 
of 5-HT2A negatively regulates agonist affinity for mGluR2 in the complex (Gonzalez-Maeso et al. 
2008) - a phenomenon that may be implicated in psychosis.  
 
In the current work we pursued to further study the interaction between D2Rs and DAT and its 
consequences. Since previous works have primarily focused on the effect of DAT/D2Rs co-
expression on DAT function and expression, we investigated whether DAT expression had any 
effect on the D2Rs function and expression. 
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Materials and Methods 
DNA vectors 
Transporter constructs: pCDNA3.1 hSERT (Rasmussen et al. 2009), pCDNA3 HA-DAT (Kniazeff 
et al. 2008) have previously been described. pmVenus-SERT was made inserting by hSERT coding 
sequence into pmVenus-C1 using XbaI and SalI. pmVenus-DAT was made by excising synDAT 
from the pCDNA3 synDAT vector using KpnI and XbaI and inserted into pmVenus-C1 using the 
same restriction enzymes. Receptor constructs: pCDNA3.1 sf-β2AR was a kind gift from Dr. Mark 
von Zastrow, pCDNA3.1 sf-D2S was a kind gift from Jonathan Javitch and sf-D2S-Rluc8 have been 
described previously (Klewe et al. 2008). sf-β2AR-Rluc8 were constructed in an analog fashion, i.e. 
with the same linker sequence separating the coding region of the receptor and the coding region for 
Rluc8. All receptors were tagged in the N-terminal with signal flag epitope (Cao et al. 1999). Other: 
pCDNA3 FLAG-tagged Tac (Madsen et al. 2008) and β-Arrestin2(R393E, R395E)-mVenus  have 
been described previously (Klewe et al. 2008). TacGlur2-mVenus has mVenus inserted between the 
Tac sequence and the glutamate receptor 2 C-terminus (the last 29 amino acids of GluR2) in 
TacGluR2 (Madsen et al. 2008). 
All constructs have been verified by sequencing. 
 
Transfections 
Transfections with DNA were done with Lipofectamine 2000 (Invitrogen), according to the 
manufacturers protocol. The ratio of Lipofectamine 2000 to DNA ratio was 4 (µL to µg). For BRET 
and cAMP experiments a total of 1000 ng of DNA (where nothing else is stated) was used per 10 
cm2 of cells grown to 90-100% confluency at the time of transfection.  
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 Chemical compounds and vehicle 
All chemical compounds were synthesized by H. Lundbeck A/S, Denmark and dissolved in DMSO 
to a stock concentration of 10 mM. For BRET measurements compounds were diluted to the 
appropriate concentration in buffer composed of HBSS with Ca2+ and Mg2+  (Invitrogen), 0.2 µM 
ascorbic acid (Sigma-Aldrich) and 5 µM final concentration of coelenterazine h (Invitrogen). In 
saturation BRET experiments control buffer was identical except that 1‰ v/v DMSO (Sigma-
Aldrich) was added corresponding to the DMSO carry-over in test solutions with 5 µM compound.  
 
BRET measurements and calculations 
β-Arrestin2 assay: 48 hours post-transfection cells were harvested by trypsination  (250 µL per 10 
cm2 for ~45 seconds) (Invitrogen). All subsequent steps were performed at room temperature. Cells 
were re-suspended in culture medium and centrifuged at 900 g for 3 minutes and subsequently re-
suspended in HBSS with Ca2+ and Mg2+ to a density of approximately 100.000-200.000 cells/mL. 
Cells were left in suspension for 45-60 minutes before incubating with appropriated diluted 
quinpirole in a buffer with a final concentration of 5 µM coelenterazine h. 10-15 minutes after the 
addition of compounds luminescence was measured on EnVision multilabel plate reader (Perkin-
Elmer, Waltham, MA, USA). Luminescence from each well was measured twice; first through a 
520-550 nm band pass filter and then through a 447.5-472.5 nm bandpass-filter (Perkin-Elmer). 
Within each experiment measurement of each condition was done in duplicate. The BRET ratio was 
calculated as the long wavelength emission divided by short wave length emission and expressed as 
the relative change compared to vehicle treated cells (Pfleger et al. 2006). 
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BRET measurements of receptor / monoamine transporter interactions: The essay were essentially 
done as described above, except cells were transfected directly in 96-well plate with a total of 60 ng 
DNA per well. BRET donor vector amount was held constant at 3 ng DNA per well, if nothing else 
is indicated. Measurements were done on ~50-100.000 adherent cells per well and in triplicate.  
 
cAMP assay 
The receptor / monoamine transporter of interest was co-transfected with the GloSensor plasmid 
(Promega, Sweden) in the cDNA ratio 1:1:2.5. 48 hours post-transfection cells were harvested by 
gentle trypsination. Cells were re-suspended to a density of ~1.000.000 cells/mL in HBSS with Ca2+ 
and Mg2+ containing 2.5% GloSensor cAMP reagent (Promega) and equilibrated at room 
temperature for 2 hours. 40 µL cell suspension were mixed with 10 µL appropriately diluted 
quinpirole and 5 µM forskolin. Total luminescence was measured 15 minutes later on an EnVision 
multilabel plate reader. The relative decrease in cAMP levels were expressed as the percentage of 
the relative cAMP level in cells transfected alone with sf-D2S and GloSensor.  
 
Cell-based ELISA assay 
HEK293 cells were transfected two days prior to the experiment with equal amounts of HA-
DAT/sf-D2S, HA-DAT/mock, sf-D2S/mock, HA-DAT/sf-ß2AR, af-ß2AR/mock (0.5ug/0.5ug + 3ul 
Lipo2000) all in the pCDNA3 vector. 24h before the experiment the cells were seeded in black 96 
well plates (35,000 cells/well) coated with poly-L-ornithine (Sigma). On the day of the experiment 
the cells were incubated with HEPES buffer (25 mM HEPES, 130 mM NaCl, 5.4 mM KCl, 1.2 mM 
CaCl2, 1.2 mM MgSO4, 5 mM D-glucose, pH 7.4)  +/- 10 μM dopamine, 10 μM amphetamine, 10 μM 
quinpirole, 10 μM haloperidol for 60 minutes. Then the cells were fixed in 4% paraformaldehyde in 
phosphate-buffered saline + calcium (PBS) for 10 minutes and subsequently blocked with 5% goat 
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serum in PBS for 30 minutes. The plates were either incubated with M1 (1:5000; Sigma) or HA.11 
(1:1000; Covance) for 1 hour to probe FLAG-tagged receptors or HA-DAT, respectively. After 4 
washes the plates were incubated with horseradish peroxidase conjugated goat anti-mouse antibody 
(1:1000; Pierce) for 30 minutes and again washed 4 times with PBS. Then the plates were incubated 
with SuperSignal ELISA Pico Chemiluminescent HRP Substrate (Pierce) for 2 minutes and then the 
luminescence was read using a Wallac Victor2. Background from empty cells was subtracted from 
raw data and receptor data is represented as percentage of receptor + mock surface expression and 
HA-DAT data is represented as percentage of DAT + mock surface expression or as percentage of 
vehicle treatment. 
 
Statistical analysis and modelling 
Data was analysed with GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, USA) using the 
statistical tests indicated in the text. Significance was set to p < 0.05. 
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Results 
DAT effect on D2R surface expression 
First we tested whether DAT/D2R co-expression affected D2R surface expression as the surface 
expression of DAT has previously been shown to be modulated by the D2/DAT interaction. We 
used an HA-tagged DAT and a FLAG-tagged D2R in a cell based ELISA assay to simultaneously 
determine surface expression of both proteins in transiently co-transfected HEK293 cells (figure 
1A). When co-expressing D2R with DAT a reduction in D2Rs surface expression (21% +/-1.6 of 
D2Rs + mock, t-test, p < 0.001) was observed whereas no significant change in DAT surface 
expression (105% +/-8.5 of HA-DAT + mock, t-test) was seen (figure 1B). To examine whether the 
effect of DAT was specific for the D2R we conducted a parallel experiment with FLAG-tagged ß2-
adrenergic receptor (ß2AR). When co-expressing FLAG-tagged ß2AR and HA-DAT in HEK293 
cells a reduction in ß2AR expression (62% +/-7.1 of ß2AR + mock, t-test, p < 0.001) was seen 
compared to expression alone whereas no significant reduction in DAT expression was seen (107% 
+/-10 of HA-DAT + mock, t-test) (figure 1C). 
 
ß-Arrestin2 recruitment to D2R 
D2R affects a variety of signalling pathways including inhibition of adenylate cyclase and 
phosphorylation of a number of kinases including Erk1/2. This happens through canonical G-
protein activation and through other protein interactions of which ß-Arrestin2 has been the most 
investigated (Beaulieu et al. 2005; Klewe et al. 2008; Lan et al. 2009; Masri et al. 2008). We 
examined to which extend D2R signalling pathways is affected by the interaction with DAT in 
HEK293 cells.  
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We used a bioluminescence resonance energy transfer (BRET) based ß-Arrestin2 recruitment assay 
(figure 2H)  to establish the effect of DAT on ß-Arrestin2-dependent D2R signalling (Klewe et al. 
2008). Co-expression of DAT reduces both the efficacy and potency of quinpirole induced ß-
Arrestin2 recruitment to the D2R (figure 2A, B, C). Co-expression of DAT with D2R reduced the 
efficacy to 35 +/- 3% compared to D2R expressed alone (ANOVA, p < 0.001, Dunnett’s post-hoc). 
Similarly the potency (Log EC50) was reduced approximately 3-fold from -7.6 +/- 0.1 to -7.0 +/- 
0.2 (ANOVA, p < 0.05, Dunnett’s post-hoc). 
 
To test the specificity of the inhibitory effect of DAT on quinpirole induced ß-Arrestin2 recruitment 
to the D2R we also co-expressed another monoamine transporter, the serotonin transporter (SERT) 
as well as the non-homologous single transmembrane protein Tac, a subunit of the interleukin-2 
receptor (Waldmann 1991) (figure 2A, B, C). Co-expression of SERT reduced the efficacy to 71 +/- 
5% compared to the basal situation and co-expression of Tac to 78 +/- 4% (ANOVA, p < 0.001 
respectively p < 0.05, Dunnett’s post-hoc).  
 
cAMP inhibition 
To detect the effect of DAT on D2R Gi-protein mediated signalling, we measured the dose 
dependent effect of quinpirole on cAMP accumulation in transiently transfected HEK293 cells 
treated with 1 µM forskolin (figure 2D). Quinpirole did not have any effect on cells not transfected 
with D2R (data not shown). By co-expressing DAT, SERT and Tac with D2R in HEK293 cells we 
found that DAT and SERT both resulted in a lower maximal D2R mediated inhibition of cAMP 
(figure 2E). Co-expression of DAT resulted in a 93 +/-3% maximal inhibition of cAMP production 
compared to what we observed in cells expressing solely D2R (ANOVA, p < 0.05, Dunnett’s post-
hoc) (figure 2E). SERT co-expression also resulted in a 93 +/- 2% maximal inhibition of cAMP 
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production (ANOVA, p < 0.05, Dunnett’s post-hoc) whereas co-expression of Tac did not affect the 
capacity of D2R to inhibit cAMP production (figure 2E). Co-expression of DAT also shifted the 
LogIC50 of quinpirole mediated inhibition of cAMP production. With DAT we found the LogIC50 
to be -8.6 +/- 0.1 compared to a control value of -9.1 +/- 0.1 (figure 2F). Neither SERT nor Tac 
significantly affected the IC50 value of quinpirole in the assay (figure 2F). To control for possible 
effects of variations in the D2 receptor levels imposed by co-expression of another membrane 
protein we varied the amount of D2R cDNA used for the transfection of HEK293 cells over a 10-
fold range and measured the maximal inhibition (cAMP baseline set equal to 1) and LogIC50 for 
quinpirole. We found that the efficacy values and LogIC50 values obtained from the assay 
correlated (linear regression, r2 ~ 0.58) (figure 2H). Furthermore we found that the efficacy and 
LogIC50 values obtained from the assay when co-expressing DAT, SERT and Tac all fell within 
the 95% prediction band of the correlation (figure 2H), suggesting that the observed effects of DAT 
and SERT in the assay can be explained by variations in D2R levels. 
 
Trafficking 
Next we investigated if changes in D2R trafficking might underlie the reduced surface expression, 
and whether DAT/D2R existed in a stable complex resulting in parallel trafficking patterns. D2R 
agonists have been reported to induce D2R endocytosis (Ito et al. 1999; Iwata et al. 1999) and DAT 
substrates have also in some cases been reported to induce DAT endocytosis (Chi and Reith 2003; 
Kahlig et al. 2004). HEK293 cells expressing DAT and D2R alone as well as cells co-expressing 
DAT and D2R were incubated with the D2R agonist quinpirole, the D2R antagonist haloperidol, the 
DAT substrate amphetamine or the endogenous D2R agonist and DAT substrate dopamine. The 
cells were incubated for 60 minutes with each of the compounds. When expressing D2R alone no 
significant changes in D2R surface expression was seen for any of the compounds (figure 3A), 
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however a tendency to a reduced surface expression was seen when incubating with the D2R 
agonists dopamine and quinpirole. When co-expressing DAT with the D2R a significant reduction 
in the surface expression of D2R was seen when incubating with the agonists dopamine and 
quinpirole but no effect was seen with either D2R antagonist haloperidol or DAT substrate 
amphetamine (Figure 3B). As both dopamine and quinpirole caused a reduction of D2R surface 
expression the effect is most likely caused by agonist effect on D2R and most likely the increase in 
effect is caused by the lower expression of D2R when co-expressing DAT. No effect of the 
compounds was observed on DAT surface expression neither when DAT was expressed alone 
(figure 3C) or co-expressed with D2R (figure 3D), indicating that neither DAT activity nor ligand 
activation of D2R affects DAT surface expression in transiently transfected HEK293. The lack of 
quinpirole and haloperidol effect on DAT was also observed in a native cellular system as we did 
not see any change in the DAT-mediated dopamine uptake upon D2R agonist or antagonist 
stimulation in dopaminergic primary cultures (figure S2). 
 
BRET 
As it was surprising to observe that the functional consequences of DAT expression on ß–Arrestin2 
recruitment to the D2R (Figure 2A) and the reduced surface expression of D2R (figure 1B-C) was -
even though more pronounced - not unique to DAT co-expression with D2R we decided to 
investigate the interaction between the GPCRs, D2R and ß2AR, and the monoamine transporters 
DAT and SERT. For this purpose we conducted what is referred to as type I and type II BRET 
interaction experiments (James et al. 2006). In the type I BRET experiments the BRET donors D2S-
Rluc8 and ß2AR-Rluc8 are expressed at a constant level while varying the BRET acceptor mVenus-
DAT expression (figure 4A). For the BRET pair D2S-Rluc8 and mVenus-DAT we observed a 
saturation of the BRET signals at increasing amounts of acceptor as is expected from a specific 
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interaction (figure 4A). The BRET signal exhibited a parallel saturation for the BRET pair β2AR-
Rluc8 and mVenus-DAT indicating that the β2AR has an affinity for DAT similar to that of D2R. 
To test whether the interaction depended specifically on DAT we tested the effect of having 
mVenus-SERT as the BRET acceptor and D2S-Rluc8 and ß2AR-Rluc8 the BRET donors in the type 
I BRET assay. Again we observed a saturating BRET signal both with D2S-Rluc8 and ß2A-Rluc8 as 
the donor when increasing the amount of mVenus-SERT (figure 4B). The saturating BRET signal 
was not only observed between transporters and receptors as the BRET pair D2S-Rluc8 and Tac-
Glur2-mVenus yielded a similar saturation curve albeit with a lower maximal BRET signal (figure 
4C). BRET pairs with β2AR-Rluc8 resulted in a relative higher BRET signal at saturation and 
BRET pairs with SERT resulted in a relative lower BRET signal at saturation. Finally the BRET 
signal was the lowest for D2S-Rluc8 and Tac-Glur2-mVenus (figure 4I).  
  
We conducted type II BRET experiments with the described BRET pairs to further substantiate that 
the interaction between the receptors and the transporters was specific and not a result of random 
collisions in the membrane. Keeping the vector donor/acceptor ratio constant (1:0.5 ratio of vector 
DNA) and increasing the total transfected cDNA of the BRET pairs we observed an increase in 
BRET signal for all the tested donor acceptor pairs that appeared to reach a plateau (figure 4D, E, 
F). A priori we would have expected a constant BRET signal in an experiment with a constant 
donor/acceptor ratio if the BRET signal represented a specific interaction and was not the result of 
random collisions. However, when measuring the relative expression level of the BRET donors by 
their luminescence signal, we observed that the expression did not linearly depend on the amount of 
cDNA transfected into the cells. Rather a fast saturation of the donor signal was seen when co-
expressing with any of the acceptors (figure 4G). In contrast, the BRET acceptors displayed a clear 
linear correlation between the amount of transfected cDNA and the expression as measured by 
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mVenus fluorescence (figure 4H, data from type I experiment). Thus, although keeping the 
donor/acceptor vector DNA ratio constant, the actual ratio between the expressed BRET donor and 
BRET acceptor varied between each data point.  
 
Finally, we tested the effects of the ligands and substrates on the receptor / transporter interaction. 
In a type I BRET interaction experiment with mVenus-DAT and D2S-Rluc8 we tested the effect of 
the DAT substrate, tyramine, the D2R agonists quinpirole and dopamine (applied for 5 minutes). 
No significant effect of either of the drugs was seen, however a tendency towards a lower BRET 
efficacy was observed for the D2R ligands quinpirole and dopamine (figure 5A). Because the signal 
did not decrease further over time (data not shown) this likely reflects a re-orientation of the 
receptor and not a receptor/transporter complex dissociation. A similar observations was made with 
Tac-Glur2-mVenus as the BRET acceptor and D2S-Rluc8 as the BRET donor (figure 5C) and in a 
parallel experiment using the BRET pair mVenus-DAT and β2AR-Rluc8 a tendency for the agonist, 
isopreteronol to decrease the maximal BRET signal (figure 5B). Seen together this indicates that the 
tendency towards a lower BRET signal depended on a ligand-activation of the GPCR. 
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Discussion 
Initially we made the surprising observation that DAT profoundly affected D2R surface expression. 
Co-expression of DAT with D2R reduced the surface expression of D2R five-fold without the 
opposite being true, i.e. we did not observe D2R to affect the surface levels of DAT even though the 
same expression vector and equal amounts of cDNA was used for both proteins (figure 1B). This 
curious unidirectional suppressive effect of surface expression led us to test the effect of DAT on 
the surface expression of the homologous GPCR, ß2AR. From these experiments we observed a 
similar if not as pronounced reduction in the ß2AR surface expression upon DAT co-expression 
(figure 1C). We did not observe any increase in the intracellular accumulation of D2R in the 
presence of DAT when analysing the co-expression of DAT and D2R by confocal microscopy 
(figure S1) suggesting that the phenotype is not the result of ER retention. We cannot rule out an 
increased lysosomal or proteasomal degradation as a possible explanation, since this could occur 
without an increased intracellular accumulation. 
 
Studying the effect of DAT of D2R signalling, we found that co-expression of DAT with D2R 
resulted in an approximately 3-fold reduction in both efficacy and potency in the agonist-induced 
(quinpirole) recruitment of ß-arrestin2 to D2R as measured by BRET between D2R and ß-arrestin2 
(figure 2A-C). We also tested whether the homologous monoamine transporter, SERT, impaired the 
ß-arrestin2 recruitment to D2R. SERT co-expression did not have any effect on the potency but 
exhibited a slight reduction in the efficacy (figure 2A-C). This pattern was also observed with co-
expression of the non-homologous single transmembrane protein Tac (figure 2A-C). Because the 
estimation of the pharmacological parameters of ß-Arrestin2 recruitment to D2R is based on BRET 
experiments there are a number of potential confounders to the imminent conclusion that DAT 
inhibits ß-Arrestin2 recruitment to the D2R receptor. First of all BRET is a very sensitive measure 
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of interaction and both orientation of the dipole moments of the donor and the acceptor as well as 
the distance between these will affect the maximal obtainable BRET signal. The distance is 
particular critical as the BRET signal will decrease proportionally with the sixth power of 
increasing radius (Vogel et al. 2006). It is very plausible that D2R interaction with different 
transmembrane proteins will affect the distance between D2R and ß-Arrestin2. However, in our 
experiments this is likely not the case because the construct used as the BRET donor, D2S-Rluc8, 
have been designed with long flexible linker connecting the receptor and Rluc8.  
Secondly, the BRET signals are sensitive to changes in the donor/acceptor ratio. However, the 
response in the ß-Arrestin2 recruitment assay has been shown be stable over a range of BRET 
donor/acceptor ratios as the maximal BRET signal increases and saturates with an increasing ratio 
of the BRET acceptor to the BRET donor (Klewe et al. 2008). We therefore rule out the possibility 
that the observed reductions in efficacy and potency in recruiting ß-Arrestin2 to the D2R in the 
spresence of DAT, SERT and Tac were a consequence reduced levels of the BRET donor D2S-
Rluc8.  
In summary, our results strongly suggest that DAT inhibits β-Arrestin2 recruitment to D2R and 
thereby β-Arrestin2 dependent signalling from D2R but due the nature of the BRET based assay 
this should be explored further before any firm conclusion is drawn. 
 
For a more comprehensive picture of the effects of DAT on D2R signalling, we also investigated 
the G protein coupled signalling properties of D2R when co-expressing DAT. Studying the D2-
mediated inhibition of cellular cAMP accumulation we found that D2R in the presence of DAT, 
SERT and Tac appeared to have effects on cAMP accumulation reminiscent of our observations 
with the ß-arrestin assay; e.g activation of D2R with quinpirole resulted in a lower agonist efficay 
and potency in lowering cAMP accumulation in the presence of DAT and to a smaller degree in the 
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presence of SERT and Tac (figure 2E, F). Whereas we reasoned that a DAT mediated reduction in 
D2R surface expression did not negatively affect the BRET signal used to asses ß-Arrestin2 
recruitment to the D2R receptor, we predicted that the relative level of D2R expression in the 
cAMP assay would affect both the efficacy and the IC50 value obtained from the assay. Indeed, we 
observed a correlation between the efficacy and potency for quinpirole in the assay with varying 
receptor levels (figure 2G). Because the efficacy and IC50 values obtained from the co-expression 
experiments with DAT, SERT and Tac did not deviate significantly from this correlation it is 
unlikely that DAT has any effect on D2/G protein-mediated inhibition of cAMP accumulation other 
than those stemming from the reduced surface expression of the receptor (figure 2D-G). 
 
As Bolan et al. reported that D2R activation increased DAT surface expression (Bolan et al. 2007) 
and as it has been shown that D2R co-traffick as a heterooligomer with both D1R (So et al. 2005) 
and A2AR (Hillion et al. 2002) we hypothesized that if DAT/D2R constitutes a stable complex, 
D2R would in parallel with DAT show an increase the surface expression upon D2R activation. 
Neither activation of D2R alone, DAT alone nor concomitant activation with dopamine increased 
D2R surface expression (figure 3A, B). Contrary, we observed a similar reduction of D2R surface 
expression upon D2R activation alone as well as with simultaneous activation of DAT and D2R 
indicating that DAT activity does not positively regulate D2R surface expression. None of the 
compounds affected DAT surface expression (figure 3C, D). This either suggests a flexible complex 
that segregates upon internalization of the D2R or that D2R and DAT only traffics to and from the 
plasma membrane when it is not associated with the other. 
 
In contrast to previous observations that D2R activation rapidly increased DAT in the plasma 
membrane (Bolan et al. 2007), we did not observe any changes DAT surface expression upon 
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agonist stimulation of the D2R in HEK293 cells (figure 2D). We cannot rule out that this 
discrepancy is due to differences in expression levels and time of agonist treatment. Bolan et al. 
observed that quinpirole treatment increasing DAT surface expression by 30% within 1 minute 
(Bolan et al. 2007). Conversely, we treated our cells with compounds for 1 hour which might 
abolish an initial effect on DAT insertion into the plasma membrane. In addition, we did not see any 
effect of quinpirole on DAT mediated dopamine uptake in cultured mesencephalic dopaminergic 
neurons (figure S2), a system that has previously been shown to be susceptible to D2R agonists 
(Congar et al. 2002; Sulzer et al. 1998). Taken together, our experiments support the result from 
Lee et al., where no change in DAT surface expression or DA uptake was seen upon prolonged (30-
60 minutes) D2R activation (Lee et al. 2007). 
 
Through BRET measurements we established that DAT and D2R interact (figure 4A). However we 
also observed a specific BRET signal from the following combinations of BRET pairs DAT/ß2AR 
(figure 4A), SERT/D2R (figure 1B), SERT/ ß2AR (figure 4B), TacGlur2/D2R (figure 4C). To 
further substantiate our findings and the specificity of the BRET signals we attempted to carry out 
type II BRET experiments with all the BRET pairs. In this type of experiment the ratio between 
BRET donor and acceptor is kept constant over a range of expression levels. However due to large 
perturbations in the ratio between donor:acceptor upon co-expression (figure 4G-H) we were not 
able to draw a firm conclusion from the type II BRET experiments (figure D-F). It should be noted 
that the type II experiments have previously been carried out successfully when studying 
homodimerization - a situation where the ratio between the BRET donor and acceptor is easily 
controllable (Angers et al. 2000; Salahpour and Masri 2007; Fung et al. 2009). Our findings suggest 
that conducting type II experiments for validating interactions between non-homologous interaction 
partners is a difficult task at best. 
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 Given that all the BRET constructs were equipped with long amino acid regions between the 
transmembrane segment and the Rluc8 or mVenus (DAT + SERT > 90 a.a.), it is feasible to assume 
that the fusion exhibits no orientation or distance constraint on neither the donor nor the acceptor. 
We therefore suggest that the BRET efficacy in the present experiments is likely to represent a 
quantitative measure of the interaction (figure 4). Following this line of reasoning we propose that 
DAT has the highest degree of interaction with the GPCRs whereas for SERT the interaction is less 
and even lower for the non-homologous TacGluR2. A conclusion that mirrors the inhibitory effects 
of DAT, SERT and TacGlur2 on β-Arrestin2 recruitment to D2R  
 
Further substantiating that the observed interactions are of a specific nature we observed a clear 
tendency towards a lower BRET signal with ligand-activation of the GPCR (figure 5A-C). This is 
presumably the result of an intramolecular re-orientation. Such a re-orientation would most likely 
not interfere with the BRET signal if it was a result of result of random collisions. 
 
Our findings suggest that the previously proposed molecular determinants for the interaction 
between DAT and D2R might only be part of the interaction interface. Lee et al. found, using GST 
pulldown assays, that the N-terminal portion of DAT interacts with a discrete part the 3rd 
intracellular loop of D2R (Lee et al. 2007). This finding has been challenged by the observation that 
D2R is capable of increasing cellular DA uptake in cells expressing N-terminally truncated DAT as 
well as co-immunoprecipitation of this truncated version of DAT (Bolan et al. 2007). Although it 
cannot be excluded that N-terminal of DAT interacts with D2R and plays a functional regulatory 
role, our findings further suggest that the interaction is mediated by additional molecular 
components as SERT and DAT are not very homologous in their N-termini (figure S3). If this fact 
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is co-evaluated by the fact that D2R has a very short C-terminus and long 3rd intracellular loop and 
ß2AR demonstrate the opposite pattern, the hypothesis immediately materialize that the interaction 
between the receptors and monoamine transporters is also mediated by interactions between 
transmembrane helices, where D2R and ß2AR respectively DAT and SERT share a larger degree of 
homology (Beuming et al. 2006). The hypothesis is further substantiated by the surprising finding 
that D2R also appears to interact with Tac-Glur2. 
 
In this respect, it is interesting to note that D2R has been shown to exist in higher order oligomers 
in the plasma membrane at physiological expression levels and to be dependent on at least two 
symmetrical interfaces in the transmembrane regions (transmembrane domains 1 and 4) (Guo et al. 
2008). Furthermore D2R has been shown to form higher order oligomers with two other GPCRs, 
the adenosine A2a receptor and the metabotropic glutamate type 5 receptor (Cabello et al. 2009). 
Transporters in the SLC6A gene family including DAT and SERT have also been reported to form 
homo-oligomers  (Hastrup et al. 2001; Schmid et al. 2001; Sorkina et al. 2003; Torres et al. 2003) 
and in the case of DAT the existence of tetrameric homomers with two symmetrical interfaces have 
been suggested (Hastrup et al. 2003). As the homo-oligomerization interfaces for both DAT and 
D2R have been reported to be in the transmembrane regions, this indicates that both DAT and D2R 
possess transmembrane parts that are prone to intermolecular interactions. Based on such inherent 
propensity to in-membrane interactions and the fact that ß2AR (Angers et al. 2001; Salahpour et al. 
2004) also homodimerize it is tempting to suggest that the observed interaction between DAT and 
D2R is based on intermolecular interactions in the transmembrane domains with no apparent 
specificity but a shared affinity between transmembrane regions since the interaction is reproduced 
between unlike partners with pseudo-Kd values that did not significantly differ between the 
different BRET pairs (Figure S4). This does not rule out that the interaction between D2R and DAT 
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could have biological consequences. Future studies will have to address this and to what degree the 
interaction quantitatively differs from other interactions between GPCRs and transporters. In this 
respect, it would be interesting to pursue experiments that could establish the actual Kd value 
between interacting pairs of transmembrane proteins expressed at physiological relevant levels in 
live cells. Such data would perhaps also enable us to decompose interactions into general and 
specific determinants. 
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 Figure legends 
 
Figure 1:  
DAT suppresses the surface expression of both D2SR and ß2AR. (A) In each batch of transfected 
cells, the FLAG-D2SR or FLAG-ß2AR surface expression was probed with M1 antibody and HA-
DAT surface expression with HA.11 antibody. (B) HEK293 cells were transfected with equimolar 
amounts of FLAG-D2SR/mock, HA-DAT/mock or FLAG-D2SR/HA-DAT. Expression of D2SR 
(brown bars) together with DAT resulted in a 5-fold reduction in D2SR surface expression 
compared to D2SR/mock (21% +/- 1.6, n=4, p<0.0001 one sample t-test) whereas no reduction was 
seen in DAT (orange bars) expression (105% +/- 8.5 of DAT/mock, n=4, p=0.56 one sample t-test). 
(C) As in B the surface expression of DAT (orange bars) and ß2AR (brown bars) was determined in 
cells transfected with equimolar amounts of FLAG-ß2AR/mock, HA-DAT/mock or FLAG-
ß2AR/HA-DAT. Co-expression of DAT and ß2AR significantly reduced ß2AR to 63% +/- 7.0 of 
ß2AR /mock (n=3, p=0.033 one sample t-test) whereas no change in DAT surface expression was 
seen (107% +/- 10 of ß2AR /mock, n=3, t=0.56 one sample t-test). 
 
Figure 2: 
(A) Quinpirole (D2R agonist) dose-response curves of β-Arrestin2 recruitment to D2R in HEK293 
cells transiently transfected with the BRET donor D2S-Rluc8 and the BRET acceptor β-
Arrestin2(R393E, R395E)-mVenus in combination with either DAT, SERT, Tac or empty vector. 
The cells were incubated with the indicated concentration of quinpirole and BRET was measured 
after 10-15 minutes. The BRET signal was normalized to the vehicle condition and expressed as a 
percentage of the maximal response within the basal assay (donor and acceptor alone). (B, C) 
Quantification of the efficacy and potency of quinpirole in recruiting β-Arrestin2 to D2R in the 
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presence of DAT, SERT or Tac compared to basal condition were D2S-Rluc8 and β-Arrestin2-
mVenus were expressed alone. Mean efficacy and LogEC50 +/- s.e.m calculated from three 
independent experiments (Efficacy: DAT and SERT, p < 0.001; Tac, p < 0.05. Potency: DAT, p < 
0.01). (D) Quinpirole (D2R agonist) concentration-response curves of forskolin (1 µM) induced 
cAMP accumulation in HEK293 cells transiently transfected with D2S and GloSensor in 
combination with DAT, SERT, Tac or empty vector. The cells were incubated with the indicated 
concentration of quinpirole and total luminescence was measured after 15-20 minutes. The 
luminescence signal was normalized to the vehicle condition (forskolin alone) and expressed as a 
percentage of the maximal and minimal accumulation of the basal assay (D2S and GloSensor 
alone). (E, F) Quantification of the efficacy and potency of quinpirole in D2S mediated inhibition of 
cAMP accumulation in the presence of DAT, SERT or Tac compared to basal condition (D2S and 
GloSensor alone). Mean efficacy and LogIC50 +/- s.e.m calculated from three independent 
experiments (Efficacy: DAT and SERT, p < 0.05. Potency: DAT, p < 0.001). (G) The amount of 
D2S vector used for transfection in the cAMP assay was varied over a 10-fold range and the 
maximal inhibition (efficacy) and potency of quinpirole were measured and correlated using linear 
regression (r2 ~ 0.58, 95% prediction band of the correlation indicated with dashed lines). Data 
points from cAMP experiments with co-expression of DAT, SERT and Tac are shown but not 
included in the correlation. (H) Diagram describing the basal β-Arrestin2 recruitment setup. Cells 
expressing D2S-Rluc8 in the plasma membrane recruit cytosolic β-Arrestin2-mVenus upon 
quinpirole stimulation, which results in an increase in the BRET signal. 
 
Figure 3: 
D2R agonists reduce D2R surface expression in the presence of DAT in HEK293 cells without 
affecting DAT surface expression. Surface expression of DAT and GPCRs was determined as 
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described in Fig. 1A. HEK293 cells transfected with FLAG-D2SR/mock (A), FLAG-D2SR/HA-
DAT (B, D) or HA-DAT/mock (C) were treated with either 10μM dopamine (DA), 10 μM 
amphetamine (Amph), 10 μM quinpirole (Quin) or 10 μM haloperidol (Halo) for 60 minutes and 
then surface expression of either D2R (A, B) or DAT (C, D) was determined. Surface expression 
was expressed as percentage of vehicle treatment (dashed line). (A) No effect of the compounds 
was seen in cells transfected with D2SR alone (D2SR/mock: p=0.064), (B) whereas a reduction in 
surface expression was seen after treatment with the D2R agonists, DA and Quin, in cells 
expressing D2SR/DAT (dopamine: p < 0.001 and quinpirole: p < 0.05). (C, D) No effect of the 
compounds was seen on DAT surface expression in the absence (C) (DAT/mock; p= 0.48) or 
presence of D2SR (D) (DAT/D2SR: p= 0.93). Data represents four independent experiments. 
 
Figure 4: 
(A) Type 1 BRET experiments with the BRET donors D2S-Rluc8 respectively ß2AR -Rluc8 and the 
BRET acceptor mVenus-DAT. HEK293 cells were transiently co-transfected with the indicated 
constructs. The amount of BRET donor vector used for the transfections was held constant as was 
the total amount of DNA while the amount of BRET acceptor vector (DAT-mVenus) was increased 
(indicated on the ordinal axis as vector DNA ratio). The BRET signal was normalized to the 
condition were D2S-Rluc8 was expressed alone and calculated as a percentage of the maximal 
BRET signal between D2S-Rluc8 and mVenus-DAT (mean +/- s.e.m., n = 3, one site binding curve 
fit). (B) As in (A) but using mVenus-SERT as the BRET acceptor. (C) As in (A) but using D2S-
Rluc8 as BRET donor and Tac-Glur2-mVenus as the BRET acceptor. (D) Type 2 BRET 
experiments with the BRET donors D2S-Rluc8 respectively ß2AR-Rluc8 and the BRET acceptor 
mVenus-DAT. The BRET donor vector and the BRET acceptor vector used for the transfection was 
held constant at a ratio of 1 to 0.5 while the combined amount of donor and acceptor DNA was 
 31
increased. The total amount of DNA was held constant (mean +/- s.e.m., n = 3, exponential one 
phase association curve fit). (E) As in (D) but using mVenus-SERT as the BRET acceptor. (F) As 
in (D) but using D2S-Rluc8 as BRET donor and Tac-Glur2-mVenus as the BRET acceptor. (G) The 
D2S-Rluc8 expression in the type 2 BRET experiments (D, E, F) was assessed by quantifying the 
relative total luminescence in each experiment. Luminescence normalized to the transfected 
condition with the lowest activity. (H) The indicated BRET acceptor levels in the type 1 BRET 
experiments (A, B, C) were assessed by quantifying the relative total fluorescence in the linear 
range for each experiment. Fluorescence normalized to background. (I) Maximal BRET ratio 
quantified for the indicated BRET pairs. The maximal BRET ratio obtained for D2S-Rluc8/Tac-
Glur2-mVenus (p < 0.01) as well the BRET donors D2S-Rluc8 (p < 0.001) and ß2AR-Rluc8 (p < 
0.001) expressed alone was significantly lower than the maximal BRET ratio obtained with the 
BRET pair D2S-Rluc8/mVenus-DAT (ANOVA, Dunnetts post-hoc). Dashed line indicates the 
maximal BRET ratio level in β-Arrestin2 recruitment assay (agonist induced).  
 
Figure 5: 
The effect of substrates/agonists in type I BRET experiments. HEK293 cells were transfected with 
fixed BRET donors and increasing amounts of BRET acceptor as in fig. 4 A and C. (A) HEK293 
cells transfected with mVenus-DAT and D2S-Rluc8 were incubated for 5 minutes with vehicle (0.1 
% DMSO), dopamine (5 μM), quinpirole (5 μM) or tyramine (5 μM) and no significant difference 
was observed between the 4 saturating curves (mean of Bmax values obtained from 3 independent 
experiments, ANOVA). (B) HEK293 cells transfected with mVenus-DAT and ß2AR-Rluc8 were 
incubated for 5 minutes with vehicle (0.1 % DMSO), dopamine (5 μM), isoproterenol (5 μM) or 
tyramine (5 μM) and no significant difference was observed between the 4 saturating curves (mean 
of Bmax values obtained from 3 independent experiments, ANOVA). (C) HEK293 cells transfected 
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with Tac-Glur2-mVenus and D2S-Rluc8 were incubated for 5 minutes with vehicle (0.1 % DMSO), 
dopamine (5 μM), quinpirole (5 μM) or tyramine (5 μM) and no significant difference was observed 
between the 4 saturating curves (mean of Bmax values obtained from 3 independent experiments, 
ANOVA). 
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Figure S1: Coexpression of mVenus-D2 and mCherryDAT did not affect either DAT or D2 
localization. (A) Confocal images of HEK293 cells transfected with mVenus-D2 (left) or mCherry-
DAT (right). Both D2 and DAT were expressed primarily at the plasma membrane. (B) HEK293 
cell expressing both mVenus-D2 and mCherry-DAT showed no indication of a changed cellular 
distribution of either DAT or D2 as both were primarily localized to the plasma membrane. Scale 
bar 10 μm. 
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Figure S2: No effect of quinpirole and haloperidol on DAT-mediated dopamine uptake. Cultured 
neurons (13-15 DIV) were incubated for 2 hours in HBS buffer and then 10 uM quinpirole, 10uM 
haloperidol or 0.1% DMSO (vehicle) was added for 30 minutes. No significant difference was 
observed between the three conditions (One way ANOVA, paired measurements, n=4, p= 0.1428). 
Cultures of dopaminergic neurons were prepared and uptake carried out as previously described as 
previously described (Eriksen et al. 2009).
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Supplementary Material 
 
Figure S4: No difference between pseudo-Kd values (mean +/- s.e.m from three independent 
experiments, arbitrary units). Values obtained by modelling the each type I BRET experiments as a 
ligand binding curve with the BRET signal as “specific binding” and the relative acceptor/donor 
level (measured as the ratio luminescence/fluorescence) as the “ligand concentration”. 
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